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Abstract 
Chemical manipulations of nucleic acids have been crucial in the development of methodologies to study 
and understand epigenetics and transcriptomes. However, a complete understanding of these complex and 
dynamic systems is still missing and therefore we believe new synthetic tools for selective nucleic acid 
engineering are required. We report here the discovery that copper(I) carbenes derived from α-
diazocarbonyl compounds selectively alkylate the O6-position of guanine (O6-G) in mono- and 
oligonucleotides. This new methodology allows the targeting of only purine-type lactam oxygen, whereas 
other types of amides or lactams are poorly reactive under the smooth guanine alkylation conditions. 
Mechanistic studies point to a substrate-directed alkylation reaction with the N7G as the key functionality 
of the purine-nucleobase that controls the high chemoselectivity. We used copper(I)-catalyzed O6-G 
alkylation to readily engineer O6-G derivatives to study two open questions in the biochemistry of O6-G 
adducts: the repair by alkylguanine transferases and their incorporation efficiency during DNA replication. 
Furthermore, with a reactivity and stability screen of functionalized water soluble N-heterocyclic carbene 
ligands we could identify tight-binding variants that permanently stabilized copper(I) in water. This system 
allowed alkylation of oligonucleotides in a reducing agent free environment maintaining the selectivity for 
the O6-G position. Most importantly, the tight-binding ligands that stabilize copper(I) provide access to 
further functionalization such as bio-conjugation. Given the importance of O6-G lesion in biology and the 
need for simple methods to engineer nucleic acids, we believe that copper(I)-catalyzed O6-G alkylation will 
find broad applicability.  
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Chapter1. Introduction: synthetic approaches to chemically modified nucleic acids 
Nucleic acids are outstanding molecules created by nature to hold all information about the growth, 
development, functioning and reproduction of a living organism. An additional, recently appreciated, facet 
of these informational molecules is that their function can be regulated by chemical modification. For 
example the inhibition of gene expression in cells is associated with methylation of cytosine.1 Many natural 
transcriptomic and genomic modifications have been found. The complexity and dynamics of these systems 
makes them difficult to study and a complete understanding of their function is still missing.2 One way to 
study nucleic acid functioning is by selective modification, thus creating a need for new chemistry to 
selectively target nucleic acids. Selective NA engineering is not only important to study their biological 
relevance it can be also applied for therapeutic issues such as chemical gene regulation, which can be 
important for diseases that are caused by overexpression of certain genes.3  
Solid-phase synthesis of oligonucleotides was a paradigm-shifting change for building short nucleic acids. 
This approach also allows the introduction of a huge variety of modifications but is often limited by the 
size of the molecule and the ease of the non-canoncial phosphoramidite synthesis. The direct modification 
of nucleic acids (NAs) may be more efficient especially for large complex oligonucleotides. Therefore, we 
are interested in the development of novel ways to directly target both: deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA). Evolving selective modification strategies of NAs is difficult due to multiple 
similar functionalities, however, new reactivities of the NAs may be revealed and can be used to change 
their biological role.  
1.1 Structure and key physical properties of nucleic acids  
Before we have a detailed look at the reaction properties of nucleic acids, the general structure of the 
polymers will be described. Nucleic acids are not as diverse as protein since they only consist of four 
repeating building blocks: adenine (A), guanine (G), cytosine (C) are common in both DNA and RNA, 
while thymine (T) and uracil (U) are specific for DNA and RNA, respectively. These so called nucleobases 
are connected to a sugar moiety, the ribose (or deoxyribose in the case of DNA). Linkage of the sugars via 
phosphodiester bonds comprise the backbone of the nucleic acids. DNA duplexes, built out of two single-
stranded DNAs in antiparallel direction, that are right-handed helices stabilized by Watson-Crick (WC) 
hydrogen bonding in different tertiary structures (Figure 1). The most common tertiary structure of dublex 
DNA is the B-form. To expand the structural diversity in dublex DNA, Hoogsten base-pairs can be formed 
by a conformation flip of the purine bases: adenine and guanine (Figure 1).4 In addition to the four canonical 
blocks in DNA and RNA, a 5th nucleoside was detected: inosine (I). While inosine is a premutagenic event 
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in DNA (false base-pairing to C) it is an essential modification in RNA.5 Inosine is introduced by enzymes 
via deamination of adenine, one function seems to be to offer higher transcriptome diversity. 
 
Figure 1. Watson-Crick base pairing that stabilize the double helices in DNA: adenine (A) and thymine (T), guanine 
(G) and cytosine (C). R corresponds to the deoxyribose. Hoogsteen base pairing that results from a conformation flip 
of the purine bases: A and G. 
For a better understanding of how nucleic acids can react it is important to know their key physical 
properties. If we look at the first proton association of adenosine monophosphate (AMP) and cytidine 
monophosphate (CMP) they are protonated at a pH around 3.5-4.2 (Figure 2A), whereby, the other bases 
are protonated at pH of 2.6 Comparing the pKa values of both monophosphates (MPs), CMP is slightly more 
basic than AMP. However, in a longer DNA or RNA strand the nucleobases in proximity can have an 
influence on the basicity and switch the order.7 RNA should not be treated with strong acids because at a 
pH below 5 the RNA starts to decompose. Summarized protonation in a nucleic acid occurs first at the N1 
position of adenine and N3 position of cytosine. 
The first deprotonation in DNA and RNA occurs on the amide like functionality in inosine › guanine  ≈ 
uracil › thymine with inosine as the most acidic nucleobase (acidity order) (Figure 2B). Again, the 
differences in the pKa values are small enough that the neighboring nucleobases can have an influence on 
the order of acidity. A second protonation or deprotonation is not described for the nucleobases because 
these would be in unrealistic pH ranges.  
Depending on the environment a pKa perturbation of the nucleic acid can occur, thereby change the 
reactivity of the oligonucleotide. For example, in DNA duplexes, the pKa values of the nucleobases are 
shifted to neutrality7. The uncharged nucleobases in double-stranded (ds) DNA are important, for example, 
for the stability of the genome because structural mistakes that result from proton gain or loss might lead 
to replication errors.8 RNA is different because it can exist as unstructured single-strands or more complex 
folded molecules with single- and double-stranded regions. The folded structures in RNA can create protein 
3 
like pockets that result in pKa shifts. Furthermore, wobble or Hoogsten base-pairing can shift nucleobase 
pKas. To achieve catalysis RNA largely relies on co-factors or acid-base chemistry.9 For example the 
hepatitis delta virus ribozyme shows a catalytically essential cytidine with pKa shifted from 4.1 to 6.4, which 
plays an essential role in the mechanism of ribozymes.10-11 
 
Figure 2. (A) First proton associations in nucleic acids occur at N1 in adenine and N3 in cytosine. (B) First proton 
dissociations in nucleic acids occur at the lactam-like unit of guanine, thymine and inosine.  
Computational studies were also done on the nucleobases to gain an insight into the dipole moments and 
polarizibalities of the  nucleobases.8 The different calculation methods were not in in agreement for all 
cases. However, the take home message is that guanine has the highest dipole moment and the greatest 
polarizability. These findings would suggest guanine as the common target in modification reactions. The 
following section will support these predictions because guanine is the primary target of oxidants and 
electrophiles.8  
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1.2 Reaction and modification mechanism of nucleic acids 
Generally, there are two main strategies to introduce modifications to nucleic acids: pre- and post-
synthetically. Depending on the complexity of the modification and the target as well as the modification 
site, one strategy can be advantageous to the other. For example pre-synthetic approaches are rather 
beneficial to introduce selectively single modifications to nucleic acids. An overview about the most 
important methodologies to introduce modification sites to nucleic acids is shown in Figure 3. The different 
methods will be discussed in detail in the following chapter. 
 
 
Figure 3. An overview of the most important methodologies to introduce modification sites to nucleic acids. 
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1.2.1 Modification mechanism of nucleobases  
Nucleic acids, bearing a diversity of functional groups, can serve as nucleophiles, electrophiles and also 
proceed in radical reactions. However, the big challenge in post-synthetically modifying them is to obtain 
site-selectivity. Generally, post-synthetic modification methods are achieved with activated electrophiles 
that react with the phosphate backbone or the nucleophilic groups of the nucleobases. If we have a look at 
the nucleobases, they all bear similar nucleophiles, such as the exocyclic amine in A, G and C; the lactam-
like functionalities in G, T and C as well as the N7- and N3- position of the purine bases. To find new 
reactions that discriminate between all these nucleophiles without the use of protecting groups is very 
difficult. However, some reactivity properties of NAs can be extracted out of the investigations with 
different electrophiles.  
In DNA duplexes, the helix is used as protection shield and most of nucleophilic groups are rather 
unreactive because they are already occupied by Watson-Crick base pairing. Guanine is reported as the 
most electron rich nucleobase and in DNA duplexes it is the primary target of electrophiles.12 The accessible 
guanines in the major groove are then modified at the most nucleophilic N7- position.  
The nucleobase nucleophilicity of the biopolymers can be better estimated in single-strands due to missing 
secondary structures and Watson-Crick base pairing. The typical chemical modification sites of NAs with 
electrophiles are presented in Figure 4A. Again guanine is the most targeted nucleobase and no real site-
selectivity can be observed. However, modification of single-stranded NAs with different electrophiles 
leads to some reactivity trends. For example the change from SN2 to SN1 type alkylating agents can change 
the modification sites (Figure 4C-D). The SN2-type electrophiles (alkyl sulfonates) predominantly modify 
N7-G but also target to a much smaller extent the N2-, and N4-G, as well as N1-, N3-, and N7-A. The SN1 
type electrophiles (N-methyl-N`-nitro-N-nitrosoguanidine (MNNG); temozolomide) also mainly modify 
the N7-G position but O6-G, N3-A and the phosphate backbone is targeted too. The use of π-electrophiles 
resulted in inosine, uridine as well as in pseudouridine modification (Figure 4E). 
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Figure 4. (A) The main nucleophilic sites that are modified in nucleic acids. (B) The representative electrophiles that 
react with nucleic acids. (C) Alkylation sites of nucleobases with SN2 types electrophiles. (D) SN1 types electrophiles. 
(E) Attack at π-electrophiles.  
 
1.2.2 Alkylation of nucleic acids by natural products  
Earlier I presented modification trends of nucleic acids with different common electrophiles to get an insight 
how these biomolecules possibly act as nucleophiles. Now we will have a look how nature found solutions 
to target nucleic acids and then see how researchers developed chemical approaches inspired by nature’s 
modification mechanisms.  
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Considering the essential role of nucleic acids it is not surprising that nature has evolved mechanisms to 
target them. We will give an overview of alkylation reactions of DNA and RNA that have been evolved by 
organisms. Nature has found some brilliant solutions to suppress the reactivity of those molecules until it 
meets its target, the nucleic acid. There are six different classes of natural products that alkylate DNA in a 
different mechanism: activated cyclopropyl groups, quionone methides, three-membered heteroatom rings, 
reactive iminium ions, photochemical cycloadditions and diazo compounds. One representative example 
for every different alkylation class is shown in Figure 5.  
(+)-Duocarmycin A bears the dienone cyclopropane motif that is quite stable until it binds to the minor 
groove of A-T rich strands of DNA.13 The molecule can only bind to the DNA after amide rotation. This 
rotation results in increased electrophilicity of the dienone cyclopropane. Then alkylation occurs at the N3-
A in close proximity (Figure 5A).14-15  
Mitomycin C is used as potent cytotoxin against various cancers.16 A reductive activation followed by 
methanol elimination and aziridine ring-opening yields the electrophilic quinone-methide. Binding to the 
minor groove of DNA the N2-G (good minor groove nucleophile for π-electrophiles) is alkylated. 
Subsequent elimination of the carbamoyl moiety generates the α,β-unsaturated iminium functionality that 
can be attacked by a second N2-G (Figure 5B).17-19 The N2-G alkylation can occur both inter-and 
intramolecularly, with the intermolecular cross-link reported as more toxic.20-22  
Three-membered ring heterocycles (epoxides, aziridines and episulfoniums) are natural products that also 
target DNA (Figure 5C-E). Aflatoxin B1 represents probably the most toxic member of this class and is 
produced by fungal food contamination. This toxin is the major cause of liver cancer, especially in countries 
that lack appropriate food storage. After uptake in food, the epoxidation of aflatoxin B1 occurs in the liver. 
DNA is then alkylated by nucleophilic attack of N7-G.23-24  
Another example of this group is azinomycin A, which bears a reactive aziridine and epoxide functionality. 
These three-membered ring heterocycles are reported to alkylate N7-G and N7-A. The presence of two 
electrophiles in one molecule can result in DNA cross-links, whereby the primary alkylation product is 
formed between the aziridine unit and the N7-G.25-26  
Leinamycin alkylates DNA with the corresponding created episulfonium ion preferentially at GG and GT 
regions of dsDNA. Nucleophillic attack of thiol delivers the reactive thioester and sulfenic acid. Subsequent 
attack of the sulfenic acid on the ester forms the oxathiolanone and the episulfonium is built by the attack 
of the nearby olefin.27-29 
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Figure 5. (A) (+)-Duocarmycin A is activated by DNA binding and alkylates it through a cyclopropyl enone 
electrophile. (B) Mitomycin C is a bifunctional electrophile. Biological reduction delivers the quinone-methide that 
alkylates N2-G in the minor groove; subsequent elimination leads to the electrophile that is attacked by another N2-
G. (C-E) Representative natural product bearing three membered rings (epoxide, aziridine and episulfonium) for DNA 
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alkylation. (F) Ecteinascidin 743 generates a reactive iminium species that alkylates N2-G upon binding to minor 
groove of dsDNA. (G) The furanocoumarin moiety can lead to photocross-linking at A-T sites in dsDNA. 
Ecteinascidin 743 is an example of a natural product that alkylates the N2-G position of DNA with a reactive 
iminium ion. The reactive iminium ion is formed upon binding of the substrate with the minor groove of 
dsDNA (Figure 5F).30 
Furocoumarins are known to react with DNA via [2+2] cycloaddition. An example of this mechanism 
shows psoralen that is found in various plants, alkylating dsDNA by photocycloaddition to the thymidine 
residues (Figure 5G). These cycloadditions can lead to toxic DNA cross-links. The toxicity of 
furocoumarins (8-methoxypsolaren) has proven for blood cancer treatment and psoriasis.31-34   
The diazo functionality is of particular interest for the present work. As we will see in later sections diazo 
compounds were chosen as alkylation source for nucleic acids. There are only a small number of natural 
compounds bearing stabilized diazo groups.35-36 The most prominent examples are kinamycin and 
lomaiviticin. These natural products seem to induce strand-breaking by radical reactions, these however 
will not be further discussed.37 More important for the present work, are the diazo natural products 
consisting of diazopeptides. The structurally simplest example is azaserine, a diazotisated α-amino acid 
(Figure 6A). These natural diazo compounds are stable enough to target intracellular structures. However, 
they fell out of clinical studies due to their toxicity.38-40 The primary mode-of-action of natural α-diazo 
carbonyl compounds was reported to act as glutamine antimetabolite but their mutagenic activities suggest 
that DNA is a likely target as well.41-43  
Diazo actetate formation is reported to happen frequently in humans. Nitrosation of the N-terminus of 
peptides or glycine itself results in diazo acetates that may cause O6-(carboxymethyl)-G (O6-(cm)-G) 
adducts in the presence of DNA (Figure 6B).44-45 These DNA damages were especially found in people 
with a high red meat diet. Summarized, the report shows that DNA alkylation by α-diazo carbonyl 
compounds is likely, however precise mechanistic studies are missing to conclude whether there is a 
biological relevance. 
The natural product streptozotocin contains a N-nitroso-N-methylurea functionality (MNNU).46 This 
moiety is related to synthetic guanidine derivatives which are precursors to the highly reactive 
methyldiazonium electrophile (Figure 6C). Unstabilized α-diazo carbonyl compounds have a very short 
half-life of a few seconds in water.47 Nevertheless, the created highly reactive alkyldiazonium ion targets 
many nucleophilic positions in DNA including O6-G modification. This lesion is reported as highly 
mutagenic and toxic.12 The glucose transporter protein GLuT2, highly expressed on the surface of beta 
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cells, is responsible for recognition of the glucosamine side chain in streptozotocin.48-49 This specific 
recognition has made the natural product an effective drug in pancreatic cancer. 
 
Figure 6. DNA alkylation by diazo and diazonium groups. (A) Structural simplest example for diazo “peptide” 
azaserine and diazonium formation under acidic condition. (B) Diazo acetates or diazopeptides formation by nitrite or 
other nitrosyl donor and O6-G adduct formation. (C) Streptozotocin as example for natural product that creates a highly 
reactive diazonium ion after thiol activation. 
 
1.2.3 Chemical alkylation of nucleic acids  
Inspired by the mechanism of natural products to alkylate DNA, researchers developed a number of 
molecules to target DNA in similar mechanism.  
For example the synthetic developed mustards follow a similar alkylation mechanism as the natural 
products that modify DNA with a reactive three membered ring heterocycles. The general structure of 
mustards includes two chloro-ethyl side chains and a central heteroatom (nitrogen or sulfur) (Figure 7A). 
Intermolecular displacement of one chloride leads to the formation of the three membered ring heterocycles 
(aziridine or episulfonium ion). Comparable to the natural products leinamycin and azinomycin, the N7-G 
position in DNA is modified (Figure 7B).50-53 The second chloride can react in the same mechanism to form 
inter-or-intrastrand DNA cross-links causing cellular damage that triggers apoptosis.54 Sulfur mustards 
were widely used as chemical weapons. Despite the fact that a different mode-of-action (hydrolysis and 
conjugation involving β-lyase and S-oxidation) was reported, many studies also indicated the related 
toxicity to DNA alkylation.55 Nitrogen mustards found application in chemotherapy and chloromethine is 
the simplest member that still remains important as an anti-cancer drug (Figure 7A).56-57 The electrophilicity 
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of the nitrogen mustard can be tuned by varying the substituent on the nitrogen from aliphatic to aromatic.58 
For example, the activation of chloromethine is much easier compared to chlorambucil.  
 
Figure 7. Three-membered ring heterocycles designed by researchers to alkylate DNA. (A) Representative examples 
for sulfur and nitrogen mustards: mustard gas, chloromethine and chlorambucil. (B) Intramolecular displacement of 
chlorine lead to DNA alkylation preferentially at N7-G. A second N7-G alkylation causes inter-or intrastrand cross-
links. 
Temozolomide (TMZ) represents another example of a DNA alkylation agent that reacts with a similar 
mechanism compared to the natural product bearing a reactive diazo group. TMZ is a synthetic anticancer 
prodrug, which acts as a methyl transfer agent. In the presence of water a spontaneous break down of TMZ 
occurs to monomethyl triazene (MTIC) and the highly reactive methyl diazonium electrophile is formed 
(Figure 8).59 The TMZ induced methylation of DNA preferentially targets the N7-G position in G rich 
regions. However, O6-G and N3-A can also be methylated. The O6-G alkylation is important for the drug 
action of TMZ. This modification is reported as highly cytotoxic and mutagenic because polymerases can 
misincorporate T opposite the O6-modified G during DNA replication resulting in mutagenesis or 
apoptosis.60-61 TMZ is used for brain cancer and glioblastoma multiform (a tumor located in the central 
nervous system) treatments. Fortunately, the effect of TMZ can be reduced or completely suppressed by 
DNA repair-mechanism: methylguanine-DNA methyltransferase or low activity of DNA mis-match repair.  
 
Figure 8. DNA alkylation by diazonium groups derived from synthetic precursors. 
In the pharmacopeia there are numerous DNA alkylating agents for example from the nitrosourea family 
that follow a similar modification mechanism. Decomposition under physiological conditions creates the 
highly reactive DNA alkylation species.56, 62 
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1.3 The pre-synthetic approach for the synthesis of modified nucleic acids 
In the previous section it was demonstrated how nature and researchers inspired by nature evolved strategies 
to target nucleic acids. All these modification strategies are useful for chemoselective nucleic acid 
alkylation but not to introduce sequence-selective functionalities. The pre-synthetic modification 
approaches are the most common ways to address this problem. 
The synthesis of modified nucleic acids in a pre-synthetic manner can be subdivided in two main classes: 
(1) Automated oligonucleotide solid phase synthesis (OSPS) with modified phosphoramidites. 
(2) Enzyme-catalyzed primer extension with synthetic modified triphosphates. 
An overview of both pre-synthetic approaches is presented in Figure 9. To obtain the target functionalized 
nucleic acid, the synthesis of either the modified phosphoramidite (Figure 9, left box) or modified 
nucleoside triphosphate ((d)N*TP) is necessary (Figure 9, right box). The two representative structures bear 
the functional group on the nucleobases. However, as later discussed other modification sites are also 
possible. The modified phosphoramidite is then incorporated in OSPS cycle and the modified (d)N*TP 
incorporated in DNA replication or transcription. Selecting between biosynthesis and chemical synthesis is 
determined by the complexity of modification, substrate availability as well as realizable chemical 
synthesis. For example, the enzyme-catalyzed approach strongly depends on the steric demand of the 
modification that has to be tolerated and accepted by the polymerase.  
 
Figure 9. Synthesis of modified NAs: Incorporation of modified phosphoramidites in oligonucleotide solid phase 
synthesis (left); Incorporation of modified triphosphates in DNA replication or transcription (right). 
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Generally the modification can be placed at any site of the nucleic acid as long as the chemical synthesis of 
the corresponding nucleoside phosphoramidite or triphosphate is possible. There are examples in the 
literature that show modification at the terminal 3`- or 5`- end hydroxyl groups as well as inside the nucleic 
acid chain. The modifications inside the chain are commonly introduced at the nucleobases (Figure 10B+C). 
Modification of the phosphate backbone is also described in the literature however this modification site is 
rarely applied due to perturbation of the resulting helix.63-64 Ribose modification at the 2`hydroxyl group 
presents another possibility to introduce the desired functionalities. Using this method, alkyne 
functionalities as well as dyes could be introduced to nucleic acid chains (Figure 10A).65-66 Nevertheless, 
functionalization at the nucleobases represents the most common strategy. The pyrimidine bases are often 
modified at position 5, since it does not interfere with Watson-Crick base pairing (Figure 10B).67-68 The 
purine bases are often modified at the deaza 7-G and A positions (Figure 10C).69-72 Again, the interference 
of the modification with Watson-Crick base-pairing is minimized. Especially, for the polymerase mediated 
nucleic acid synthesis, the incorporation efficiency depends strongly on proper Watson-Crick base pairing. 
There are also examples of the synthesis of modified purines dNTPs at position 8. They are reported as 
poor substrates for polymerases and therefore rarely applied.73 
 
Figure 10. (A) Modification at the 2`-hydroxyl group of the ribose moiety. (B) Modification at pyrimidine bases 5-C 
and 5-U. (C) Modification at purine bases 7-deaza-G and 7-deaza-G A. (D) Examples for modifications that can be 
introduced: alkyne, biotin as pull-down tag or fluorophores. 
The general process for nucleic acid synthesis with phosphoramidite chemistry is explained first and then 
how modified phosphoramidites are introduced into this cycle. The oligonucleotide solid-phase synthesis 
(OSPS) is an automated process that is most widely used for nucleic acid synthesis. In a four step cycle: (1) 
detritylation, (2) coupling, (3) oxidation and (4) capping the nucleic acid chain is elongated in a 3`-
5`direction to synthesize small and medium sized nucleic acids (up to 200 bases) (Figure 11).74-75 The 
commercial solid supports for nucleic acid synthesis bear the nucleoside of choice (A, G, T, C, U), which 
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are detritylated under acidic conditions in the first step of synthesis. The second monomer is then coupled 
as commercial phosphoramidite with a 5`-OH dimethoxytrityl protection group. Tetrazoles are used as 
activation agents for the coupling step. Subsequent treatment with iodine results in the desired oxidation 
state of the phosphate backbone. The yield of the coupling step is never quantitative and therefore a capping 
step is necessary. Treatment with acetic anhydride acetylates the unreacted 5`-OH groups, avoiding 
elongation of incomplete reaction products from previous synthesis cycles. The acetylated products (aka. 
truncated products) will not react further and are excluded from the synthetic cycle. In the next step another 
monomer can be coupled to the chain or the chain can be cleaved from the resin including nucleobase 
deprotection under basic conditions. In a final reverse-phase (RP)-column chromatography purification step 
the truncated products can be separated yielding the target nucleic acid.  
 
Figure 11. Synthetic cycle for automated oligonucleotide solid phase synthesis using phosphoramidite chemistry with 
DNA as example. (1) Detritylation: Trichloracetic acid in CH2Cl2. (2) Coupling: 5-(Benzylthio)-1H-tetrazole in 
MeCN. (3) Oxidation: Iodine in THF/pyridine/H2O. (4) Capping: (a) Ac2O, THF/acetic anhydride, (b) 
Methylimidazole, THF/pyridine. (5) Cleavage and deprotection: 32 % NH3 in H2O, rt 2h then 55°C for 16 h. 
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The pure chemical pre-synthetic modification approach uses the OSPS strategy to introduce single 
modification sites to nucleic acids (Figure 12A). To synthesize the modified nucleic acid of choice the 
corresponding modified phosphoramidite is incorporated in the OSPS cycle. The advantage of this method 
is that point modifications can be introduced at the desired positions in the nucleic acid strand. Using this 
strategy, access modified oligonucleotides of arbitrary complexity is possible, but syntheses of the precursor 
phosphoramidite are often difficult. Out of numerous examples of modified phosphoramidites that are 
successfully incorporated in the OSPS cycle, one is presented in Figure 12B. This example was chosen to 
demonstrate the laborious synthesis of O6-G modified DNA without the ability for direct modification. 
Johnson and coworkers synthesized the O6-G alkylated phosphoramidites in 6 steps and the final O6-G 
modified nucleic acids were then tested as substrates for the repair protein O6-alkylguanine transferase 
(AGT).76 This protein transfers the alkyl group from the O6-G position to a reactive cysteine residue and 
regenerates the native DNA.77 The repair of O6-G alkylation is important because these lesions are reported 
as highly mutagenic and carcinogenic.78 The human AGT (hAGT) protein is also expressed in tumor cells 
and its inhibition can increase the efficiency of DNA alkylating chemotherapeutic drugs. Therefore 
determination of hAGT activity in cell extracts is important.  
 
Figure 12. (A) Synthetic procedure for the synthesis of modified nucleic acid with OSPS. (B) Structure examples of 
synthetized O6-G modified phosphoramidites that were successfully incorporated in OSPS cycle. (C) Structure 
examples of commercially available phosphoramidites for direct introduction in OSPS cycle and nucleic acid labelling 
(left box). Commercially available phosphoramidites that bear nucleophilic groups for further functionalization after 
oligonucleotide synthesis (right box). 
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Figure 12C illustrates several examples for commercially available monomers that bear either a fluorophore 
or a nucleophile moiety.64 Using the OSPS the fluorophores can be introduced at 3`- and 5`-end and as well 
as in the chain. Labelling of nucleic acids is important for bioanalytic applications, genomics and 
diagnostics. The introduction of a nucleophile to the nucleic acid chain is used for further functionalization. 
Often this method is reported as post-synthetic modification strategy but in reality the modification is 
introduced pre-synthetically.64  
The chemical synthesis of nucleic acids with OSPS is facile, robust and scalable. However there are also 
limitations: difficulties in the synthesis of longer oligonucleotides (›100nt); the chemical synthesis of the 
desired modified phosphoramidite can be very difficult and a laborious multistep procedure is necessary.76, 
79 Additionally the modification site has to be stable during the whole OSPS process (deprotection, 
coupling, oxidation, capping and cleavage).  
One way to prepare more complex nucleic acid structures and to overcome the length limitations is to ligate 
several nucleic acid fragments together. In this approach a short modified nucleic acid fragment is 
synthesized with OSPS and then ligated to a larger oligonucleotide that is 5`phosphorylated (Figure 13). 
The ligation is catalyzed by T4 DNA polymerase and a complementary nucleic acid template (splint) is 
used to bridge both fragments.  
 
Figure 13. Approach for the synthesis of longer single-point modified nucleic acids: (A) The shorter fragment bearing 
the modification is synthesized with OSPS and a modified phosphoramidite. (B) Commercial longer NA that is 
5`phosphorylated. (C) The shorter fragment bearing the modification  is enzymatically ligated to the second 
5`phosphorylated nucleic acid fragment using the splint template and T4 DNA polymerase. 
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An alternative to the classical phosphoramidite chemistry to pre-synthetically modify nucleic acids is 
enzyme catalysis (therefore called biological pre-synthethic approach see Figure 3). Scientists have taken 
inspiration from nature and used DNA or RNA polymerases to introduce modified (deoxy) nucleoside 
triphosphates (dN*TP or N*TP) to nucleic acid chains. The incorporation efficiency of the new synthesized 
modified triphosphate (dN*TP or N*TP) is always first tested in primer extension experiments (PEX) 
(Figure 14). In this approach a primer is hybridized with a complementary DNA template. The 
functionalization is than installed if the modified dN*TP is incorporated by the polymerase instead of the 
natural dNTP (Figure 14B, representative for modified DNA synthesis). For successful nucleic acid 
synthesis it is not only important that the functionalized dN*TP is accepted and incorporated by the 
polymerase, further extension is mandatory. A lot of investigations were done to develop new polymerases 
that tolerate a broader substrate scope.80-81 However, there is no polymerase that can be universally applied. 
For every new synthetic (d)N*TP investigation of several polymerases are necessary and the reaction 
conditions (amount of polymerase, ratio of natural to modified (d)N*TP) have to be optimized. 
 
Figure 14. (A) General structure of nucleobase functionalized dN*TP and N*TP. (B) Synthesis of modified DNA via 
primer extension (PEX) in the presence of dN*TP and natural dNTPs catalyzed by DNA or RNA polymerase. 
The first investigations in this field were done in 1981. Langer and coworkers incorporated a biotinylated 
dUTP in DNA synthesis.82 Later, Famulok and colleagues were the first ones who presented a full set of all 
four modified dN*TPs and studied them towards PEX.83 Different functionalities including guanidine,84 
amino acids,85 ferrocenes86 and saccharide87 were successfully incorporated. Carell and coworkers 
demonstrated that alkyne functionalization is also possible with this approach. The alkyne moiety was then 
further modified by copper-catalyzed alkyne cycloaddition.67-68, 72, 88-91 
Base-modified nucleotide triphosphates (N*TPs) were also investigated as substrates for RNA polymerases 
but they gained less attention due to the difficult handling of modified RNA compared to DNA. However, 
a groundbreaking example was demonstrated by Hirao, who expanded the genetic alphabet with the 
development of new base pairs such as 2-amino-6-(2-thienyl)purine (s) and 2-oxo-(1H) pyridine (y) (Figure 
15A).92-93 The bulky 6-thienyl group disfavors s-T pairing (Figure 15B). The transcriptional specificity for 
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s-y pairing is comparable to the natural base pairs and site selective incorporation of functionalized yTP 
opposite s by T7 transcription yielded the single modified RNA. In the follow-up studies transcribed RNA 
from dsDNA could be site selective labeled with fluorophores such as TAMRA and biotin (Figure 
15C+D).94-96 In the first step the target dsDNA is amplified by polymerase chain reaction (PCR) with a 
5`primer bearing the T7-promoter sequence and a 3`primer bearing the artificial base s. Transcription of 
the PCR product with the modified yTPs yields the target functionalized RNA. This method represents so 
far the best solution to introduce single functionalization to RNA molecules.  
 
Figure 15. (A) Non-canonical base pair s-y. (B) Bulky 6-thienyl group disfavors s-T pairing (C) Synthesis of single 
modified RNA by s-y pairing and primer extension catalyzed by T7 transcription. 
The major drawbacks of nucleic acid modification by PEX are the limited scale of the reaction and obstacles 
in the synthesis of the functionalized (d)N*TPs. There are many strategies for their preparation. However, 
depending on the modification site (especially for O6-G), there is only the possibility to introduce the 
functionality to the nucleoside first and then a final chemical triphosphorylation step is necessary. Already 
in the `80s, Yoshokawa showed that the reaction of nucleosides with phosphorylchloride (POCl3) followed 
by pyrophosphate and triethylammoniumcarbonate yielded the desired 5`triphosphate.97 There are 
alternatives in the literature for triphosphorylation, but the method developed by Yoshokawa is most 
commonly used.98 In some cases protection groups are required, for example for nucleophilic 
functionalities, due to the use of the strong electrophilic phosphorous reagents in the triphosphorylation 
step. Then the final deprotection step has to be mild and compatible with the TP. Considering all these facts, 
laborious multistep procedures are often necessary for the preparation of functionalized (d)N*TPs. 
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A better synthetic alternative was developed in 2003: the direct functionalization of (d)NTPs via cross 
coupling reaction. Burgess and coworkers presented the Sonogashira alkynylation of dUTP.99 Afterwards 
efficient protocols for Suzuki-Miyaura reactions of halogenated (d)NTPs were published;100-102 Challenges 
were faced with hydrolysis of the triphosphate, but these could be mitigated by using mild cross-coupling 
conditions as well as fast isolation of the product. It should be mentioned that these cross-coupling 
approaches are only applicable for modification of position 5 in pyrimidines and 7 in purines. 
The PEX method allows the synthesis of medium-size DNA (15-100 bp). Polymerase chain reactions (PCR) 
are necessary to obtain longer modified strands. In this method a forward and reverse primer are used for 
DNA amplification. The DNA synthesis is run in several cycles (20-40) that always repeat: denaturation, 
annealing and extension using a thermostable DNA polymerase. PCR amplifications are generally more 
challenging for the enzymes than PEX because the polymerase has also to read through the modified 
template in the 2nd cycle. Therefore smaller modifications or functionalities bearing a flexible linker are 
substrates for PCR amplifications.91, 103  
Unfortunately, neither the PEX nor the PCR modification methods are suitable for internal site-specific 
point functionalization as the OSPS phosphoramidite chemistry approach. One way to introduce site-
selective modification to longer nucleic acids is the combination of both: the synthesis of the modified 
primer with the OSPS followed by PEX with (d)NTPs and replication or transcription (Figure 16). 
 
Figure 16. Synthesis of longer point modified nucleic acids: combination of chemical OSPS approach with biological 
PEX catalyzed by DNA/RNA polymerases with (d)NTPs. 
 
1.4 Chemical sequence-selective alkylation of nucleic acids 
The combination of pre-and post-synthetic modifications strategies allowed researchers to develop 
sequence-selective alkylation of nucleic acids. A short nucleic acid strand (or nucleic acid mimic) bearing 
a reactive moiety is designed to be complementary to the target nucleic acid and guides the reactive group 
to the desired location (Figure 17A). The nucleic acid strand bearing the reactive group is synthesized using 
OSPS with the modified phosphoramidite. Sasaki and coworkers presented a templated cross-link 
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formation via a Michael type addition of cytidine to the reactive allyl unit (Figure 17B).104 Another example 
was reported by Rokita and coworkers. They used quinone methides to target nucleic acids and form cross-
links (Figure 17B).105-106 Both alkylation methods are site-selective and the functional group reacts after 
annealing of the strands. However, after the successful reaction the guiding sequence is still covalently 
bound to the target sequence and will change the native function of it. Therefore, the presented methods are 
likely useful for nucleic acid labeling and detection. Sasaki and coworkers found a solution for this problem. 
They developed a new strategy using a functionality transfer technique where the guiding sequence is 
released after the addition reaction (Figure 17C).107 In this technique a carbon-sulfur bond connects the 
electrophile (α,β-unsaturated diketone) to the guiding sequence and in the transfer process this bond is 
cleaved, releasing the guiding sequence. This technique is unique and allows DNA and RNA alkylation 
without affecting their function by the covalent bound guiding sequence. 
 
Figure 17. (A+B) Sequence selective modification of nucleic acid by a short nucleic acid complement bearing a 
reactive group. The methods highlighted in the box lead to cross-links and are used as detection systems, however the 
functionality transfer of malonyldienone-type electrophile releases the guiding sequence (C). 
 
1.5 Catalytic approaches for nucleic acid modification 
As already mentioned in the previous section, direct modification of nucleic acids would be more efficient 
and may provide access to more complex structures. However, the development of such strategies also has 
challenges due to multiple similar reactive groups in nucleic acids. Nature has solutions to introduce 
sequence-selective modifications to nucleic acids. For example, methyltransferases (MTases) catalyze the 
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methyl transfer from the cofactor S-adenosylmethionine (AdoMet) to various positions of DNA and RNA 
(C, A and G). The cofactor AdoMet is the main natural source of electrophilic methyl groups (Figure 18A). 
Various AdoMet analogues were synthesized and investigated in the reaction of alkyl transfer. The first 
alkyl transfer analogues targeted DNA with an aziridine moiety.108 This strategy was rather useful to target 
DNA than functionalized RNA. However, optimization of the AdoMet design allowed sequence-specific 
targeting of dsDNA, transfer RNA (tRNA), dsRNA and ssRNA with alkyl, alkenyl, alkynyl and azide 
functionalities (Figure 18A, B). Furthermore, Rentmeister and coworkers developed a strategy to use 
human trimethylguanosine synthases (GlaTgs) to transfer alkyl groups to 5`-cap structures of messenger 
RNAs (mRNAs) (Figure 18C).109-110 Recent developments in this field published by the same group showed 
the successful transfer of a vinylbenzyl motif. The vinyl group can be further functionalized e.g. using 
tetrazine inverse electron demand Diels-Alder reaction.111  
 
Figure 18. Natural enzymes for transcript labelling. (A) S-adenosylmethione (AdoMet) and its analogues (highlighted 
in the box). (B) Reaction of nucleophilic group (Nu) of nucleic acid with AdoMet analogues catalyzed by 
methyltransferases (MTase). (C) mRNA 5`-cap targeting with AdoMet analogues catalyzed by trimethylguanosine 
synthases (GlaTgs). 
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1.6 Chemical nucleobase modification for sequencing of natural nucleic acid modification 
In this section one example is presented to show how chemical modification of nucleic acids has been used 
to sequence non-canonical bases in the whole genomes at single base resolution.  
The chemical reactivity of nucleic acids was explored to understand which chemicals can be dangerous for 
genomes. Already in the `70s the different reactivity of uracil and cytosine with bisulfite was reported. The 
cytosine addition product is unstable and hydrolyses to uracil. In contrast the uracil addition product 
eliminates the bisulfite and restores uracil (Figure 19A). These different reactivities were used to develop 
a sequencing strategy for modified cytosine (Figure 19B). 5-methylcytosine (m5C) is widespread in DNA112 
and RNA.113 This modification is known to regulate gene expression in eukaryotes. The existence of this 
modification has been known since 1925, but only with the development of modern DNA sequencing 
methods were many biological roles revealed. It was shown that m5C could react with bisulfite but the 
reaction is slow enough to discriminate between C and m5C (Figure 19).114-115 The target isolated DNA is 
sequenced by normal methods. This method cannot discriminate between C and m5C. Then the DNA is 
treated with bisulfite and all Cs are converted to Us that are read as Ts after PCR amplification and 
sequencing. The first data set is then compared with the data set from bisulfite treatment and all m5C sites 
can be determined. The Cs that are not converted were m5C in the original DNA strand. 
 
Figure 19. “Selective” reaction of DNA with bisulfite enabled the development of a sequencing method to 
discriminate between Cs and m5Cs. (A) Bisulfite adds to the position 6 in pyrimidines resulting in deamination of 
cytosine and restorage of uracil. (B) Concept of bisulfite sequencing strategy to map m5Cs. 
The optimization of the reaction condition allowed the detection of m5Cs in whole epigenomes at single-
base resolution.116-118 In addition the construction of oxidative and reductive bisulfite sequencing allowed 
the detection of all m5C oxidation derivatives (hydroxymethyl, formyl and carboxyl). For a more detailed 
description about oxidative and reductive bisulfite sequencing as well as other sequencing methods derived 
from chemical nucleobase modification the reader is referred to our recently published review.8 The 
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bisulfite sequencing methods was shown to demonstrate how important chemical modifications are for 
structure elucidation of nucleic acids. Limitations of these methods are the multistep procedure and the loss 
of the analyte due to harsh conditions. Therefore deep sequencing is needed in order to achieve enough 
reads for reliable results.  
Inspired by nature, researchers have developed fantastic solutions to introduce modifications to nucleic 
acids in post-synthetic as well as in pre-synthetic approaches. There are plenty of modification methods 
presented in the literature, however, a complete understanding of the properties and reactivities of nucleic 
acids is missing. Therefore, new selective chemistry is needed to find answers to these questions and 
potentially also find new modification sites. With the present work we want to contribute to this field with 
the study of copper(I) as catalyst for nucleic acid modification. 
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Chapter 2: Electrophilic Cu(I) carbenes react chemoselectively with guanine through a substrate 
directed reaction 
2.1 Catalytic X-H insertion reactions of diazo carbonyl compounds: early developments and 
mechanistic insights. 
The bond formation between a heteroatom and a carbon is an important process for both natural and man-
made molecules. Construction of this type of bond is crucial for chemists and has numerous applications in 
chemical biology. The extensive use of Buchwald-Hartwig C-N and C-O couplings catalyzed by palladium 
is an important example of these methodologies.119,120 Another strategy to form carbon-heteroatom bonds 
is carbenoid based X-H insertion (XHI). In this transformation the nucleophile X can be a nitrogen, oxygen, 
sulfur, selenium, phosphorous or halogen atom. The present work is focused on metal carbenoid chemistry. 
This strategy to link a heteroatom to a carbon is the method of choice for selective nucleic acid modification. 
Formation of the crucial metal-carbenoid complex typically occurs in situ starting from a diazo precursor. 
Subsequent nucleophilic attack of the XH group in a concerted or stepwise reaction, results in the desired 
X-C bond (Scheme 1). The underutilization of this type of reaction in synthetic chemistry is rather 
surprising considering the broad reaction scope and functional group tolerance of XHI catalyzed by 
rhodium, copper, ruthenium or iron. Additionally, recent developments such as the enantioselective variant 
expand the scope of potential application in chemical synthesis. 
 
Scheme 1. (A) General scheme for X-H insertion reaction with metals. 
The first example of XHI was documented by Reichstein and Casanova in 1950.121 They showed that 
treatment of an α-diazo ketone with copper(I) oxide in the presence of methanol yielded the corresponding 
α-methoxyketone (Figure 20A) instead of the expected Wolf rearrangement product. Two years later, Yates 
presented a more detailed investigation into XHI reactions with α-diazo ketones catalyzed by copper. He 
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illustrated the possibility to use various alcohols and amines (thiophenol, aniline, piperidine, ethanol) to 
yield the corresponding XHI products (Figure 20B).122 For the first time a carbene-type mechanism was 
proposed. Further studies demonstrated that rhodium(II) carbenoids derived from dirhodium tetraacetate 
(Rh2OAc4) were excellent catalyst for insertion into O-H bonds (Figure 20C). Already in the `80s it was 
shown that XHI was applicable to industrial processes. The key step in the synthesis of the antibiotic (+)-
thienamycin is a rhodium(II) catalyzed N-H insertion reaction (Figure 20D).123 However, most 
investigations in the carbenoid field were carried out on C-H insertion reactions and cyclopropanation. 
Reasons why catalyzed XHI reactions are underexploited could be that there are already reliable classical 
methods available to form a carbon-heteroatom bond e.g. the substitution reactions without the need of a 
catalyst. However, catalytic pathways have unique advantages over stoichiometric ones, like controlling 
reaction selectivity (chemo-, enantio-, diasterio-, and regioselectivety) by choosing the appropriate ligand 
system. This is particularly advantageous in the synthesis of large molecules, like natural products, where 
selective reactions are very important. Besides the selective synthesis of complex molecules, applications 
of XHI in chemical biology can be crucial to study biological systems. In this chapter, the examples for 
XHIs are focused on X = N, O and S due to their relevance in biological systems. 
 
Figure 20. Initial investigations on XHI catalyzed by copper or rhodium (A-D). 
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2.2 Metal carbenoids: different diazo compound as carbenoid precursors and electronic features of 
the metal carbenoid bonds. 
In this section the reactivity and stability of diazo compounds is briefly discussed to present the structural 
influence on carbene formation that can be relevant for XHI. As already mentioned in the previous sections, 
diazo compounds are reactive building blocks and used as carbene precursors for XHI reactions catalyzed 
by transition metals. Their reactivity and thermal stability can be tuned by the electronic character of the 
substituents in the α-position of the diazo group. Generally, the substituents can be used to classify the diazo 
substrates in four different groups (Figure 21A). The acceptor/acceptor species bearing two carbonyl 
functionalities show the highest stability, whereas, species with only electron donating groups are very 
unstable. Several resonance structures contribute to the stabilization of the diazo compound via 
delocalization of the negative charge. The anion of stabilized diazo compounds shows poor interaction with 
metals (Figure 21A). Thus, acceptor/acceptor and acceptor/donor stabilized diazo substrates need more 
active catalysts to form the corresponding metal-carbene.  
 
Figure 21. (A) Structure and stability of α-diazo compounds. (B) General synthetic routes for α-diazo compounds. (a) 
diazotization of α-acceptor-substituted primary amines with nitrous acid; (b) oxidation (dehydrogenation) of 
hydrazones with e.g silver oxide; (c) cleavage of sulfonylhydrazones under basic conditions; (d) diazo-group transfer 
onto activated methylene or methine substrates; (e) cleavage of N-alkyl-N-nitroso sulfonamides, carboxamides, ureas 
or urethanes in the presence of a base; (f) electrophilic substitution at diazomethyl substrates; (g) triazene 
fragmentation; (h) post synthetic modification of an existing diazo compound. 
The simplest and most reactive example of a diazo compound is diazomethane. However, this compound 
is also the most hazardous diazo substrate and should be handled with care. Generally, unstabilized diazo 
compounds are considered as potentially explosive and their thermal stability should be taken into 
consideration during synthesis. The major synthetic routes for diazo compounds are summarized in Figure 
21B. For a detailed description of the synthesis of diazo compounds, the reader is referred to the excellent 
review by Maas.124  
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2.3 Copper(I) catalyzed X-H insertion reactions with α-diazocarbonyl compounds. 
The development of copper carbene chemistry is of particular interest for the present study and is therefore 
described in detail.  
The first important application of X-H insertion reactions with copper(I) carbenoids derived from α-
diazocarbonyl compounds was reported in `60s by Rajagopalan. He presented the alkylation of the active 
site carboxyl residue of pepsin with α-diazocarbonyl compound 1 and a large excess of copper(II) salt 
(Figure 22A).125 Unfortunately, the copper(I) carbenoid chemistry was overshadowed by other transition 
metal carbenes until the discovery of Jørgonsen and coworkers, who used chiral copper(I) complexes 
catalytically for stereoselective insertion reactions into aniline with diazo compound 2.126 Investigations of 
diverse chiral ligands (diphosphines, diamines, diimines, bisoxazolines or P-N ligands) resulted in an ee up 
to 28 % (Figure 22B). Two representative chiral ligands 3 and 4 with the highest ee are shown in Figure 
22B. Furthermore, the Jørgenson group showed that a change in either the diazo substrate or amine source 
did not improve the enantioselectivity. However, variation of the copper source and chiral ligand was later 
demonstrated by other groups to achieve an enantioselectivity up to 98% ee for NHI and OHI (Figure 22C 
and D).127-128 In all stereoselective XHI reactions, the chiral catalyst was formed in situ by mixing a copper 
salt with the chiral ligand.  
 
Figure 22. Copper(I) catalyzed carbenoid XHI. (A) Pepsin modification via OHI catalyzed by excess of copper. (B) 
First example of stereoselective NHI catalyzed by copper(I). (C) Stereoselective OHI catalyzed by copper(I). (D) 
Recent example of stereoslective NHI catalyzed by copper.  
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In the mechanism of XHI reactions different transition metals can lead to slightly different reaction 
pathways. However, there are two general mechanisms: a concerted insertion into non-polar bonds (as in 
the case of C-H bonds), and a stepwise ylide formation (typically occurs with polar bonds). The mechanism 
for the copper catalyzed carbenoid insertion reaction is shown in Figure 23. Kochi129 and Tessi130 
demonstrated that the catalytically active species is copper(I). If necessary, a reductant such as ascorbate 
can be added to create the desired oxidation state of copper. However, it was also shown that α-
diazocarbonyl compounds can act as reducing agent by undergoing a sacrificial coupling.  
A number of scenarios, for example some coordination modes of the substrate or Lewis bases can 
potentially slow or inhibit the XHI reaction (top line in Figure 23). A crystal structure of an unproductive 
substrate binding shows one way that copper catalysis could be blocked (Figure 23, dashed box).131 
However, if the XHI reaction is successful, it will follow the general mechanism for XHIs via steps A-D. 
The first step is the coordination of the negatively polarized diazo substrate to the metal, (Figure 23, step 
A), which is then followed by loss of nitrogen to form the metal carbenoid (Figure 23, step B). A 
representative example of a metal carbenoid characterized by X-Ray and NMR is shown in Figure 23 (blue 
box).131 In rhodium(II) catalysis, step B, the loss of nitrogen, is the rate-determining step (RDS). However, 
the computational studies for XHI catalyzed by copper showed similar transition state energies for all steps 
A-D.132-133 Therefore, it is likely that the rate is determined by the copper source. Coordination of the 
nucleophilic XH group to the metal gives the corresponding ylide (Figure 23, step C) and electrophilic 
insertion of the carbene bond into XH followed by a proton shift (Figure 23, step D) yields the final XHI 
product. Computational studies by Liang and coworkers suggested that the insertion step D includes a 
migration of the copper to the carbonyl oxygen (Figure 23, green box).133 
 
Figure 23. Mechanistic insights of copper(I) catalyzed carbenoid chemistry. 
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2.4 Metal-carbenoid XHI reactions in chemical biology 
In chemical biology the selective chemical manipulation of biomolecules is used to label, modify, probe or 
pull-down a molecule of interest. Methods for nucleic acid modifications have many applications, one of 
which is use as tools to understand their biological role or for adaption in diagnostics and therapeutics. The 
major challenge in modification of biomolecules for biorthogonal chemistry is to achieve high efficiencies 
and the right selectivity without destroying the corresponding activity of the biomolecule. Considering that 
most of these reactions should take place under mild and physiological conditions: neutral pH, ambient 
temperature and in an aqueous environment; the possibility for competing side reactions is very high. 
Furthermore, these complex biomolecules show diverse functionalities and contain multiple reactive sites. 
Therefore the development of a selective biomolecular modification is difficult.  
Nevertheless, there are examples in the literature of bioconjugation using metal carbenoid chemistry for 
nucleic acids and proteins. Both substrate classes have nucleophilic sites for possible XHIs. In proteins the 
amino acid side chains or the N-terminus can be targeted and the nucleic acids provide nucleophiles on the 
nucleobases as well as in the ribophosphate. 
The challenge in the bioconjugation of proteins is the selective introduction of the new functionality without 
affecting its structure and activity. Thus, the metal-carbenoid method should remain efficient at reasonable 
protein concentrations, and ideally should target a specific single site or a single functional group while 
leaving the remainder of the protein untouched.  
Following the discovery by Rajagopalan and coworkers in 1966 that protein can be studied by diazo 
modification,125 Antos and Francis presented a rhodium carbenoid system for protein labelling in 2004. The 
proteins (myoglobin and subtilisin) were successfully modified at their tryptophan units using Rh2OAc4 
and α-diazoesters at low pH.134-135 The reaction conditions yielded not only the NHI product of tryptophan, 
but also some cyclopropanation of the tryptophan indole moiety (Scheme 2A). The presence of the buffer 
salt hydroxylamine hydrochloride was important for this transformation to proceed, however, its detailed 
role in the catalytic mechanism was never discovered. In the follow-up studies improved reaction conditions 
(t-butylhydroxyl amine) for smooth alkylation of mellitin, lysozyme and FKBP-mellitin were presented. 
Yet, protein alkylation using rhodium carbenoid chemistry is limited to proteins bearing solvent accessible 
tryptophans (else the protein denaturation is required before alkylation). Later, Ball and coworkers reported 
a catalytic system where the rhodium carbenoid is generated from a rhodium bearing peptide α-helix 
delivering the alkylation group in direct proximity to the target functional group via coiled-coil interactions 
of both helices (Scheme 2B).136-137 This strategy allowed modification of nearly all natural amino acid side-
chains bearing a nucleophile. 
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Scheme 2. Rhodium carbenoid-mediated modification of proteins. (A) Rh(II) carbenoids for covalent modification of 
tryptophan residues in proteins. (B) Site-specific modification of amino acid chains by specific binding of Rh(II) 
catalyst, that brings the resulting Rh(II) carbenoid in close proximity to the modification site. 
In 2010, Che and coworkers presented a protein labelling method for site-selective alkylation of the N-
terminus using dansyl-functionalized diazoacetate 8, catalyzed by a water soluble ruthenium porphyrin 
complex 15 (Scheme 3).138 Water solubility was introduced by attaching α-D-glucosyl groups to the 
porphyrin ring. The first model peptide 7 bearing multiple reaction sites (primary and secondary alcohols, 
phenol, guanyl and amino groups) was efficiently alkylated at the N-terminus. Only traces of lysine side 
chain alkylation 10 were detected (Scheme 3A). The high selectivity for terminal NHI was interesting 
considering that the pKa value of the amino group in the lysine side chain is more basic (pKa = 9.3-9.5) 
compared to the N-terminus (pKa = 7.6-8.0). However, the reaction was run at pH 7.4-8.4 and therefore 
most of the lysine side chains were protonated. The absence of O-alkylation can be explained by the higher 
nucleophilicity of the nitrogen. More investigations with different peptides, for example peptide 11, showed 
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that the selectivity could be switched to SHI if only one cysteine was present (Scheme 3B). SHI was shown 
to be faster than NHI using metal carbene chemistry. However, the selectivity could be tuned back to 
terminal NHI by introducing a disulfide link between two cysteine side chains (Scheme 3C). Further 
investigation extended the method to allow modification of the terminal amine in different proteins. Those 
examples include the NHI of terminal lysine in RNase A; glycine in insulin A; and phenylalanine in Insulin 
B. The limitations of this alkylation method were shown by the failure of modifying myoglobin and 
ubiquitin where only traces of the corresponding alkylation product were detected.  
 
Scheme 3. Ruthenium carbenoid substrate-dependent NHI or SHI derived from a dansyl functionalized diazoacetate 
8 and peptide 7/11 and 13. (a) Ru catalyst 15, phosphate buffer saline (PBS), room temperature, 1 h. 
The discovery of metal carbene chemistry for biomolecules functionalization, especially nucleic acids, is 
of outstanding interest for the present study. In 2012, a method for post-synthetic nucleic acid alkylation 
was developed in our group. The method allowed modification of short and medium sized single-stranded 
DNAs and RNAs using rhodium(II) carbenoids derived from α-diazocarbonyl compound 16 and Rh2OAc4 
(Scheme 4).139 This alkylation method targets only the nucleobases resulting in a number of mono and 
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double alkylation products. NMR studies revealed that only the exocyclic amino groups in adenine, guanine 
and cytosine were modified.   
One year later, Dr. Tishinov investigated other transition metals in nucleic acid modification. Particularly, 
the copper(I) carbenoid alkylation reactions showed promising results. Using the donor-acceptor stabilized 
diazo substrate 16, Cu(II)SO4 and sodium ascorbate (as the reductant) several model oligonucleotides were 
successfully alkylated.140 The copper(I) catalytic system showed to be more efficient than rhodium(II) 
catalysis. The presence of the reducing agent is important to sustain the copper(I) oxidation state, which is 
the catalytically active species in this system.  
 
Scheme 4. Rh(II)/ Cu(I) carbenoid nucleic acid alkylation using the donor-acceptor substituted diazo substrate 16. 
The copper(I) catalyzed alkylation reactions of nucleic acids proceed under similar conditions as the 
copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) for bioconjugation. The tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) ligand was used to scavenge hydroxyl radicals generated 
by transition metals and ascorbate in the presence of molecular oxygen.141,142 In the absence of a radical 
scavenger the formed radicals by an copper(I)-catalyzed electron transfer to molecular oxygen can lead to 
oxidation or cleavage of the nucleic acids.  
The potential of copper(I) catalyzed carbenoid alkylation compared to rhodium catalysis was shown with a 
small series of model oligonucleotides (Table 1). In all alkylation reactions the modification was more 
efficient in the presence of copper(I) rather than  rhodium(II). Additional differences are shown in d(TGT) 
and the T 4-mer alkylation (Table 1, Entry4/5 and 9/10). Modification of d(TGT) by Rh(II) carbenoids was 
only possible upon the addition of a second nucleotide (Table 1, Entry 3) and thymine could not be targeted 
at all (Table 1, Entry 9).  
As previously discussed the alkylation products of d(TGT), d(TCT) and d(TAT) catalyzed by rhodium(II) 
were characterized by NMR. By comparison of the MS and HPLC traces for the rhodium(II) method with 
the copper(I) catalyzed reactions, the same regioselectivity and modification of the exocyclic amino group 
in cytidine, adenine, and guanine, was assumed. 
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A further advantage of the copper(I) catalyzed alkylation was the ability to run the reaction in tandem with 
CuAAC in a one-pot reaction  mixture. Reaction of d(ATGC) with an alkyne functionalized diazo substrate 
17 in the presence of an azide bearing biotin 18 yielded several NHI/click products. Unfortunately, the 
efficiency of the one pot reaction was rather low. It is likely that the click product 19 is formed first and the 
alkylation then took place. The ssDNA modification with a more bulky diazo substrate 19 could slow down 
the reaction rate and decrease its efficiency (Scheme 5).  
Table 1. Comparison of copper(I) and rhodium(II) alkylation with model substrates and α-diazocarbonyl compound 
16. 
Entry Metal 
source 
Asc 
[mM] 
ssDNA Number 
mono:     double: 
ssDNA 
conversion, %[a] 
1 Rh2OAc4 - d(TAT) 2 - 20 
2[b] CuSO4 10 d(TAT) 2 - 37 
3[c] Rh2OAc4 - d(TGT) 2 - 25 
4[b] CuSO4 10 d(TGT) 4 1 46 
5 Rh2OAc4 - d(TCT) 2 - 16 
6[b] CuSO4 10 d(TCT) 4 - 27 
7 Rh2OAc4 - d(ATGC) 4 - 56 
8[b] CuSO4 10 d(ATGC) 7 4 70 
9 Rh2OAc4 - d(T4) - - - 
10[b] CuSO4 10 d(T4) 7 1 19 
Reaction conditions: 5 mM ssDNA, 0.5 mM metal source, 50 mM diazo substrate 16, 50 mM MES buffer pH 6.0, 24 
h, room temperature. [a] Determined by HPLC analysis of the reaction mixture. [b] 2.5 mM THPTA. [c] 5 mM 
d(TAT), 5 mM d(TGT), 1mM Rh2OAc4. 
Scheme 5. Tandem CuAAC/NHI labeling of d(ATGC) with alkyne conjugated diazo substrate 17 and biotin-azide 
derivative 18. 
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2.5 Copper carbene selective alkylation of the O6 position of guanine in mono- and oligonucleotides  
The aim of the work discussed within this chapter was the development of a selective post-synthetic 
alkylation method for nucleic acids with copper(I) carbenoids.  
2.5.1 Reaction discovery and scope of O6 alkylation reaction 
As presented in the last section, single-stranded nucleic acids were successfully alkylated by rhodium(II) 
and copper(I) carbenoids derived from the donor-acceptor stabilized α-diazocarbonyl compound 16. These 
NHI reactions primarily targeted the exocyclic amino group of C, A and G. So far, only donor-acceptor 
stabilized diazo substrates were investigated in this catalytic system. Here, we present that changing the α-
diazocarbonyl compound 16 to more reactive acceptor stabilized diazoacetates and amides dramatically 
changed the alkylation profile and chemoselectivity: the O6 position in guanine (G) and inosine (I) was 
selectively targeted. As an example for the dramatic change in the alkylation profile TGT modification in 
the presence of ethyl α-diazoacetate (EDA) or diazo compound 16 was compared (Figure 24). The crude 
HPLC trace of TGT alkylation in the presence of the acceptor stabilized diazo compound shows one single 
peak for the O6 G alkylation product (Figure 24A) compared to several alkylation products in the presence 
of the donor-acceptor stabilized diazo compound 16 (Figure 24B). 
The potential of copper(I) carbenes derived from ethyl α-diazoacetate (EDA) selective alkylating the O6 
position of guanine and inosine in monophosphates (MPs), triphosphates (TPs) and short ssDNAs is 
presented in Table 2. All alkylation products were analyzed by tandem mass fragmentation and showed the 
corresponding ions for nucleobase (guanine and inosine) alkylation (representative examples: Figure 25 
and Figure 26). A detailed verification of the alkylation site at the nucleobase is presented in section 2.5.2 
pointing to the O6 position. We explored the efficiency and selectivity of O6-G alkylation by characterizing 
reactions with nucleotide monophosphates. Treatment of dGMP or GMP with 20 mol% copper(I) and 
commercial EDA in aqueous buffer gave the corresponding O6 alkylation products in high yields within 30 
min reaction time (Table 2, Entry 1 and 2). Copper(I) was created in situ by mixing Cu(II)SO4 and sodium 
ascorbate. Under the same conditions, the structural analogues IMP, GTP and dGTP were also efficiently 
modified at their O6 positions (Table 2, Entry 6, 11 and 12). However, the absence of the copper(I) catalyst 
did not led to modification (Table 2, Entry 5); and replacing the starting material with AMP, CMP, UMP 
or TMP resulted in little or no detectable alkylation (Table 2, Entry 7-10). In short, only substrates that 
contain either a guanine or inosine in the structure were converted to the desired alkylation product, while 
the other substrates were partially converted through unselective pathways that we could not completely 
characterize. In each case the mass for alkylation was usually detected, but these did not give substantial 
peaks in the HPLC that we could isolate. A similar observation was found for d(TAT) (Table 2, Entry 14). 
Some starting material was consumed but no reasonable amount of any alkylation product could be isolated. 
35 
In contrast, when guanine was present post-synthetic modifications of a DNA 3-mer d(TGT) and 9-mer 
d(TTTTGTTTT) with copper(I) carbenes derived from EDA yielded efficiently a single alkylation product 
(Table 2, Entry 13 and 17, Figure 25D+E).  
 
 
Figure 24. (A) HPLC analysis of d(TGT) alkylation in the presence of the acceptor stabilized diazo compound ethyl 
α-diazoacetate (EDA) and in situ formed copper(I) after 45 min reaction time (Table 2, Entry 13). (B) HPLC analysis 
of d(TGT) alkylation with the donor-acceptor stabilized diazo compound 16 and in situ formed copper(I) after 24 h 
reaction time (Table 1, Entry 4). 
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Table 2. Alkylation potential of copper(I) carbenoids derived from ethyl α-diazoacetate (EDA) with mono- and 
oligonucleotides. 
 
Entry substrate Time 
[min] 
Cosolvent Conversion of 
substrate [%] 
Yield 
[%] 
1 dGMP 30 none 98[d] 86 
2 GMP 30 none 96[d] 92 
3 GMP 30 DMSO 93[d] - 
4[b] GMP 30 none 87 - 
5[c] GMP 150 none 0 - 
6 IMP 30 none 92[d] 81 
7 AMP 30 none 40 - 
8 CMP 30 none 38 - 
9 UMP 30 none 21 - 
10 TMP 30 none 13 - 
11 GTP 30 tBuOH 98[d] 73 
12 dGTP 30 tBuOH 97[d] 65 
13 d(TGT) 15/45 none 62/8[d] - 
14 d(TAT) 120 none 35[e] - 
15 d(ATGC) 150 tBuOH 38[d] - 
16 d(ATGC) 150 dioxane 64[d] - 
17 d(TTTTGTTTT) 30 DMSO 82[d] - 
18 G 19[f] DMSO 70 - 
19 A 19.5[f] DMSO 11 - 
[a] Complete reaction conditions: 5 mM substrate, 1 mM CuSO4, 5 mM sodium ascorbate, 50 mM EDA, 100 mM 
MES buffer pH 6, H2O, 20% (v/v) cosolvent, 25°C. [b] No sodium ascorbate added. [c] No CuSO4 and sodium 
ascorbate added. [d] G-alkylation site was verified on the basis of tandem MS fragmentation ions. [e] Six mono 
alkylation products were detected by ESI, but the amount was too low for isolation. [f] Reaction time corresponds to 
hours not minutes.  
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Figure 25. HPLC-MS/MS analysis of O6-G alkylation with copper(I) carbenoids derived from EDA (Table 2) (A) 
IMP (Entry 6). (B) GTP (Entry 11). (C) dGTP (Entry 12). (D) d(TGT) (Entry 13). (E) d(TTTTGTTTT) (Entry 17). 
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Figure 26. d(ATGC) HPLC-MS/MS analysis of O6-G alkylation reactions with copper(I) carbenoids derived from 
EDA (Table 2, Entry 15). 
While oligonucleotides were also selectively alkylated at the O6-G position, the reactions were slower. For 
example, the O6-G alkylation of d(ATGC) with copper(I) carbenoids (Table 2, Entry 15; Figure 26), 
required longer reaction time and the conversion of the ssDNA 4-mer was lower compared to 
mononucleotides (cf. Table 2, Entries 11 and 15). This reduced reactivity of d(ATGC) can likely be 
attributed to the unproductive sequestration of copper(I) to other binding sites in the oligonucleotide, for 
example the nucleobases A, T and C as well as the ribophosphate backbone. These results already indicated 
the limitation of this alkylation method by the length of the oligonucleotide. However, the lower reactivity 
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of oligonucleotides could be diminished by the addition of 1,4-dioxane as co-solvent and showed almost 
twice the amount of d(ATGC) conversion when using a stock solution of EDA in 1,4-dioxane instead of 10 
% tBuOH in water (Table 2, Entry 16).  
Diazo substrate variation is another way to improve the reaction efficiency with challenging nucleic acids. 
In the previous section it was mentioned that the electronic character of the substituents in α-position to the 
diazo functionality has an influence on its stability and reactivity. Here, we demonstrate that the diazo 
substrate change from the diazoacetate (EDA) to acetamides has an influence on the catalytic system. The 
alkylation of ssDNAs with diazoacetamides (DAAs) led to higher conversion numbers and the high O6 
selectivity was maintained (Table 3). Modification of the model substrate d(ATGC) for example, delivered 
the O6-G adduct with more than 60% conversion of the starting material with both DAAs 23 and 24 as 
carbene source (Table 3, Entry 1 and 2), whereas the same substrate led to only 38% conversion with EDA 
(Table 2, Entry 15).  
The DAAs were efficiently synthesized in two steps, according to an adapted procedure by Fukuyama and 
coworkers.143 Reaction of commercially available bromoacetyl bromide (BrAcBr) with the secondary 
amines (piperidine, N,N-diisopropylamine and 1-amino-3-butyne) followed by treatment with N,N-
ditosylhydrazine in the presence of DBU yielded the final DAAs 23-25 (Scheme 6). 
 
Scheme 6. Synthesis of diazo acetamides (DAAs). (a) N,N-diisopropylamine/piperidine, CH2Cl2, -60°C to 25°C, 30 
min (20: 31%), (21: 52%), (22: 75%). (b) N,N-ditosylhydrazine, DBU, THF, 0°C-25°C, 20 min, (23 and 24: 60%), 
(25: 34%). 
While the DAAs are better substrates in nucleic acid modification, they are also less stable. For example, 
the preparation of accurate stock solutions in 10 % tBuOH and water was impossible for the DAAs due to 
rapid decomposition. These findings can be explained by the change of the “acceptor” substituent in α-
position to the diazo group. While the amide group in DAAs stabilizes the diazo group, it does this to a 
smaller extent than a carboxy group due to the higher electron density of amides. Therefore, DMSO was 
used as co-solvent to stabilize the highly reactive DAAs in the alkylation reactions. Unfortunately, the 
coordinating co-solvent lowers the reactivity of the nucleic acids. Changing the reaction medium to a less 
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coordinating co-solvent such as dioxane was the best compromise between these competing affects, 
d(ATGC) was efficiently modified in a fifth of the time (cf. Table 3 Entry 3 and 4). Summarized, the DAAs 
are better substrates for nucleic acid modification and even longer ssDNA 16-mers were efficiently 
alkylated (Table 3 Entry 8 and 9).  
Table 3. Alkylation reactions of diazoacetamides (DAAs) with oligonucleotides 
 
Entry ssDNA Diazo- 
acetamide 
Time 
[min] 
Conversion 
of ssDNA [%][d] 
1 d(TGT) 23 15 78[b] 
2 d(TGT) 24 15 78[b] 
3 d(ATGC) 23 150 62[b] 
4 d(ATGC)[c] 23 30 74[b] 
5 d(ATGC) 24 150 61[b] 
6 d(TTTTGTTTT) 23 30 92[b] 
7 d(TTTTGTTTT) 24 30 81[b] 
8 d(AACAGTCATATCCTTA) 23 180 48 
9 d(AACAGTCATATCCTTA) 24 180 40 
10 d(ATGC)[c] 25 150 66[b] 
[a] Complete reaction conditions: 5 mM substrate, 1 mM CuSO4, 5 mM sodium ascorbate, 50 mM diazoacetamide, 
100 mM MES buffer pH 6, H2O, DMSO 20% (v/v), 25°C. [b] G-modification was verified on the basis of tandem MS 
fragmentation ions. [c] Same conditions as a but 20 % (v/v) of dioxane was used instead of DMSO. [d] Determined 
by HPLC-analysis of the reaction mixtures. 
The stability of the amide bond in the DAAs offers also the advantage to introduce different functional 
groups by simply changing the amine source in the diazo synthesis. The attached functionalities can be 
further used for bio-conjugation reaction, labelling or pull downs. As an example, the model substrate 
d(ATGC) was modified at the O6-G position with a DAA bearing a terminal alkyne 25 (Table 3 Entry 10) 
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and further functionalized by click reaction with biotin azide derivative 26. In summary, our developed 
copper(I) carbene chemistry allowed the efficient post-synthetic O6-G modification of a ssDNA 4-mer 27 
with a complex pull-down tag in only two steps (Scheme 7).  
 
Scheme 7. Example for DAA substrate modularity - can be used for pull down enrichment. (A) Click reaction of O6-
G alkyne modified d(ATGC) with biotin azide. (B) HPLC analysis of the click reaction mixture after 0 h (red trace) 
and after 1h (black trace) with corresponding mass trace for click product detected by UPLC-MS analysis. (a) CuSO4, 
sodium ascorabate, DMSO, TEAA pH 7, 25°C, 1 h. 
  
42 
2.5.2 Determination of the alkylation site 
The surprising selectivity of copper(I) carbenoids derived from α-diazocarbonyl compounds prompted us 
to investigate the alkylation site in detail. The tandem mass analysis of the short ssDNA and MP already 
showed that the alkylation took place at the nucleobases guanine and inosine, respectively. Therefore a 
model substrates dGMP was chosen to determine the modification site on the nucleobase via 2D-NMR 
analysis of the isolated alkylation products 28 (Figure 27A). The arrows in Figure 27A show all possible 
alkylation sites of guanine. The obtained coupling over four bonds in the heteronuclear multiple-bond 
correlation (HMBC) spectra from the imidazole proton H8 of guanine led us to identify the chemical shift 
of the carbon C6 (Figure 27B). A second coupling over three bonds from this carbon C6 to the CH2 group 
of the newly attached moiety narrowed the possible points of attachment to either the O6 or N1 position. 
The two possible structures are presented in the black box in Figure 27B. Furthermore, the 13C chemical 
shifts were calculated for both possible alkylation products 29 and 30 using Chemdraw (Figure 27B dashed 
box). Comparison of the calculated 13C chemical shifts (highlighted with blue numbers) with the measured 
one from the CH2 group of compound 28, suggested modification at the O6 position. Additionally, no 
correlation between N1 and the attached CH2 functionality was obtained in the 15N-HMBC analysis. This 
correlation over two bonds would be expected if N1 is alkylated. (Figure 27B).  
 
Figure 27. (A) Determination of the alkylation site with the model substrates dGMP. (B) Important signals for 
structure elucidation isolated from 2D-NMR analysis. Predicted 13C-NMR chemical shift with Chemdraw (dashed 
box); two representative 3J couplings for either O6 or N1 alkylation, respectively (black box). (a) CuSO4, sodium 
ascorbate, MES buffer pH 6, H2O, 25°C, 5 h (60 %). 
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Nevertheless, we decided to synthesize an O6-(ethyl carboxymethyl)-inosine (O6-(ethylcm)-I) adduct 31 by 
a traditional synthetic route as additional verification of the alkylation site (Figure 28, pathway B). 
Commercially available 6-chloropurine riboside was protected as tert-butyldimethysiliyl (TBDMS) ether 
at the 2`, 3`and 5` hydroxyl groups. Nucleophilic aromatic substitution of the chloride bearing 
ribonucleoside 32 with ethyl glycolate followed by deprotection of the silyl groups yielded the O6-
(ethylcm)I 31 in 37% over three steps. Furthermore, the copper(I) carbene chemistry derived from EDA 
was used to yield the inosine alkylation product 31 in 60% in one step (Figure 28, pathway A). Subsequent 
structure elucidation of both compounds 31 isolated from the different pathways A and B showed identical 
NMR spectra as well as HPLC traces (Figure 29) and confirmed the proposed O6 modification site. 
 
Figure 28. Verification of O6 alkylation. Pathway A: synthesis of O6-(ethylcm)I 31 using copper(I) carbenoid 
chemistry in one step. Pathway B: synthesis of O6-(ethylcm)I 31 via 3 steps synthesis. (a) CuSO4, sodium ascorbate, 
MES buffer pH 6, H2O, 6% (v/v) DMSO, 25°C, 5 h (60 %). b) TBDMS-Cl, imidazole, DMF, 25°C, on. (77 %). c) 
ethylglycolate, NaH, THF, reflux, 4 h (48 %). d) Pyridine.HF, pyridine, 25°C, 16 h (99%). 
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Figure 29. HPLC analysis O6-(ethylcm)-I 31 synthesized via pathway A (blue trace) and pathway B (black trace) and 
corresponding tandem MS fragmentation. 
 
2.5.3 Mechanistic hypothesis accounting for the high O6-G chemoselectivety 
The obtained selectivity for copper carbenes derived from acceptor-stabilized diazo compounds does not 
reflect the reported nucleophilicity for the DNA nucelobases.8 The N7-G for example is reported as the 
most potent nucleophile in dsDNA and ssDNA and targeted by other alkylating agents five to tenfold higher 
than the O6-G position. We assumed that a pre-association of the copper(I) catalyst with guanine is the key 
for the resulting selectivity, since unstabilized copper(I) carbene should readily react with water. Guanine 
is reported as the most electron rich nucleobase and is able to form chelates with divalent metals such as 
copper(II).144-145 Additionally, DFT calculations of the molecular dipoles of nucleobases indicated that 
guanine has the largest dipole (6.9 D), negatively polarized between O6 and N7 (Scheme 8). Unfortunately, 
not much is known about the interaction between copper(I) and DNA.146 The sensitive oxidation state of 
copper(I) in aqueous buffer at neutral pH could be the reason for the lack of investigations.147 However, 
copper(II) is reported to bind to the N7 position of guanine and therefore we hypothesize that the selectivity 
derives from the carbene formation with an N7-G bound copper(I) catalyst. The crystal structure of 
copper(II)148 and other divalent metals145 demonstrate a strong preference for N7-G coordination placing 
the copper center approximately 3.5 Å away from the O6 position.  The formed copper carbene would be 
poised in the same manner to form the metal ylide with the O6 position (Scheme 8). Subsequent protonation 
would yield the O6 alkylation product. 
The obtained selectivity reflects also the preferred site for copper-catalyzed oxidative DNA damage 
(induced by copper with peroxide and superoxide) that shows enhanced oxidation at and around guanines.149 
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There are two possible pathways reported for copper-mediated redox damage. The first pathway goes 
through a hydroxyl radical that is formed by unbound copper(I) induced hydrogen peroxide cleavage or 
reduction of reactive oxygen compounds. If the hydroxyl radical is close to DNA it can lead to DNA 
fragmentation. This unselective mechanism poses a constant danger for DNA and RNA degradation but it 
is also inefficient. In the other pathway the copper(I) is bound to guanine and forms a copper(II) oxo 
complex with peroxide that guides the oxidative damage to guanine itself or the neighbouring bases. 
Unfortunately, the reports about oxidative damage of DNA gave little insight into the mechanism or why 
guanine is targeted or where exactly copper is bound. We assume that the specificity in our alkylation 
reaction with copper(I) carbenes and the oxidative damage induced by copper is a results from the same 
thing: the ability of guanine to coordinate to the copper species. 
 
Scheme 8. Mechanistic hypothesis accounting for the selective O6-modification in guanine. 
Our hypothesis that the pre-coordination of copper to guanine guides the selectivity of the reaction would 
predict the following: 
(1) Poor reactivity of other amides or lactones that do not bear the same coordination ability  
(2) Blocking the coordination site of the copper center by strongly chelating ligands would extinguish 
the reactivity because coordination of both substrates the guanine and the chelating ligand would 
not leave coordination space to form the copper(I) carbene. 
1. Poor reactivity of other amides or lactones that do not bear the same coordination ability. The first 
substrate of choice to investigate the influence of the coordination ability of guanine in the alkylation 
reaction was the 7-deaza variant 34 of dGTP. Comparing the alkylation reaction of normal guanine in dGTP 
(HPLC traces Scheme 9) with the reaction outcome of the 7-deaza variant 34 a substantial reduced reactivity 
and selectivity is observed. Additionally, the dTMP and the lactam piperidine-2-alkylation are similarly 
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unreactive. These results add further weight that the N7 coordination is the important factor for selective 
O6 alkylation. 
 
 
Scheme 9. Mechanistic studies that point to the important role of the N7 in guanine guiding the alkylation reaction to 
the O6 position. The HPLC traces were recorded after 30 min reaction time. The reactions conditions: 5 mM substrate 
(dGMP, 7-deaza dGTP 34, TMP or a-valerolactone), 1 mM CuSO4, 5 mM sodium ascorbate, 50 mM EDA, 100 mM 
MES pH 6, dioxane 20 % (v/v), H2O, 25 °C. 
 
2. The guanine alkylation is inhibited in the presence of multidentate ligands, however, promoted 
with N-heterocyclic carbene (NHC) ligands. 
In the CuAAC that is widely used for biochemical transformation, ligands such as tristriazoles and 
bathocuproine are employed for copper(I) stabilization and acceleration of the click reaction.150-152 
However, the presence of strong coordinating ligands such as tris(3-hydroxypropyltriayolylmethyl)amine 
(THPTA) or bathocuproinedisulfonic acid disodium salt (BCA) prohibited alkylation of dGMP (Scheme 
10, left pathway). Even after several hours, however, little to no alkylation products were detected. In the 
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presence of THPTA, EDA was completely consumed after one hour but no dGMP alkylation occurred. The 
copper carbene derived from EDA is formed in this case but decomposed in an unproductive manner, likely 
through reaction with water. 
In contrast, N-hetreocyclic carbene (NHC) stabilized copper(I) behaved different in dGMP alkylation. The 
reaction of dGMP with EDA in the presence of commercial mesitylimidazolium copper chloride (MesCuCl) 
yielded a similar alkylation profile as the standard conditions (CuSO4 and ascorbate) with O6-
(ethylcm)dGMP 35 as main product (Scheme 10, right pathway). The NHC, as monodentate ligand, still 
allows the coordination to the N7-G and therefore the desired alkylation can proceed. These types of ligands 
have other favorable properties such as, the reduction of oxidative damage; These are explored in detail in 
chapter 3 in nucleic acid alkylation reactions. 
 
Scheme 10. Multidentate ligands such as THPTA and BCA prevent dGMP alkylation (left pathway) and efficient 
dGMP alkylation catalyzed by MesCuCl (right pathway). (a) 20 mol % CuSO4, 20 mol% Ligand L1 or L2, 10 eq. 
EDA, 1 eq. sodium ascorbate, Mes buffer pH 6, 20% (v/v) dioxane, H2O, 25°C. (b) 20 mol % MesCuCl, 10 eq. EDA, 
Mes buffer pH 6, 30% (v/v) dimethoxyethane, H2O, 25°C, 30 min. The HPLC traces were recorded after 30 min.  
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2.5.4 Copper(I) carbenoid alkylation of double-stranded DNAs (hairpin motifs, mismatch double 
stranded DNA)  
Double-stranded (ds) DNA is primary structure present in cells if the DNA is not being actively replicated. 
In that sense, the copper(I) alkylation system to modify double-stranded DNA is an important feature 
concerning the reaction scope of nucleic acids alkylation. 
In order to test the post-synthetic alkylation reaction on dsDNA, three model substrates that form hairpin 
structures were selected (Table 4). The advantages of using hairpin instead of linear dsDNAs are reflected 
in the synthesis and pre-preparation as the duplex has not to be formed by annealing equimolar amounts of 
two single-strands. The hairpin is synthesized as single strand that ensures the quantitative duplex 
formation. Two similar hairpin structures were chosen bearing a small change in the loop and at the 
3`position. Both hairpins contained a small loop of five nucleotides and a duplex region of six base pairs. 
The third hairpin had a longer duplex region with a length of 10 base pairs and an additional 5` guanine 
overhang. 
Table 4. Scope of copper(I) alkylation with double stranded DNA 
Entry  Hairpin substrate Hairpin 
Structure 
CuSO
4
 
[mM] 
Time 
[h] 
Conversion[a] 
[%] 
1 d(CGAACGTTTTTCGTTCG) 
     
1 mM 10 8 
2 d(CGAACGTTTTTCGTTCG) 
     
5 mM 24 40 
3 d(CGAACGTTGTTCGTTCGG) 
 
1 mM - 19[b] 
4 d(CGAACGTTGTTCGTTCGG) 
 
5mM 22 38 
5 d(GCGGAATTCCGTTTTTCGGA
ATTCCG) 
 
1 mM 6 48[c] 
6 d(GCGGAATTCCGTTTTTCGGA
ATTCCG) 
 
5 mM 2 60[c] 
Reaction conditions: 5 mM hair-pin, 50 mM EDA, 5 eq. of sodium ascorbate compared to CuSO4 concentration, 100 
mM Mes buffer pH 6, 25°C. [a] The conversion was determined by HPLC analysis of the reaction mixtures. [b] The 
conversion was determined at the time point when all EDA was consumed, due to co-elution of EDA with the hair-
pin. [c] 100 mM DAA 23 was used instead of EDA.  
The alkylation of the hairpins was investigated with copper(I) carbenes derived from EDA under the 
standard conditions that were worked out for the MPs/TPs and single-stranded DNAs. The hairpin bearing 
no guanine in the loop or as overhang was not modified under these conditions (Table 4, Entry 1, Figure 
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30A), indicating that guanines engaged in double strands are not targeted. The hairpin structure bearing two 
accessible guanines (in the loop and as 3`overhang) was reacted under the same condition resulting in 
moderate conversion of the starting material (Table 4, Entry 3). Unfortunately, the concentration of the 
newly formed species was too low to characterize it (Figure 30C). 
 
Figure 30. HPLC traces of hair-pin alkylation reaction in the presence of copper(I) carbenoids. (A) hair-pin (T-loop) 
alkylation reaction with 20 mol% copper(I) and EDA (Table 4, Entry 1). (B) hair-pin (T-loop) alkylation reaction with 
1 eq. of copper(I) and EDA (Table 4, Entry 2). (C) hair-pin (3`G and G in the loop) alkylation reaction with 20 mol% 
copper(I) and EDA (Table 4, Entry 3). (D) hair-pin (5`G) alkylation reaction with 20 mol% copper(I) and DAA 23 
(Table 4, Entry 4). (E) hair-pin (5`G) alkylation reaction with 1 eq. copper(I) and DAA 23 (Table 4, Entry 5). 
In order to improve the conversion and isolate a sufficient amount of product, the reaction conditions were 
slightly changed. Attempts with stoichiometric amounts of copper(I) enhanced the conversion of the hairpin 
(Table 4, Entry 4). However, a similar increasing reactivity was also observed for the hairpin that was 
unreactive with catalytic amounts of copper(I) (Table 4, Entry 2). It is likely that the higher amount of 
copper induces single-strand formation in the hairpins. We assume that the coordination of copper to the 
double strand can interfere with Watson-Crick base pairing resulting in duplex opening and accessible 
guanines for alkylation. 
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DAA 23 was also investigated as carbene source in hairpin alkylation. Treatment of the hair-pin bearing 10 
base pairs in the duplex and a 5` guanine overhang with the copper(I) carbene derived DAA 23 yielded a 
single monoalkylation product (Table 4, Entry 5 Figure 30D). Analysis of the second new peak by MALDI 
TOF did not show a reasonable mass that could be correlated to any expected alkylation product. The 
presence of stoichiometric instead of catalytic amounts of copper(I) showed again a different alkylation 
profile (Figure 30E). This supports the hypothesis that single-strands are formed based on copper 
concentration.  
Nevertheless, selectively targeting single-stranded guanines over double stranded is an important 
characteristic and could be used for site selective structure depending modification of DNA.  
As previously discussed, guanines in double-stranded DNAs are not targeted as long the copper 
concentration is catalytic and does not interfere with Watson-Crick base pairing. A single mismatch base 
pair such as G:A in a DNA duplex could free the guanine from the duplex and make it accessible for 
alkylation. A DNA 16-mer duplex 36 was synthesized bearing a mismatch base-pair G:A at position five 
and the reactivity in alkylation reaction was investigated (Scheme 11). Unfortunately, the mismatch DNA 
36was unreactive in the presence of copper(I) carbenoids derived from DAAs 23 and 24. It is likely that 
only one mismatch pair is not enough to make the guanine accessible for modification.  
 
Scheme 11. Alkylation of a double-stranded DNA bearing one G:A mismatch in the duplex. (a) NaCl, MES buffer 
pH 6, 80°C for 10 min then to 25°C over 3 h. (b) DAA 23 or 24, CuSO4, sodium ascorbate, 25°C, 24 h. 
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2.5.5 Biochemical studies with O6-G alkylated substrates 
The developed post-synthetic alkylation method allows the ready synthesis of O6-G derivatives. In the next 
step we investigated two open questions in the biochemistry of these adducts: the repair of O6-G 
modification by the alkylguanine transferase (AGT) and the incorporation of O6-G modified triphosphates 
during DNA replication. 
AGT proteins are found in all domains of life and play an important role in repairing genomic O6-G 
damage.153-155 This protein is able to repair O6-(alkyl)-G adducts from single and preferentially from double-
stranded DNA. Removing of the alkyl group from the O6 position can be essential to prevent mutagenesis. 
DNA replication relies on proper Watson-Crick base pairing of the nucleobases. For example, during 
replication T can be misincorporated opposite O6-G adducts due to altered proton donor and acceptor 
properties of the modified nucleobase (Figure 31A). This misincorporation can be highly mutagenic if not 
repaired because after a second cycle of replication a permanent G to A transition mutation takes place. 
AGT can prevent this point mutation by nucleophilic attack of the active site cysteine residue that removes 
the modification in a SN2 manner and restores the native guanine. This process is irreversible and therefore 
hAGT is a suicide protein that is degraded from the cell after it performs repair.  
Diazotized peptides produced by bacteria may be a possible alkylation source for nucleic acid 
modification.156-158 Therefore, we investigated whether the amide functionality can also be repaired by the 
alkyl guanine transferase protein hAGT (Scheme 12A-C). Treatment of the O6-(alkyl)-G adduct 39 (Table 
3, Entry 6) with the repair protein at 37°C showed the desired restoration of the natural G. The slow removal 
of the modification by hAGT was not surprising because reduced reaction rates are expected for short 
ssDNAs, due to lower binding constants to the protein.159 Nevertheless, guanine in the ssDNA 9-mer 39 
was successfully repaired and the carboxymethyl amide functionality can be added to the substrate list of 
adducts repaired by hAGT. 
52 
 
Figure 31. Two possible pathways for pyrimidine transition mutations. (A) Guanine is modified (R = methyl, ethyl 
carboxymethyl etc) at the O6-position in the DNA template and after the 2nd cycle of replication a G to A transition 
mutation may occur. D = proton Donor; A = proton acceptor. (B) The guanine triphosphate dGTP is modified (R = 
methyl, ethyl carboxymethyl etc) at the O6-position and wrong misincorporation opposite C or T led to G:A or A:G 
transition mutation after the third cycle of replication.  
Another pathway for pyrimidine transition at modified G is presented in Figure 31B. Instead of a damaged 
template the natural dGTP is modified at the O6-position and may be either incorporated opposite cytidine 
(right route) or opposite thymine (left route). Both routes lead to an A:G or G:A transition mutation after 
the third cycle of replication. To investigate if also a repair mechanism for damaged dGTP exists, we tested 
the O6-dGTP substrate 41 as a potential substrate for hAGT. Treatment of the modified triphosphate 41 
with hAGT in aqueous buffer showed 70% conversion of the starting material after 4.5 hours at 37°C 
(Scheme 12 D-E), whereas the control reaction without the enzyme showed 27 % decomposition of 
compound 41 after 6.5 hours. Unfortunately, HR-MS analysis of hAGT from the reaction mixture did not 
show the target mass for the modified protein 42. With these results in hand the question whether hAGT 
can repair O6-modified dGTPs remains unanswered. 
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Scheme 12. (A) De-alkylation of O6-G modified ssDNA 9-mer 39 with hAGT. (B) HPLC analysis of the reaction 
mixture after 0 (blue), 0.5 (red) and 4 hours (black). (C) High resolution ESI-MS from hAGT after 4 h at 37°C. (D) 
De-alkylation of O6-G modified dGTP 41 with hAGT. (E) HPLC analysis of de-alkylation reaction from after 1 and 
4.5 hours. (a) 50 mM TrisHCl buffer pH 7.6, 250 mM NaCl, 5 mM DTT, 37°C. 
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We tested than the impact of O6-alkylation on nucleotide incorporation during DNA synthesis and 
characterized O6-modified dGTPs as polymerase substrates. We synthesized the O6-modified dGTPs 41 
and 43 with our copper(I) carbenoid methodology. Commercial dGTP was selectively alkylated at the O6-
position with EDA as carbene source. Hydrolysis of the ethylester with lithium hydroxide yielded the 
carboxymethyl (cm) modified dGTP 43 in two steps. Our methodology provides the alkylated O6-dGTP 
motifs 41 and 43 very efficiently without the use of any protecting group or the need of a phosphorylation 
step. The O6-G modified nucleosides and triphosphates reported in the literature were synthesized in a 
laborious four to seven steps.160-163 Especially, for the synthesis of O6-alkylated dGTPs the triphosphate is 
always introduced at the end with strong electrophilic phosphorous reagents resulting in low yield due to 
side product formation.98 
 
Scheme 13. Synthesis of dO6-(alkyl)-GTPs 41 and 43 with Cu(I) carbenoid chemistry. (a) EDA, CuSO4, sodium 
ascorbate, MES buffer pH 6, H2O, rt, 30 min (65 %). (b) LiOH, H2O, rt. 1h (57 %). 
To study the incorporation of the O6-G adducts 41 and 43 in DNA synthesis, we planned single nucleotide 
primer extension experiments (PEX) using DNA polymerases (Scheme 14A). The primer for PEX is usually 
labeled with a fluorophore or radiolabel. Synthesis of the primer was planned with OSPS. Coupling of an 
O6-G modified phosphoramidite 44 bearing the fluorophore, lissamine would introduce the desired label to 
the primer (Scheme 14B). Commercial Sulforhodamine B acid chloride was treated with ethylenediamine 
to yield the corresponding sulfonamide 45 (Scheme 14C). Commercial guanosine was alkylated with 
copper(I) carbene derived from EDA to yield the O6-G adduct 46. Unfortunately, subsequent treatment with 
sulfonamide 45 did not yield the desired aminolysis product 47 (Scheme 14C). Several conditions (different 
solvents and bases) were investigated, however, the two derivatives 45 and 46 could not be connected 
together. The strategy was changed to an alkyne functionalized inosine phosphoramidite 50 that should be 
introduced in the OSPS cycle and post-labeled with a lissamine azide derivative via click reaction (Scheme 
15A). Commercial inosine was efficiently alkyne functionalized at the O6-position to yield 48 (Scheme 
15B). However, dimethoxytrityl (DMT) protection of the O6-modified inosine derivative 48 yielded only 4 
% of the DMT protected product 49.  
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Scheme 14. (A) Primer extension experiments of O6-(alkyl)-dGTPs using DNA polymerases. (B) Structure of O6-
(lissamine)-G phosphoramidite 44. (C) Synthetic strategy for O6 lissamine functionalized guanosine 47 via aminolysis 
of lissamine sulfonamide 45 with O6-G adduct 46. (a) ethylenediamine, DMAP, NEt3, CH2Cl2, rt, on (55 %). (b) EDA, 
CuSO4, sodium ascorbate, MES buffer pH 6, H2O, 4 % (v/v) DMSO, rt, 5h (56 %). (c) Na2CO3, MeOH, reflux, 1.5 d 
or Na2CO3 in H2O/MeCN, rt, 2d or in H2O/MeCN, rt, 2d. 
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Scheme 15. (A) Post-functionalization of DNA via click reaction with Lissamine azide derivative. (B) Synthetic 
strategy for O6 alkyne functionalized inosine phosphoramidite 50. (a) 25, CuSO4, sodium ascorbate, MES buffer pH 
6, H2O, 4 % (v/v) DMSO, rt, 4 h (72 %). (b) DMT-Cl, pyridine, rt, on (4-7 %). 
 
In collaboration with the group of Prof. Sturla we could finally investigate the incorporation of O6-modified 
dGTPs 41 and 43 in primer (5`-end [y-32P] radiolabeled) extension catalyzed by the KlenTaq mutant: 
KTqM747K. This enzyme is reported to bypass several modifications.164-166 Several unmodified 28-mer 
ssDNA templates (5`-ATT ATG CTG AGT GAT ATC CCT CTX CTC A) with X = G, A, T or C were 
annealed with the complementary 5`-end [y-32P] radiolabeled 23-mer primer (5`-AGA GGG ATA TCA 
CTC AGC ATA AT) and treated with the O6-(alkyl)-dGTPs 41 and 43 (Figure 32A). The primer extension 
reaction were quenched after 10 min at 55°C and separated by denaturing polyacrylamide gel 
electrophoreses and visualized with a phosphor imager (Figure 32B). Both O6-(alkyl)-dGTPs 41 and 43 
were efficiently incorporated opposite C but also to a smaller extent opposite T. After successful 
incorporation of the O6-(alkyl)-dGTPs opposite T the polymerase stalled, however, the O6-(alkyl)-G:C 
mismatch was tolerated and a second extension occurred. These experiments demonstrated as a proof-of-
concept that O6-(cm)-G damaged nucleotides are substrates for DNA replication and can be incorporated 
in DNA synthesis.  
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Figure 32. (A) single nucleotide primer extension experiment with O6-(alkyl)-dGTPs 41 and 43 opposite DNA 
templates with X = G, A, T, C catalyzed by KTqM747K. Reaction were run at 55°C for 10 min and contained 50 µM 
O6-(alkyl)-dGTPs 41 and 43. (B) PAGE analysis of the primer extension experiments with M corresponding to blank 
primer. 
 
As a next step, a full study about how different human polymerases deal with a variety of carboxymethyl 
damaged DNA during replication was planned in collaboration with the group of Prof. Sturla. Post-synthetic 
modification of ssDNA 13-mer 51 using our copper(I) carbene chemistry should yield the O6-G adduct and 
subsequent ligation elongates the DNA strand to a 42-mer. Finally the different O6-G modifications are 
introduced by amide coupling (Scheme 16).  
Treatment of commercially available ssDNA 13-mer 51 with copper(I) carbene derived from EDA and 
subsequent hydrolysis of the ethyl ester with lithium hydroxide yielded the O6-cm-DNA 13 mer 53. The 
ligation with the commercial 5`-phosphorylated DNA 29-mer 54 was done by Dr. Zhanybekova. 
Unfortunately, the ligation was pretty inefficient. The reason for this inefficiency could be the low quality 
of the commercial 5`-phosphorylated DNA 29-mer 54: around 50 % corresponded to the non- 
phosphorylated species. The subsequent amide couplings were investigated although purification of the 
ligation mixture was unsuccessful. Treatment of the ligation mixture with three different amino acids 
glycine (Gly), alanine (Ala) and phenylalanine (Phe) in the presence of a large excess of coupling reagents, 
however, yielded only the modified ssDNA 13-mer (highlighted with the dashed box) instead of the 
modified 42-mer. These results showed that the amide coupling was successful; however the ligation step 
was too inefficient and has to be improved. Therefore, the question whether these amide functionalities are 
substrates for human DNA polymerase is still not answered. 
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Scheme 16. (A) Synthesis of O6-G modified ssDNA 42-mer via ligation of O6-(cm) DNA 13-mer 53 with commercial 
5`phosphorylated 29-mer £130 and subsequent amide coupling with different AA such as Gly, Ala and Phe. (B) HPLC 
traces of the alkylation reaction mixture after 1 h (red) and hydrolysis of the ethyl ester after 1h (black). (a) EDA, 
CuSO4, sodium ascorbate, Mes buffer pH 6, H2O, 25°C. (b) LiOH, H2O, 25°C, 1 h. (c) 1000 eq. EDC, 1000 eq, HOBt, 
1000 eq amino acid (AA), 1000 eq. DIPEA, 25°C, on. 
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2.6 Conclusion and future directions 
A new way to create O6-G adducts post-synthetically from nucleic acids of different size starting from 
mono- or triphosphates to longer oligonucleotides was discovered. The method allows an efficient and clean 
modification of the O6-G position using CuSO4 (reduced with sodium ascorbate) and α-diazoacetates or 
acetamides. The ability to synthesize precisely defined O6-G adducts in high yields allowed studies in their 
biochemistry. This we presented with the first synthesis of O6-(cm)-dGTP and the first analysis of its effect 
on DNA replication.  
The developed method, the copper(I) catalyzed O6-G alkylation, represent an easy synthesis set-up 
including readily available material. The stability of α-diazoacetates is high enough that some are 
commercially available, otherwise an easy two step protocol facilitates the synthesis of nearly any α-
diazoester. To study O6-G adducts in biology or biotechnology a ready synthesis of these compounds is 
needed. The method we described here is the simplest reported so far. 
 
Future work on the copper(I) carbenoid system could be continued in the following directions: 
(a) Modification of longer oligonucleotides bearing several reactive guanines, such as tRNAs.  
- Reverse transcription of the O6-G adducts with DNA polymerase enzymes that do not tolerate 
the modification site and result in a replication stop. Length directed separation of the DNA 
fragments using electrophoresis would provide an insight about the modification site. 
- Digestion to shorter oligonucleotides or nucleotides using enzymes without affecting the 
alkylation site. Comparing the digestion profile with the unmodified oligonucleotide  
(b) Synthesis of other biologically relevant O6-G adducts  
- Test the substrates as either templates or O6-modified dNTPs in primer extension experiments 
using human DNA polymerases 
- Test the O6-G adducts as substrates for de-alkylation reactions with hAGT 
(c) Studying the catalyst scope with the use of enzymes that contain copper(I). 
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2.7 Experimental  
2.7.1 General Experimental Information and Synthetic Schemes 
All reagents and solvents used were of analytical grade. Buffers were prepared with ultrapure water. All 
chemicals were purchased from Sigma-Aldrich, Alfa Aesar or Acros and used as received. Unlabeled 
dNTPs were obtained from Invitrogen and [γ-32P]ATP was purchased from PerkinElmer Life Sciences. 
KTqM747K DNA polymerase was purchased from myPOLS Biotec. Oligonucleotides used in primer 
extension experiments were obtained from VbC Biotech. Solid-phase oligonucleotide synthesis was carried 
out on an Expedite 8909 nucleic acid synthesis system (PerCeptiveBiosystems) on 1µmol CPG columns 
using standard phosphoramidite chemistry with 0.3 M 5-benzylthio-1-H-tetrazole as activator. Purification 
was carried out on a preparative Shimadzu UFLC system with a Gemini-NX 5 µm C18 21.2 x 250 mm 
(Phenomenex) column using 100 mM triethylammonium acetate (TEAA pH 7.25)/acetonitrile (MeCN) 
gradients as mobile phase. Elution was carried out at a flow rate of 20 mL/min monitored at 254 nm using 
Method A: 0-15 % MeCN in 30 min, 15-95 % MeCN in 10 min, 95 % MeCN for 5 min for short ssDNA 
and Method B: 0-12% MeCN in 25 min, 12-16 % MeCN in 10 min, 16-95 % MeCN in 5 min, 95 % MeCN 
for 5 min for longer ssDNA. Alkylation and de-alkylation reactions were analyzed on an analytical 
Shimadzu UFLC system or Agilent 1100 LC system with an Eclipse XDB-C8 4.6 x 150 mm (Agilent) 
column using 100 mM TEAA/MeCN gradient. Elution was carried out at a flow rate of 1 mL/min using 
Method C: 0-16 % MeCN in 18 min, 16-80 % MeCN in 5 min, 80 % MeCN for 3 min with peak detection 
at 254 nm. Purification was carried out on the preperative Shimadzu UFLC system as described above using 
Method D: 0-16 % MeCN in 20 min, 16-20 % MeCN in 5 min, 20-95 % in 1 min, 95 % MeCN for 5 min. 
Aqueous product fractions were freeze dried on a Christ Alpha 2-4 LDplus flask lyophilizer at 0.1 mbar. 
1H, 13C and 31P-NMR, HMQC and HMBC spectra were acquired on a BrukerAvance (400, 500 or 600 MHz 
proton frequency) spectrometer at 298.15 K. Chemical shifts relative to TMS were referenced to the 
solvent’s residual peak and are reported in ppm. ESI MS spectra were measured on a Bruker 
Esquire3000plus mass spectrometer by direct injection in positive polarity of the ion trap detector. 
Polyacrylamide gel electrophoresis (PAGE): PAGE was done with 12.5 % gel (29:1 w/w 
acrylamide/bisacrylamide) in 1×TBE (89 mM Tris-borate, 2 mM EDTA) with Orange G, Bromophenol 
blue and XylenCynol FF as tracer dyes. The samples were prepared by mixing 5 µL of sample with 2.5 µL 
4×TBE in 40 % (v/v) glycerol. Five microliters from the resulting mixtures were then applied on the gel 
without further pre-treatment. Trace dye mixtures were applied on separate wells. The gels were run at 30 
V/cm until the Orange G migrates to approximately 1 cm from the end of the gel. The gels were then washed 
briefly with deionized water and soaked with Coomassie Brilliant Blue R-250 for 1 h, destained and 
visualized using Bio-RadChemiDoc MP system equipped with Image Lab 5.0 software.  
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Synthetic Schemes: 
 
Scheme 17. Synthesis of O6 modified GMP 1, dGMP 2, IMP 3, dGTP 4 and GTP 5 using Cu(I) carbene chemistry. a) 
20 mol% Cu(I), MES buffer pH 6, H2O, 25°C, 1 h, 1: 92 %, 2: 86 %, 3: 81 %, 4: 73 %, 5: 65 %.  
 
Scheme 18. Synthesis of O6-(cm)dGTP 43. a) LiOH, 1 h, 25°C, 57 %. 
 
2.7.2 Chemical synthesis  
 
General Procedure: Synthesis of Diazoacetamides (DAAs) 
A: To a solution of bromacetyl bromide (BrAcBr) in dry CH2Cl2, amine (freshly filtered over neutral 
aluminium oxide) was added at -60°C. The cooling bath was removed and the reaction mixture was stirred 
for an additional hour. Water was added and the reaction mixture was extracted with EtOAc. The solvent 
was removed under reduced pressure and the residue purified by flash chromatography on Si60 in 
cyclohexane and EtOAc.  
 
B: To a solution of bromoacetamide derivative in THF, N,N-ditosylhydrazine (TsNHNHTs) was added.  
The reaction mixture was cooled to 0°C, DBU was added and the mixture was stirred for 20 min at room 
temperature. Saturated NaHCO3 was added while precipitation was observed. The mixture was centrifuged 
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at 4400 g for 2 min. The supernatant was extracted with Et2O (3 x 10 mL). The combined organic layers 
were dried over Na2SO4, filtered and the residue purified by flash chromatography on Si60 in CH2Cl2 and 
MeOH (prior to purification, the column was neutralized with two column volumes CH2Cl2 containing 5 % 
NEt3).  
 
2-bromo-N,N-diisopropylacetamide (20). According to the general procedure A BrAcBr (100 µL, 1.15 
mmol) and N,N-diisopropylamine (324 µL, 2.30 mmol) were reacted to yield 20 as colorless 
liquid (133 mg, 52 %). The analytical data were in agreement with literature.2 1H-NMR (500 
MHz, CDCl3) δ/ppm: 3.96 (dt, J = 13.2, 6.7 Hz, 1H), 3.82 (s, 2H), 3.43 (p, J = 7.2, 6.6 Hz, 1H), 1.38 (d, J 
= 6.9 Hz, 6H), 1.25 (d, J = 6.7 Hz, 6H). 13C-NMR (126 MHz, CDCl3) δ/ppm: 165.57, 50.62, 46.47, 28.71, 
20.78, 20.20.  
 
2-bromo-1-(piperidin-1-yl)ethan-1-one (21). According to the general procedure A, BrAcBr (100 µL, 
1.15 mmol) and piperidine (228 µL, 2.30 mmol) were reacted to yield 21 as colorless liquid 
(74.5 mg, 31 %). The analytical data were in agreement with the literature.3 1H-NMR (500 
MHz, CDCl3) δ/ppm: 3.86 (s, 2H), 3.58 – 3.52 (m, 2H), 3.50 – 3.40 (m, 2H), 1.65 (p, J = 2.8 
Hz, 4H), 1.56 (t, J = 5.6 Hz, 2H). 13C-NMR (126 MHz, CDCl3) δ/ppm: 166.15, 48.05, 43.39, 26.31, 26.28, 
25.49, 24.39.  
 
2-bromo-N-(but-3-yn-1-yl)acetamide (22). According to the general procedure A, BrAcBr (252 µL, 2.90 
mmol) and 1-amino-3-butyne (250 µL, 2.90 mmol) were reacted to yield 22 as colorless 
liquid (415 mg, 75 %). The analytical data were in agreement with the literature.3 1H-
NMR (250 MHz, CDCl3) δ 6.84 (s, 1H), 3.91 (s, 1H), 3.46 (q, J = 6.3 Hz, 1H), 2.45 (td, J = 6.4, 2.6 Hz, 
1H), 2.05 (t, J = 2.6 Hz, 1H). 
 
2-diazo-N,N-diisopropylacetamide (23). According to the general procedure B, 20 (123.3 mg, 555 µmol), 
TsNHNHTs (378 mg, 1.11 mmol) and DBU (414 µL, 2.78 mmol) were reacted to yield 23 as 
yellow liquid (56.0 mg, 60 %). 1H-NMR (500 MHz, CDCl3) δ/ppm: 4.94 (s, 1H), 3.65 (p, J = 
7.2 Hz, 2H), 1.28 (s, 12H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 164.68, 47.83, 47.10, 21.25. HRMS (ESI): 
C8H15N3NaO+ calcd.: 192.1107, found: 192.1110. 
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2-diazo-1-(piperidin-1-yl)ethan-1-one (24). According to the general procedure B, 21 (66.3 mg, 322 
µmol), TsNHNHTs (219 mg, 643 µmol) and DBU (240 µL, 1.61 mmol) were reacted to 
yield 24 as yellow waxy solid (29.5 mg, 60%). 1H-NMR (500 MHz, CDCl3) δ/ppm 1H NMR 
(400 MHz, CDCl3) δ/ppm: 4.99 (sbr, 2H), 3.35 (sbr, 4H), 1.67 – 1.62 (m, 2H), 1.58 – 1.51 
(m, 4H). 13C-NMR (126 MHz, CDCl3) δ/ppm: 164.34, 59.87, 48.39, 46.31,43.40,25.88,24.47. HRMS 
(ESI): C7H12N3O+ calcd.: 154.0975, found: 154.0976. 
 
2-diazo-1-(piperidin-1-yl)ethan-1-one (25). According to the general procedure B, 22 (414 mg, 2.18 
mmol), TsNHNHTs (1.48 g, 4.36 mmol) and DBU (1.63 mL, 10.9 mmol) were reacted 
to yield 25 as yellow waxy solid (102 mg, 34%). 1H-NMR (500 MHz, CDCl3) δ/ppm 
1H NMR (400 MHz, CDCl3) δ/ppm: 5.42 (sbr, 1H), 4.75 (s, 1H), 3.45 (q, J = 6.2 Hz, 2H), 2.42 (td, J = 6.3, 
2.6 Hz, 2H), 2.01 (s, 1H). 13C-NMR (126 MHz, CDCl3) δ/ppm: 165.84, 81.60, 70.19, 47.34, 38.62, 19.95. 
LRMS (ESI): C6H7N3NaO+ calcd.: 160.0, found: 159.8. 
 
O6-(ethylcm)I (31) (via pathway A, Figure 28). To a solution of CuSO4 (27.9 mg, 112 µmol) in H2O (94 
mL) and MES buffer (10.8 mL), inosine (150 mg, 559 µmol, dissolved in 7 mL 
DMSO), EDA (676 µL, 5.59 mmol) and ascorbate (111 mg, 559 µmol) were 
added and the reaction mixture stirred at room temperature. Analysis of the 
reaction mixture after 5 h via RP-HPLC showed 66% conversion of inosine. The 
reaction was stopped, lyophilized and taken up in CH2Cl2 while a precipitate was 
observed. The resulting suspension was centrifuged at 4400 g for 5 min followed by lyophilizing of the 
supernatant. The residue was purified by flash chromatography on Si 60 in CH2Cl2 and MeOH. Residual 
MeOH sticking to the product was removed by adding H2O and lyophilization to obtain 31 as white solid 
(119 mg, 60 %). 1H-NMR (400 MHz, MeOD) δ/ppm: 8.59 (s, 1H), 8.48 (s, 1H), 6.10 (d, J = 5.8 Hz, 1H), 
5.19 (s, 2H), 4.74 (t, J = 5.4 Hz, 1H), 4.36 (dd, J = 5.1, 3.3 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 4.17 (q, J = 
3.1 Hz, 1H), 3.91 – 3.3.88 (m, 1H), 3.78 – 3.753 (m, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
MeOD) δ/ppm: 169.76, 160.99, 153.06, 152.70, 144.35, 122.65, 91.01, 87.79, 75.73, 72.29, 64.05, 63.12, 
62.44, 14.40. HRMS (ESI): C14H18N4NaO7+ calcd.: 377.1068, found: 377.1073.  
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Figure 33. Important HMBC correlations of O6-ethylcmI 31 synthesized via pathway A (Figure 28).        
 
2`, 3`, 5` (TBDMS) 6-chloropurine riboside (32). To a solution of 6-chloropurine riboside (108 mg, 376 
µmol) in dry DMF (1.5 mL), imidazole (256 mg, 3.76 mmol) and TBDMS-Cl (283 
mg, 1.88 mmol) were added and the reaction stirred at room temperature for 22 h. 
The reaction was diluted with CH2Cl2 (5 mL) and H2O (5 mL). The water layer 
was extensively extracted CH2Cl2 (5 x 5 mL) and the combined organics were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue 
was purified by flash chromatography on Si 60 in cyclohexane/EtOAc to obtain 32 as white solid (182 mg, 
289 µmol, 77 %). 1H-NMR (250 MHz, CDCl3) δ/ppm: 8.8 (s, 1H), 8.51 (s, 1H), 6.08 (d, J = 4.6 Hz, 1H), 
4.54 (t, J = 4.5 Hz, 1H), 4.27 (t, J = 4.0 Hz, 2H), 4.12 (dd, J = 6.1, 3.2 Hz, 1H), 3.98 (dd, J = 11.5, 3.5 Hz, 
1H), 3.76 (dt, J = 11.6, 2.2 Hz, 1H), 0.91 (s, 9H), 0.88 (s, 9H), 0.74 (s, 9H), 0.08  (m, 12H), -0.07 (s, 3H), 
-0.28 (s, 3H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 152.08, 151.65, 151.14, 144.21, 132.23, 88.73, 85.87, 
76.54, 71.96, 62.54, 26.26, 25.97, 25,76, 18.71, 18.22, 17.97, -4.24, -4.54,-4.91, -5.19. HRMS (ESI): 
C28H53ClN4NaO4Si3+ calcd.: 651.2955, found: 651.2956.  
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2`, 3`, 5` (TBDMS) O6-(ethylcm)I (33). NaH (15.9 mg, 397 µmol, 2.50 eq.) was placed in a pressure tube 
and THF (1.5 mL) was added. Then ethyl glycolate (82.7 mg, 794 µmol) 
was added and the reaction mixture stirred for 30 min at room temperature. 
Then chloropurine riboside derivative 32 (100 mg, 159 µmol) was added 
and the reaction heated to reflux for 4 h. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography on 
Si 60 cyclohexane/EtOAc to obtain 33 as white solid (53.0 mg, 76.0 µmol, 48 %). 1H-NMR (500 MHz, 
CDCl3) δ/ppm: 8.47 (s, 1H), 8.39  (s, 1H), 6.08 (d, J = 4.7 Hz, 1H), 5.12 (s, 1H), 5.10 (s, 1H), 4.57 (t, J = 
4.4 Hz, 1H), 4.32 (t, J = 4.2 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 4.14 (td, J = 3.9, 2.5 Hz, 1H), 4.04 (dd, J = 
11.4, 3.7 Hz, 1H), 3.79 (dd, J = 11.5, 2.6 Hz, 1H), 1.25 (m, 2H), 0.95 (s, 9H), 0.92 (s, 9H), 0.80 (s, 9H), 
0.14 (s, 3H), 0.13 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), -0.03 (s, 3H), -0.19 (s, 3H). 13C-NMR (101 MHz, 
CDCl3) δ/ppm: 168.19, 159.52, 152.25, 151.8, 141.64, 121.47, 88.80, 85.41, 76.39, 71.69, 63.14, 62.42, 
61.45, 26.27, 25.99, 25.82, 18.72, 18.22, 18.00, 14.25, -4.21, -4.57, -4.60, -4.84, -5.18, -5.25. HRMS (ESI): 
C32H60N4NaO7Si3+ calcd.: 719.3662, found: 719.3672. 
 
O6-(ethylcm)I (31) (pathway B, Figure 28). The TBDMS protected inosine derivative 33 (26.0 mg, 37.0 
µmol) was co-evaporated with pyridine (2 mL), dissolved in pyridine (0.5 mL) 
followed by dropwise addition of hydrogen fluoride pyridine (73.4 µL, 530 
µmol) and the reaction mixture was stirred at room temperature for 15 h. The 
solvent was removed under reduced pressure and the residue purified by flash 
chromatography Si60 CH2Cl2/ MeOH. Residual pyridine was co-evaporated with 
toluene then H2O was added and the residue was lyophilized to obtain 31 as yellowish solid (13.2 mg, 37.0 
µmol, 99%.). 1H-NMR (500 MHz, MeOD) δ/ppm: 8.59 (s, 1H), 8.48 (s, 1H), 6.10 (d, J = 5.8 Hz, 1H), 5.19 
(s, 2H), 4.74 (t, J = 5.5 Hz, 1H), 4.36 (dd, J = 5.1, 3.3 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 4.17 (q, J = 3.1 
Hz, 1H), 3.90 (dd, J = 12.4, 2.8 Hz, 1H), 3.77 (m, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C-NMR (101 MHz, 
MeOD) δ/ppm: 169.76, 160.99, 153.06, 152.7, 144.35, 122.65, 91.01, 87.79, 75.73, 72.29, 64.05, 63.12, 
62.44, 14.40. HRMS (ESI): C14H18N4NaO7+ calcd.: 377.1068, found: 377.1071. 
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General Procedure for Cu(I)-catalyzed monophosphates (MPs) and triphosphates (TPs) alkylation 
using EDA (small scale) 
Typically 20 µL of total reaction volume contained 1 mM of CuSO4, 5 mM of MP or TP, 100 mM MES 
buffer, 50 mM EDA. Stock solutions of each compound were prepared and combined in an Eppendorf tube 
in the given order. The reactions were monitored by injection of 1 µL of the reaction mixture into RP-HPLC 
using Method C. The conversion of MP or TP`s were directly calculated from the corresponding peak areas 
in the HPLC traces (Table 2). The peaks were separated using Method C (6 µL injection of reaction 
mixture), collected and analyzed by ESI-MS/MS. 
 
Stock solutions: CuSO4: 5 mM in H2O; MP/TP: 50 mM in H2O; MES buffer: 500 mM in H2O, pH 6 
EDA: 250 mM in DMSO; ascorbate: 100 mM in H2O  
 
General Procedure for Cu(I)-catalyzed MP and TP alkylation using EDA (big scale) 
To a solution of CuSO4 (1 mM) in H2O (degassed), MES buffer stock solution (100 mM), MP/TP (5 mM), 
EDA (50 mM) and ascorbate (5 mM) were added and the reaction mixture was stirred at room temperature 
for 1 h. The reaction mixture was lyophilized and the residue was purified by preparative RP-HPLC using 
Method D. The corresponding product fractions were combined and lyophilized. The residue was dissolved 
in H2O and NaClO4 (15 eq.) was added. The mixture was stirred for 16 h at room temperature followed by 
addition of acetone (400 % v/v). The mixture was centrifuged at 4400 x g for 3 min. The supernatant was 
carefully discarded and the pellet was dissolved in ultra pure H2O and lyophilized to give the final modified 
MP/TP. 
 
O6-(ethylcm)dGMP (35). According to the general procedure CuSO4 (5.62 mg, 22.5 µmol), dGMP (50.0 
mg, 112 µmol), EDA (136 µL, 1.12 mmol) and ascorbate (22.3 mg, 112 
µmol) in H2O (25.5 mL) and MES buffer stock solution (51.0 µL) were 
reacted to yield 35 as white solid (41.8 mg, 86 %.). 1H-NMR (500 MHz, 
MeOD) δ/ppm: 8.27 (s, 1H), 6.34 (t, J = 6.7 Hz, 1H), 5.04 (s, 2H), 4.71 (s, 
br, 1H), 4.22 (q, J = 7.1 Hz, 2H), 4.10 (s, br, 1H), 4.01 (s, br, 2H), 2.84 (dt, 
J = 13.2, 6.5 Hz, 1H), 2.38 (ddd, J = 13.2, 6.0, 3.1 Hz, 1H), 1.25 (t, J = 7.1 Hz, 2H). 13C-chemical shifts 
were extracted from 2D HMQC and HMBC spectra (500 MHz, MeOD) δ/ppm: 168.81, 159.59, 153.94, 
139.15, 86.98, 83.79, 71.84, 63.88, 61.91, 60.79, 38.98, 13.02. 31P-NMR (202 MHz, MeOD) δ/ppm: 5.05 
(s, 1P). HRMS (ESI): C14H19N5Na2O9P+ calcd.: 478.0710, found: 478.0716. 
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O6-(ethylcm)GMP (35b). According to the general procedure CuSO4 (4.78 mg, 19.2 µmol), GMP (50.0 
mg, 95.8 µmol), EDA (116 µL, 958 µmol), ascorbate (18.98 mg, 95.8 µmol) 
in H2O (24.7 mL) and MES buffer stock solution (50.0 µL) were reacted and 
purified to yield 35b as white solid (45.7 mg, 92 %.). 1H-NMR (500 MHz, 
MeOD) δ/ppm: 8.32 (s, 1H), 5.97 (d, J = 5.8 Hz, 1H), 5.06 (s, 2H), 4.77 (t, 
J = 5.4 Hz, 1H), 4.49 (dd, J = 5.1, 3.1 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 4.21 
(s, 1H), 4.12 – 4.04 (m, 1H), 1.27 (s, 3H). 13C-chemical shifts were extracted from 2D HMQC and HMBC 
spectra (500 MHz, MeOD) δ/ppm: 168.82, 159.63, 154.34, 139.34, 113.68, 87.81, 84.92, 74.21, 71.14, 
63.67, 61.96, 60.91, 13.08. 31P-NMR (202 MHz, MeOD) δ/ppm: 4.89 (s, 1P). HRMS (ESI): 
C14H19N5Na2O10P+ calcd.: 494.0659, found: 494.0668. 
 
O6-(ethylcm)IMP (35c). According to the general procedure CuSO4 (4.73 mg, 18.9 µmol), IMP (50.2 mg, 
94.7 µmol), EDA (115 µL, 947 µmol), ascorbate (18.7 mg, 94.7 µmol) in 
H2O (25.4 mL) and MES buffer stock solution (51.0 µL) were reacted to 
yield 35c as white solid (33.1 mg, 81 %.). 1H-NMR (500 MHz, MeOD) 
δ/ppm: 8.88 (s, 1H), 8.47 (s, 1H), 6.21 (d, J = 5.6 Hz, 1H), 5.17 (s, 2H), 4.78 
(t, J = 5.1 Hz, 1H), 4.49 (sbr, 1H), 4.29 – 4.17 (m, 3H), 4.07 (sbr, 2H), 1.25 
(t, J = 7.1 Hz, 3H). 13C-chemical shifts were extracted from 2D HMQC and HMBC spectra (500 MHz, 
MeOD) δ/ppm: 168.51, 159.10, 152.44, 151.45, 143.06, 87.92, 85.39, 75.16, 71.23, 63.64, 62.61, 61.0, 
13.03. 31P-NMR (202 MHz, MeOD) δ/ppm: 4.96 (s, 1P). HRMS (ESI): C14H19N4NaO10P+ calcd.: 457.0731, 
found: 457.0730. 
 
O6-(ethylcm)dGTP (41). According to the general procedure CuSO4 (5.24 mg, 20.9 µmol), dGTP (70.0 
mg, 101 µmol), EDA (122 µL, 1.01 mmol), ascorbate (20.0 mg, 
101 µmol) in H2O (22.9 mL) and MES buffer stock solution (46.0 
µL) were reacted to yield 41 as white solid (39 mg, 65 %). 1H-
NMR (600 MHz, D2O) δ/ppm: 8.28 (s, 1H), 6.41 (t, J = 6.8 Hz, 
1H), 5.12 (s, 1H), 5.11 (s, 1H), 4.83 (dt, J = 7.0, 3.6 Hz, 1H), 4.32 
– 4.27 (m, 3H), 4.24 (ddd, J = 10.4, 6.2, 4.1 Hz, 1H), 4.21 – 4.15 (m, 1H), 2.83 (dt, J = 13.8, 6.8 Hz, 1H), 
2.54 (ddd, J = 14.1, 6.3, 3.6 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H). 13C-chemical shifts were extracted from  2D 
HMQC and HMBC spectra (600 MHz, D2O) δ/ppm: 171.02, 159.71, 153.64, 139.38, 114.1, 85.72, 83.43, 
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70.84, 65.27, 63.26, 62.74, 38.50, 13.22. 31P-NMR (243 MHz, D2O) δ/ppm: -6.74 (s, 1P), -10.9 (d, J = 19.4 
Hz, 1P), -22.04 (s, 1P). HRMS (ESI): C14H19N5Na4O15P3+ calcd.: 681.9676, found: 681.9685. 
 
O6-(ethylcm)GTP (41b). According to the general procedure CuSO4 (6.15 mg, 24.6 µmol), GTP (70.0 mg, 
118 µmol), EDA (143 µL, 1.18 mmol), ascorbate (23.5 mg, 118 
µmol) in H2O (26.7 mL) and MES buffer stock solution (54.0 µL) 
were reacted to yield 41b as white solid (53.2 mg, 73 %). 1H-
NMR, peak broadening caused by stacking of compound 41b in 
D2O (400 MHz, D2O) δ/ppm: 8.40 (sbr, 1H), 6.11 (sbr, 1H), 5.14 
(sbr, 2H), 4.56 (sbr, 1H), 4.37 (sbr, 1H), 4.36 – 4.08 (m, 5H), 1.24 (t, J = 6.6 Hz, 3H). 13C-chemical shifts 
extracted from 2D HMQC and HMBC spectra,  (600 MHz, D2O) δ/ppm: 173.78, 84.66, 74.42, 71.15, 66.06, 
64.19, 63.29, 30.85, 13.78 (four carbon signals could not be detected due to the peak broadening). 31P-NMR 
(243 MHz, D2O) δ/ppm: -5.39 (sbr, 1P), -10.49 (sbr, 1P) ), -19.39 (sbr, 1P). HRMS (ESI): C20H38N6O16P3+ 
calcd.: 711.1552, found: 711.1551. 
 
O6-(cm)dGTP (43). O6-(ethylcm)dGTP 41 (15.3 mg, 22.5 µmol) was placed in an Eppendorf tube (0.5 
mL) dissolved in 1M LiOH (33.7 µL, 33.7 µmol) and stirred at 
25°C. The reaction mixture was monitored by RP-HPLC using 
method C. After 1 h full conversion of the starting material was 
observed. The mixture was freeze dried and purified by preperative 
RP-HPLC using method D. The corresponding fraction were 
combined and lyophilized. The residue was dissolved in H2O (600 µL) and NaClO4 (41.1 mg, 338 µmol,) 
was added. The mixture was stirred for 5 h at room temperature and then acetone (4 mL) was added. The 
obtained suspension was centrifuged at 4400 g for 2 min. The supernatant was carefully discarded. The 
pellet was re-dissolved in ultra pure H2O and lyophilized to yield 6 as a white solid (12.8 mg, 57%). 1H-
NMR (400 MHz, D2O) δ/ppm: 8.35 (sbr, 1H), 6.40 (d, J = 7.7 Hz, 1H), 4.83 (s, 2H), 4.33 – 4.06 (m, 3H), 
2.81 (dd, J = 14.3, 7.3 Hz, 1H), 2.56 (d, J = 10.2 Hz, 1H). 13C-chemical shifts were extracted from  2D 
HMQC and HMBC spectra (600 MHz, D2O) δ/ppm: 176.20, 160.56, 138.94, 85.42, 83.21, 70.83, 65.14, 
63.34, 38.52. 31P-NMR (243 MHz, D2O) δ/ppm: -5.29 (s, 1P), -10.42 (s, 1P), -19.09 (s, 1P). HRMS (ESI): 
C18H33N6 NaO15P3+ calcd.: 689.1109, found:. 689.1107. 
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2.7.3 Alkylation of ssDNA catalyzed by Cu(I) carbenes 
Synthesis of ssDNA 
Solid-phase DNA synthesis was carried out on 1-µmol CPG columns using standard phosphoramidite 
chemistry with 0.3 M 5.benzylthio-1-H-tetrazole as activator. The DNA was cleaved from the resin with 
32 % (v/v) aqueous ammonia for 2 h at room temperature. Deprotection was carried out at 55°C for 18 h. 
The residue was freeze dried and purified as described in Methods A and B. The identity of all ssDNA was 
confirmed by ESI-MS or MALDI TOF MS. 
 
Cu(I)-catalyzed ssDNA O6-G modification using EDA or DAAs 
General procedure for ssDNA alkylation 
Typically 20 µL of total reaction volume contained 1 mM of CuSO4, 5 mM of ssDNA, 100 mM MES 
buffer, 50 mM EDA or DAA and 5 mM ascorbate. Stock solutions of each compound were prepared and 
combined in an Eppendorf tube in that order. The reactions were monitored by injecting 1 µL of the reaction 
mixture into RP-HPLC using Method C. The conversions of the ssDNA`s were directly calculated from the 
corresponding peak areas in the HPLC traces. The peaks were separated using Method C (6 µL injection of 
reaction mixture), collected and analyzed by ESI-MS or UPLC-MS. 
Stock solutions: CuSO4: 5 mM in H2O; MES buffer: 500 mM in H2O, pH 6; EDA: 250 mM in H2O 
containing 10 % (v/v) tBuOH or DMSO; DAA: 250 mM in DMSO or dioxane; ascorbate: 100 mM in H2O. 
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Figure 34. (A) HPLC-MS/MS analysis of O6-G alkylation of d(TGT) with DAA 23 following the general procedure 
(conversion see Table 3, Entry 1). (B) HPLC-MS/MS analysis of O6-G alkylation of d(TGT) with DAA 24 following 
the general procedure (conversion see Table 3, Entry 2). 
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Figure 35. HPLC-MS/MS analysis of O6-G alkylation reaction of d(ATGC) with DAA 23 following the general 
procedure (conversion see Table 3, Entry 3). 
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Figure 36. HPLC-MS/MS analysis of O6-G alkylation reaction of d(ATGC) with DAA 24 following the general 
procedure (conversion see Table 3, Entry 5).  
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Figure 37. HPLC-MS/MS analysis of O6-G alkylation reaction of d(ATGC) with DAA 25 following the general 
procedure (conversion see Table 3, Entry 10).  
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Figure 38. (A) HPLC-MS/MS analysis of O6-G alkylation reaction of d(TTTTGTTTT) with DAA 23 following the 
general procedure (conversion see Table 3, Entry 6). (B) HPLC-MS/MS analysis of O6-G alkylation reaction of 
d(TTTTGTTTT) with DAA 24 following the general procedure (conversion see Table 3, Entry 7). 
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Figure 39. HPLC-UPLC-MS analysis of O6-G alkylation reaction of d(AACAGTCATATCCTTA) with DAA 24 
following the general procedure (conversion see Table 3, Entry 8). 
 
2.7.4 Click reaction with alkyne O6-G modified d(ATGC) and azide biotin conjugate 
According to the genereal procedure (see section 2.2), d(ATGC) was modified using Cu(I) carbene 
chemistry and DAA 12. The alkylation product was purified using Method C and directly used for click 
reaction with azide biotin conjugate 16, synthesized by a literature known procedure.4 d(ATO6-akyneGC) 
stock solution (100 µL, 34.8 µM stock solution in 1mM TEAA buffer pH 7.25) was mixed with azide biotin 
conjugate 16 (53 µL, 100 µM stock solution in DMSO), sodium ascorbate (17.4 µL, 1 mM stock solution 
in H2O), DMSO (28.2 µL) and degassed for 30 seconds. The CuSO4 stock solution (1.40 µL, 12.5 mM 
stock solution in H2O) was added (see Figure S15, panel A) and the mixture was stirred at room temperature 
for 1 h.  Analysis of the reaction mixture by RP-HPLC using method C (40 µL injection) showed 81 % 
conversion of the starting material to the target click product (Scheme 7B).  
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2.7.5 Reparation of O6-G modified ssDNA 9-mer by hAGT 
Expression and purification of hAGT 
hAGT WT carrying an N-terminal hexa-histidine-tag was produced in Escherichia coli (E.coli) BL21 cells 
were grown in LB medium containing 50 mg/L ampicillin and 34 mg/L chloramphenicol. Protein 
expression was induced by adding 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18°C. After 
16 h at 18°C the cells were harvested, re-suspended in lysis buffer (20 mM TrisHCl pH 8 and 300 mM 
NaCl), lysed by sonication and centrifuged for 20 min at 4°C. The protein was purified by 
nickelnitrilotriaceticacid affinity (Ni-NTA) by mixing the clear lysate with Ni(II)-NTA agarose (Qiagen) 
for 20 min at 4°C. The agarose beads were washed with lysis buffer containing 10 mM and 20 mM 
imidazole. After elution of the protein using 200 mM imidazole the fractions found to contain the hAGT 
using SDS PAGE (Figure 40) were pooled and precipitated with 72% ammonium sulfate. The pellet was 
re-dissolved in urea and dialyzed in 50 mM Tris-HCl pH 7.6, 250 mM NaCl and 5 mM DTT and stored at 
-20°C. 
 
Figure 40. SDS PAGE analysis of the purified hAGT protein. 
De-alkylation of O6-G modified ssDNA 9-mer 
The O6-G modified ssDNA 9-mer 39 (79 µM) was incubated with hAGT (86 µM) for 4 h at 37°C (Scheme 
12A+B). After 0.5 and 4 h aliquots of 30 µL were taken, centrifuged, the supernatant analyzed by RP-
HPLC using Method C and the pellet re-dissolved in 0.1 % formic acid containing water and analyzed by 
HR-MS (ESI).  
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2.7.6 Single primer extension experiment with synthetic O6-(cm)dGTP  
Oligonucleotides and DNA sequences 
Table 5. Oligonucleotides and DNA sequences for primer extension experiment.  
Primer Sequence (5' - 3') 
23-mer TAA TAC GAC TCA CTA TAG GGA GA 
Templates   
28-mer G ACT CGT CTC CCT ATA GTG AGT CGT ATT A 
28-mer A ACT CAT CTC CCT ATA GTG AGT CGT ATT A 
28-mer T ACT CTT CTC CCT ATA GTG AGT CGT ATT A 
28-mer C ACT CCT CTC CCT ATA GTG AGT CGT ATT A 
 
Primer extension assays 
Radioactive labeling of primer strands at their 5’end was performed using T4 polynucleotide kinase 
(Promega) and [γ-32P]ATP following the manufacturer protocol. 1 μM of primer was annealed with 1.5 μM 
of corresponding templates at 95°C for 5 minutes followed by a slow cooling over 2 hours. Standard primer 
extension reactions (10 μL) contained 1x reaction buffer (50 mM Tris HCl pH 9.2, 16 mM (NH4)2SO4, 2.5 
mM MgCl2, 0.1% Tween 20), 5 nM DNA polymerase, 15 nM DNA (15 nM primer and 22.5 nM template), 
and 10 μM dNTPs. Reactions were initiated by adding dNTP(s) to the enzyme/DNA mixtures and allowed 
to react at 55°C for 10 min. Reactions were then quenched by the addition of 10 μL PAGE gel loading 
buffer (80% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanole FF) and the 
product mixtures were analyzed by 15% polyacrylamide/7M urea denaturing gels and subjected to 
autoradiography (Bio-Rad).  
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Chapter 3: N-heterocyclic carbene complexes  
The aim of this work was the development and synthesis of a water soluble copper complex for 
oligonucleotide modifications. In contrast to the Cu(I) catalyst in situ formed by mixing Cu(II)SO4 with 
ascorbate we sought to identify a tight-binding ligand that permanently stabilize Cu(I). Such system might 
be able to overcome challenges with oxidative damage occurring by reducing the ability of Cu(I) to activate 
oxygen. Furthermore, a tight-binding ligand makes the catalyst modular, a feature that becomes important 
for further bio-conjugation such as linking the catalyst to a short oligonucleotide and use it as guiding 
catalyst in a templated directed modification of a second oligonucleotide. 
3.1 N-heterocyclic carbene properties and their complexes 
N-heterocyclic carbene (NHC) ligands derived from imidazole (Figure 41A) are known to form strong 
bonds with transition metals and to tolerate a broad scope of functional groups,167 thereby providing an 
excellent choice of ligand to stabilize Cu(I). These carbenes form excellent catalysts for a large number of 
homogenous processes such as metathesis168, hydrosilation169, hydrogenation170, cross couplings171 and 
enatioselective transformations.172 The majority of theses transformations were traditionally carried out 
with phosphine ligands, but the use of NHC complexes has in many cases improved thermal stability as 
well as sensitivity towards oxygen. In 1962 the reactivity and stability of NHCs were investigated for the 
first time by Wanzlick.173 Six years later he reported the first synthesis of a NHC metal complex (Figure 
41B).174 Surprisingly, in following two decades NHCs were not further investigated in transition metal 
chemistry until Arduengo and coworkers isolated the first crystalline adamantyl substituted NHC (Figure 
41C).175 This bench-stable carbene showed extremely high stability in the absence of moisture and oxygen. 
 
Figure 41. (A) Structure of imidazole NHC ligand. (B) First synthesized NHC-metal complex. (C) First crystalline 
and storable NHC.   
Following Arduengo`s discovery the interest in NHCs increased dramatically and the electronic and steric 
contributions to the NHC-metal bond were investigated. At the beginning, σ-donation was considered as 
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the sole contributor to the NHC-metal bond. Later, more precise investigations showed that also π-
interactions contributed. The most important electronic contributions to the NHC-metal bond, namely σ -
donation, π -donation and π * back-donation are summarized in Figure 42. The electronic contributions to 
the metal carbene bond have also been extensively investigated by calculations.176,177 Jacobsen and 
coworkers reported that in a system with a low d electron count both π  interactions contribute to stability 
of the metal carbon bond.178 However, in a system with a high d electron count the π -back donation alone 
represents the major contribution. Measuring IR spectroscopy and X-ray diffraction are possible methods 
to compare the electronic properties of NHC ligands.179,180  
There are examples in the literature that correlate the bulkiness on the nitrogens with the stability of the 
resulting complexes.181 Bulky substituents have the additional benefit that they can protect the free carbene 
from dimerization.12 The majority of NHCs are stronger donors than the strongest phosphine ligand, 
however the behavior differences between NHCs themselves are more likely related to their steric 
properties.182 
 
3.2 N-heterocyclic copper carbene complexes as catalysts in chemical transformations 
The synthesis of the first N-heterocyclic copper carbene complex as a cationic di-carbene [(NHC)2Cu]+ was 
reported in 1993 by Arduengo (Figure 43).183  One year later, Raubenheimer presented a neutral mono-
carbene copper complex [(NHC)CuCl].184 Since then, many modifications have been made to the NHC 
ligands in order to tune their steric and electronic properties. Two structural alterations became very 
important in this field: the introduction of chiral centers to create steroeselective catalysts and the addition 
of functional groups to form, for example, chelating ligands.185 
A      
      NHC → M  σ-donation 
B     
     NHC → M  π-donation 
C  
 M → NHC  π*-back-donation 
 
 
 
 
Figure 42. MO diagram representing the electronic contributions for NHC-metal complex stability. (A) NHC to metal 
σ-donation. (B) NHC to metal π-donation. (C) Metal to NHC π*-backdonation.  
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Figure 43. Structures of the first cationic [(NHC)2Cu]+ and neutral [(NHC)CuCl] complexes. 
Since 2001 [(NHC)-CuX] complexes have been employed in homogenous catalysis. In addition to their use 
as catalysts these Cu(I) species also displayed toxicity against human tumor cells.186 The pioneering work 
of Woodward showed that these complexes can catalyze the conjugate 1,4-addition of diethylzinc to enones 
(Figure 44A).187 This conjugation proceeded with in situ catalyst formation, which still represents a 
common approach nowadays. Two years later, Buchwald and Sadighi presented a reductive addition 
catalyzed by a NHC-Cu complex (Figure 44B).188 Besides conjugate addition many other reactions are 
reported for NHC-Cu(I) catalytic systems (Figure 44C) namely hydrosilation reactions,189,190 carboxylation 
and carbonylation,191 allylic substitutions192 and the [3+2] cycloaddition of a terminal alkyne with organic 
azides.193 
 
  
Figure 44. (A). The first example of an in situ formed NHC-Cu catalyst. (B) The first example of a [(NHC)Cu] 
complex used in catalysis. (C) Various transformation catalyzed by [(NHC)Cu] complexes. a) IMes.HCl/KOtBu, 
Cu(OTf)2. (b) [(IPr)CuCl], KOtBu, polymethyldydrosilan (PMHS). 
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Related to this work [(NHC)CuX] complexes are reported to catalyse carbene transformations with diazo 
compounds. However, only a few NHC-metal systems are suitable to form the carbene from the diazo 
substrate. Pérez and Nolan developed the first carbene formation with the [(NHC)CuX] catalysts IPrCuCl  
and EDA in the presence of styrene (Figure 45).194 Suprisingly, no consumption of EDA was detected 
without the metal coordinating substrate (Figure 45). In addition, aniline, pyrolidine, ethanol and sec-
butanol were successfully alkylated under these conditions. It is likely that the [(NHC)CuCl] catalyst does 
not represent the catalytic active species, instead the nucleophilic substrate helps to form it.  
 
Figure 45. Reactions of EDA in the presence of IPrCuCl. 
Two years later Pérez and Nolan expanded the scope of carbene transfer to include C-H insertion, copper 
carbenoids derived from EDA and [(NHC)CuCl] or [(NHC)AuCl] alkylate alkanes in the presence of a 
halide scavenger.195 This methodology showed that the metal source, the counter ion and bulkiness of the 
NHC ligand have a big influence on the overall yield and regioselectivity of C-H functionalization. In 2008 
nitrene transfer to aliphatic alkenes was reported by Apella and coworkers.196 The nitrene is created in situ 
by iodoxybenzene and sulfamide (trichloroethylsulfamate ester). Further investigations into different 
[(NHC)CuX] sources showed that Cu(II) was a better catalyst for this transformation (Figure 46).  
 
Figure 46. Aziridination of aliphatic alkenes using in situ formed nitrenes catalyzed by NHC-Cu(II) complex. (a) 
IPrCu(DBM), PhI=O, H2NSO3CH2CCl3. 
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3.3 Water soluble N-heterocyclic carbene metal complexes  
As already mentioned in chapter 2 the nucleic acid modification using carbene chemistry proceed in water. 
Therefore, we were concentrated on the synthesis of NHC bearing water solubilizing functionalities. 
3.3.1 Carboxylate or sulfonate functionalized NHC and corresponding metal complexes  
The first water soluble NHC metal complex 60 was reported in 1997 by Gossen and coworkers.197 Water 
solubility was achieved by the introduction of two carboxylate side chains (Scheme 19). The carboxylates 
were formed, following rhodium complexation, via ethyl ester hydrolysis. The NHC functionalized ligand 
58 was synthesized via standard alkylation of commercially available imidazole with the corresponding 
bromo alkyl source.  
 
Scheme 19. Structure of the first water soluble rhodium complex. (a)[((cod)Rh(OEt))2]. (b) KOH. 
Later similar strategies were developed to synthesize the carboxylate functionalized NHC ligands 63 and 
64 prior to metal complexation (Scheme 20).198 Using water as the reaction medium the corresponding 
silver complexes were 65 and 66 synthesized by Shaugnessey and coworkers. NaCl was added to the 
reaction medium to avoid cationic coordination of silver to the carboxylate and polymerization. 
Transmetalation of these complexes led to the corresponding gold species. 
 
Scheme 20. Synthesis of carboxylate functionalized NHC 63 and 64 and the corresponding silver complex 65 and 66. 
(a) Br(CH2)2CO2 then Na2CO3. (b) Ag2O, NaCl. 
 
As demonstrated in both Scheme 19 and Scheme 20, the metal source of carboxylate-functionalized NHCs 
is introduced as metal precursor (silver complex) with an internal base. To date no strategy has been 
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described to synthesize the corresponding complexes via free carbene; deprotonation under basic condition 
followed by metal complexation. A possible explanation might be that nucleophilic attack on the carbonyl 
is prevented using the transmetallation strategy.  
  
Another possibility to introduce polarity to the NHC ligand is sulfonate functionalization. The sulfonate 
group is known to induce excellent water solubility due to its changed nature at most pHs. Two types of 
sulfonate functionalized NHCs are reported: the alkyl and aryl substituted NHC ligands (Scheme 21 and 
Scheme 22). Synthesis of the alkyl variant was reported in 1995 via two routes: the alkylation of 
commercially available imidazole with 2-bromoalkylsulfonates to obtain the symmetric NHC ligand  67; 
Cleavage of sultones to yield NHC ligands 68-71.199,200 Comparable to carboxylate functionalized NHCs, 
the silver substrates 72-75 are available via complexation with silver oxide in the presence of NaCl. 
Transmetalation of the NHC-silver complexes 72,73 and 75 with chloro(tetrahydrothiophene)gold(I) 
resulted in a mixture of the dimeric and monomeric carbene gold complexes 76-78.201 In contrast to NHCs 
bearing carboxylates the synthesis of sulfonate functionalized NHC-metal complexes via a free carbene is 
reported.202,203  
 
Scheme 21. Synthesis of alkyl sulfonate functionalized NHCs and corresponding gold complexes. (a) 
Br(CH2)2SO3Na. (b) propane/butane sultone or C2H4CX then Na2SO3. (c) Ag2O, NaCl. (d) [Au(tht)Cl], NaCl. 
In 2007 Hoveyda and coworkers presented the synthesis of a chiral arylsulfonate substituted NHC ligand 
with good water solubility.204 Plenio`s group reported the synthesis of aryl-sulfonate functionalized NHCs 
81 and 84.205 These ligands were synthesized by the conventional condensation route starting from an 
aniline source (Scheme 22). Subsequent sulfonation, condensation with glyoxal to the Schiff base, reduction 
to the diamine and final cyclization with triethyl orthoformate yielded the target arylsulfonates. In the 
follow-up studies direct sulfonation of the NHC ligands was reported.206 
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Scheme 22. Synthesis of arylsulfonate functionalized NHCs. a) oleum. b) glyoxal. c) H2, Pd/C. d) HC(OEt)3. e) 1,4-
dioxane-2,3-dio. f) chloromethyl pivalate. 
 
Comparable to alkylsufonate substituted NHC ligands, the majority of the corresponding complexes were 
synthesized by Ag2O complexation followed by transmetalation.207 Roy and coworkers showed that 
synthesis of Pd complexes starting from these ligands is possible via the free carbene intermediate.206 
 
3.3.2 Amine/ Ammonium functionalized NHC and corresponding copper(I) complexes  
Amine or ammonium functionalization represents a different strategy to introduce water solubility to NHC-
metal complexes. Quaternization of amines to the corresponding ammonium species is necessary to achieve 
the desired polarity of the ligands. The first amine functionalized NHC was reported in 2001 by Oezdemir 
and coworkers (Figure 47A).208 Treatment with HCl yielded the desired water solubility of the Ru(II) 
complex as an ammonium chloride salt. However, the complex stability in water is described to be low. 
Later, a backbone modified NHC-Ru(II) complex was synthesized by Grubbs et al (Figure 47B).209 The 
backbone functionalization allows introduction of the favored polarity without affecting the steric and 
electronic properties around the metal center.  
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entry catalyst Time 
[h] 
Yield click 
product, [%] 
1 85 3 98 
2 86 6 Trace 
3 87 6 92 
 
Figure 47. (A) The first amine functionalized NHC-metal complex. (B) Backbone functionalized water soluble NHC-
Ru complex. (C) Ammonium tagged [(NHC)CuX] complexes 85-90 used in three component click reaction. (D) 
CuAAC catalyzed by NHC-Cu(I) catalysts 85-87. (a) 5 mol % catalyst, NaN3, H2O, rt.    
Sharpless introduced the concept of “Click” chemistry in 2001210 and since then Cu(I) catalyzed azide-
alkyne cycloadditions (CuAAC) has become the most popular click reaction due to its high reliability.211 
Wang and co-workers reported the synthesis of different ammonium functionalized [NHC-CuX] complexes 
85-90 (Figure 47C) that catalyze the three component cycloaddition of benzyl bromide, phenylacetylene 
and NaN3 in water (Figure 47D).212 A clear effect of the electronic properties of the NHC ligand as well as 
the counter ion is reflected in the reaction yields and times. Of these compounds 85 proceeded as the best 
catalyst. Reuse of catalyst 85 following liquid-liquid extractions with ether was possible for up to four 
cycles. Nevertheless, an argon atmosphere was necessary to maintain a similar catalytic activity. One year 
later, Gaulier and coworkers presented the first ammonium functionalized [(NHC)CuI] complex 91, 
catalyzing the CuAAC of peptides bearing sensitive side chains (Figure 48A).213 This catalyst showed high 
stability towards the oxidation of Cu(I). The cycloaddition was able to proceed under open air conditions. 
Many solvents including MeOH, DMSO, NMP and HFIP were compatible with catalyst 91, only α-amino 
acids prevented the click reaction. The test substrates, three pentapeptides containing sensitive amino acids 
towards copper-mediated oxidation (His, Met, Cys), were investigated (Figure 48B). Five-fold excess of 
the corresponding azides and 40 to 100 mol % catalyst loading yielded the target click products 92-96. No 
oxidation of sulfide and thiol containing peptides occurred. Additionally, the N-terminal octapeptides were 
successfully modified under these conditions (Figure 48B). Surprisingly, the [(NHC)CuI] catalyst 91 was 
synthesized via free carbene intermediate using NaOH and CuI in the presence of two alcohol functional 
groups, which are known to form alcohol adducts with these types of free carbenes.214 Unfortunately neither 
the proton and carbon NMR spectra (only chemical shifts) nor a crystal structure of complex 91 has been 
published. Complete structural elucidation, monomeric or dimeric Cu carbene complex, is impossible 
without a crystal structure. Additionally, the mass for compound 91 reported in the paper is incorrect.  
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Figure 48. (A) Ammonium functionalized [(NHC)CuI] 91catalyzing the CuAAC of unprotected peptides. (B) 
Synthesized peptides using catalyst 91in the presence of 0.2 M HEPES pH 7.6. 
Considering all of this information I believe the results from this paper require further examination. It is 
impossible to make any conclusive statements about the origin of the high complex stability without full 
structural elucidation.  
Nonionic water-solubilizing elements can be introduced by alcohol or ether functionalization of the NHCs. 
To achieve the desired water solubility a variety of NHCs were substituted with either glycol or ether 
groups. For a detailed report the reader is referred to reviews by Schaper and coworkers.215-216 
The most recent data on the synthesis of water soluble [(NHC)CuX] catalysts was reported in 2014 by 
Velazquez and coworkers. The [(NHC)2Cu] compounds 97 and 98 bearing an alkyl sulfonate on one side 
(Figure 49)216 successfully catalyze the standard CuAAC reaction of benzyl azide and phenylacetylene. 
However, once again mass spectrometry was used for structural determination instead of crystal structures. 
Ionization of [(NHC)CuX] complexes can cause ligand dissociation or dimerization products which not 
represent the actual structure. Additionally, the quality of the corresponding proton and carbon NMR 
spectra are low. It is therefore impossible to identify the corresponding structures with the given data.  
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Figure 49. Bis-carbene structure of water soluble [(NHC)2Cu] 97-98 bearing alkyl sulfonate on one side. 
 
In conclusion, only a few water soluble [(NHC)CuX] complexes 85-91, 97 and 98 have been described to 
date. All these reported water soluble [(NHC)CuX] complexes were developed for CuAAC chemistry. 
Unfortunately, their structure validation is poor, especially for complex 91, preventing any detailed insight 
into their properties. In the remainder of this chapter I will discuss my efforts towards creating water soluble 
NHC complexes and testing them in catalysis. 
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3.4 Synthesis of water soluble NHC ligands and their Cu(I) complexes 
Our first design of a [(NHC)CuX] catalyst to proceed in reducing agent free oligonucleotide alkylation is 
shown in Figure 50. Two hydrophillic functionalities were introduced in a para position to the nitrogens, to 
minimize their influence on the electronic properties of the metal center. The diisopropyl variant was 
choosen to maintain the correct steric properties, that would prevent carbene dimerization during 
complexation (Figure 50A). Our focus was the synthesis of a monomeric water soluble [(NHC)CuX] 
complex to use a similar synthetic strategy for the long term goal the development of a [(NHC)Cu] catalyst 
bound to single stranded oligonucleotides. This catalyst should further be used for template directed 
oligonucleotide modification (Figure 50B). 
 
Figure 50. (A) General design of water soluble [(NHC)CuX] catalyst for oligonucleotide alkylation. (B) Template-
directed oligonucleotide modification with guiding NHC-Cu(I) catalyst. 
 
3.4.1 Synthesis of NHC-Cu(I) complex bearing sulfonate functionalization 
Our first choice of functionality to promote water solubility of the [(NHC)CuX] catalyst were sulfonates. 
As reported by Plenio and coworkers in 2007 the NHC ligand 101 bearing two sulfonates was synthesized 
starting from commercial 2,6-diisopropylaniline.205 Selective sulfonation at the para position, subsequent 
transformation to the Schiff base with dihydroxydioxane and the final cyclization using chloromethyl 
pivalate yielded the corresponding imidazolium ring 101 (Scheme 23). The synthesis of the sulfonate 
functionalized NHC ligand 101 was straight forward and the yield for cyclization could be improved, 
compared to literature yield, by extending the reaction time. The first challenges were faced during 
complexation with Cu(I). Singlet carbene formation using different bases including NH3, NaOH and sodium 
tert-pentoxide, in the presence of CuCl did not yield full conversion to the target [(NHC)CuCl] complex 
103. Additionally, the formation of dicarbene Cu(I) complex 104 was detected. Interestingly, deprotonation 
with NaOH yielded solely the biscarbene species 104. Use of an excess of sodium tert-pentoxide improved 
the conversion to compound 103 and prevented di-carbene 104 formation, however purification by column 
chromatography was still necessary. Unfortunately, partially oxidation of Cu(I) to Cu(II) occurred during 
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this process resulting in a low yield. The alternative route to install Cu(I) via transmetalation was 
unsuccessful. The silver replacement by copper only resulted in decomposition to the free NHC ligand 101. 
Nevertheless, the water soluble [(NHC)CuCl] complex 103 was successfully isolated after 4 steps in an 
overall yield of 10% and tested towards oligonucleotide alkylation (see section 3.5).   
 
Scheme 23. Synthesis of water soluble NHC-Cu complex 103. a) H2SO4, 180°C, 5 h then 1.7 M NaOH, reflux, 1.5 h 
(43 %). b) dihydroxydioxane, formic acid, 25°C, EtOH (38 %). c) chloromethypyvalate, 45°C, 5 d, (95 %). d) aqu. 
NH3, CuCl, H2O, rt - 60°C, on. e) NaOH, CuCl, MeOH (63 % of 104). f) sodium tert-pentoxide, THF, rt, 1h then 
CuCl, rt, on. g) Ag2O, H2O, reflux, 24 h. h) CuCl or CuSPh. 
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3.4.2 Ammonium functionalized NHC-Cu(I) catalyst 
In order to broaden the scope and test the reactivity and stability of [(NHC)CuX] compounds as catalysts 
towards oligonucleotide alkylation two different ammonium functionalized [(NHC)CuCl], 105 and 106, 
were synthesized (Figure 51). We thought the introduction of a positive charge through ammonium groups 
would be beneficial since the positively charged catalyst would be coulombically attracted to negatively 
charged oligonucleotides. The steric demand of the NHCs around the metal center are similar to the 
sulfonate functionalized [(NHC)CuCl] complex 103, however, with the ammonium series, we chose as well 
to investigate different electronic parameters in the NHC skeleton by looking at both saturated and 
unsaturated backbones. The saturated [(NHC)CuCl] version 105 was synthesized according to a published 
procedure by Wang and coworkers.212 The target Cu(I) catalyst was isolated in 9 % yield from a laborious 
synthesis of seven steps (see steps a-g in Scheme 24). Additionally, the complex stability was very poor in 
its solid state. Rapid decomposition was detected after isolation at room temperature.  
 
 
Figure 51. Structure of ammonium functionalized [(NHC)CuCl] complexes 105 and 106. 
 
In contrast to complex 105, the unsaturated ammonium modified [(NHC)CuCl] catalyst 106 showed 
improved stability towards oxygen and moisture. Purification by column chromatography was possible 
after post-synthetic functionalization via azide-alkyne cycloaddition. The azide functionalized NHC ligand 
111 was synthesized starting from commercial 2,6-diisopropylaniline according to a published procedure 
by Gautier et al.217 Iodation at the para position followed by aromatic substitution with sodium azide yielded 
aniline 109 (Scheme 25). The corresponding Schiff base 110 was formed in the presence of glyoxal. After 
the final cyclization with paraformaldehyde, the NHC ligand 111 was isolated in 11% over six steps.  
There are two possibilities to introduce the water solubilizing ammonium functionality 106: before (Scheme 
25 path A) or after complexation with CuCl (Scheme 25 path B). The ammonium functionalized alkyne 
114 was synthesized in one step via alkylation of commercial dimethylaminoethanol (Scheme 25). Both 
strategies were tested, but the post-complexation functionalization was found to be more efficient. First, 
the corresponding [(NHC)2Ag] complex was synthesized and then Cu(I) was introduced by 
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transmetallation. The final click reaction between the [(NHC)CuCl] species 112 with the ammonium 
functionalized terminal alkyne 114 yielded the target water soluble [(NHC)CuCl] complex 106.  
 
Scheme 24. Synthesis of ammonium functionalized NHC-Cu(I) catalyst 105 and £14 (a) morpholine, CH2O, EtOH, 
H2O, reflux, 14 d. (b) glyoxal, MeOH, HCO2H cat., rt, 2h (55%). (c) LiAlH4, THF, rt, 24 h (85 %) (d) HC(OEt)3, 
NH4Cl, mw, 5 min, 145°C (76 %). (e) ethylchloroformate, MeCN, rt, 1 h (59%). (f) NEt3, MeOH, rt, 24 h (65 %). (g) 
KOtBu, CuCl, MeOH, reflux, 13 h (69 %). (h) Iodine, NaHCO3, Et2O, 2h, rt (98%). (i) NaN3, CuI, sodiumascorbate, 
N,N-dimethylethylenediamine, DMSO, H2O, 50°C, on (96 %). (j) glyoxal, acetic acid, MeOH, rt, 4 h (41 %). (k) 
paraformaldehyde, chloro(trimethyl)silane, EtOAc, 70°C, 16 h (74 %). (l) Ag2O, LiCl, THF, 70°C, 2 h then CuCl, 
CH2Cl2, 37°C, on (69 %). (m) alkyne 114, CuSO4, sodium ascorbate, DMSO, H2O, 55°C, 2h (58 %). 
 
Scheme 25. Synthesis of ammonium functionalized alkynes 114. (a) propargyl chloride, toluene, rt (64%).  
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3.4.3 Alkyl substituted NHC-Cu(I) catalysts 
We also made alkyl N-substitution in the NHC ligand since this promised a simple way to access a diverse 
range of NHC ligands. In one step commercial imidazole or methyl imidazole was alkylated with different 
bromo alkyl species to yield the target water soluble NHC ligands 115-117 (Scheme 26). Unfortunately 
complexation reactions of all NHC ligands 115-117 in the presence of CuCl and KOtBu only yielded the 
NHC dimer 118 instead of the target Cu(I) complex 119. 
 
Scheme 26. Synthesis of alkyl substituted NHC ligands 115-117. (a) DMF, 3 h, reflux (115: 40 %), (116: 44%), (117: 
73%). (b) KOtBu, CuCl, MeOH, reflux, on. 
Complete structural elucidation of the isolated compounds after treatment with KOtBu and CuCl was 
difficult (Figure 52A). In all cases there was no signal for the imidazole proton in the 1H-NMR spectra, 
indicating carbene formation occurred, however, the other signals did not show the expected chemical shift, 
that would result from copper(I) complexation. The reaction mixtures were also analyzed by UPLC-MS, 
but no reasonable mass could be detected. Finally, comparison of the 13C chemical shifts isolated from 
HMBC correlation with reported chemical shift of different carbenes (Figure 52B, C and D) was suggestive 
of dimeric NHC carbenes 119 (Figure 52). Therefore, alkyl substituted NHC ligands showed to be 
inappropriate to stabilize Cu(I) in the corresponding carbene complexes.  
 
Figure 52. (A) 13C chemical shift from HMBC correlation of the substrate £18 after complexation reaction. Examplex 
for 13C chemical shifts from literature. (B) Aryl substituted [(NHC)Cu] complex. (C) Alkyl substituted NHC dimer. 
(D) Alkyl substituted free carbene.   
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3.4.4 Synthesis of chelating NHC ligands to improve Cu(I) stability 
Given the failure of alkyl substitution, we returned to more bulky aryl substitution on the nitrogens for the 
next series. Complex formation of stability was a constant problem for our copper complexes so here we 
thought to introduce chelating groups such as hydroxyl, sulfonate and pyridyl on one site of the NHC ligand 
to improve the stability of the final [(NHC)Cu] complex (Figure 53). The sulfonate functionality in the para 
position was maintained to ensure water solubility of the final catalyst. Two isopropyl groups were kept in 
the design to prevent ligand dimerization.  
 
Figure 53. General structure of chelating [(NHC)Cu] complex. 
Three different NHC ligands 127-129 were successfully synthesized (overall yields 127: 4 %, 128: 2 %, 
129: 6 %) according to an adapted procedure by Fürstner et al.218 Sulfonation at the para position, starting 
from commercial 2,6-diisopropylaniline was followed by N-alkylation with commercial 
bromoacetaldehyde diethylacetal under basic conditions yielding the aminoacetal 121 (Scheme 27). 
Starting from the polar compound 120, it was necessary to change the solvent system and base for successful 
N-alkylation. Different solvent and bases were tested, however only Cs2CO3 in DMF resulted in a decent 
amount of product 121. All investigations (different bases and solvents, excess of reagents) to improve the 
yield were unsucessfull. Either decomposition of the starting material or side product formation like the 
double alkylated species was observed. The formamide 122 was synthesized with acetic anhydride and 
further cyclized to the oxazolinium salt 123 using the strong mineral acid HBF4. Direct reaction with the 
second amine species, without isolation of 123, yielded the hemiaminals 124-126. Final treatment with an 
excess of HBF4 at 80°C yielded the target unsymmetric imidazolium salts 127-129. However, complexation 
with CuCl was impossible. Neither direct complexation with CuCl in the presence of KOtBu nor carbene 
transfer reaction from the silver complexes yielded the target [(NHC)Cu] complexes 130-132. NMR studies 
revealed that deprotonation had occurred in all cases in the presence of KOtBu without formation of the Cu 
carbene bond. One possibility is that only the alkoxy protected compound 134 was present because 70°C 
was not the required temperature to form the singlet carbene 135 (Scheme 28A). However, for the reported 
NHCs, 60-80°C was enough to form carbene 135 from the corresponding alkoxy species 134.219 It is more 
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likely that the distance between the singlet carbene and the chelating groups are not appropriate for both 
interactions, the Cu(I) carbene and Cu(I) coordination to the chelating group, to occur (Scheme 28B).  
 
Scheme 27. Synthesis of unsymmetric water soluble NHC-Cu(I) complexes. (a) conc. H2SO4, 5 h, 180°C, 47 %. (b) 
bromoacetaldehyde diethylacetal, Cs2CO3, DMF, 120°C, on (39 %). (c) Ac2O, formic acid, CH2Cl2, reflux, 6 h then 
formic acid, room temperature, 24 h (51 %). (d) HBF4*OEt2, Ac2O, room temperature, 15 min (quant). (e) 2-
aminobenzenesulfonic acid, DMF, rt, 5 h (19 %). (f) 2-aminophenol, DMF, rt, 5 h (33 %). g) 2-(pyridin-2-yl)aniline, 
DMF, rt, 5 h. (h) HBF4*OEt2, DMF, 80°C, 3 d, (127: 43 %), (128: 21 % over 3 steps), (129: 71 %). (i) 3.00 eq. KOtBu, 
CuCl, MeOH, reflux, 1 d. 
The hemiaminals 124-126 were also treated with KOtBu and CuCl. Surprisingly, the NHC-Cu(I) catalyst 
133 could be isolated and was shown to be bench stable for longer than two weeks. Unfortunately, complex 
133 was unreactive in alkylation reactions (see section 3.5).  
         
Scheme 28. (A) Singlet carbene formation 135 by thermal elimination of alkoxy species 134 in the presence of KOtBu. 
(a) KOtBu, THF, 60-80°C. (B) Demonstration of distance between NHC model and the chelating group X. 
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3.4.5 Synthesis of skeleton functionalized NHC-Cu(I) complex 
Increasing the [(NHC)CuX] catalyst stability by chelating groups was unsuccessful due to failure in the 
complex formation step. It is reported that the NHCs donor properties are influenced by the nature of the 
heterocyclic skeleton.220 In 2014 Zhang and coworkers reported a new set of skeleton modified NHC 
ligands.221 Inspired from earlier work modification with one or two amino groups in the heterocycle should 
enhance the electronic donor properties of the ligand. IR-stretching frequencies of the corresponding 
[(NHC)RhCl(CO)2] complexes 136 and 137 (Figure 54) was consistent with this idea giving a 2 cm-1 change 
of the Tolman electronic parameter (TEP) compared to the non-substituted analogues. The TEP is described 
as the change of IR stretching frequency of the carbonyl ligands depending on the electron density at the 
metal center. The crystal structures of the carbene ligands and their corresponding calculated buried volume 
revealed the steric contribution of the skeleton modification resulting in two air and moisture stabile 
palladium complexes 138 and 139 (Figure 54).  
 
Figure 54. Structures of skeleton modified NHC-metal complexes 136-139. 
To reach similar stability of a water soluble [(NHC)CuX] complex we designed an amino skeleton modified 
NHC, bearing an azide group 142 (Scheme 29). Post-synthetic functionalization of the [(NHC)CuX] 
complex 144 with polar groups should increase the water solubility of the final catalyst. The NHC ligand 
142 was synthesized by Dr. Rasale starting from commercial 2,6-diisopropylaniline which was transformed 
to the formamidine 140 using triethylorthoformate. Further alkylation with the azide 151 followed by 
cyclization in the presence of triflic anhydride yielded the target functionalized NHC 142. The azide tag 
151 was synthesized in three steps. Bromination of commercial 2-(methylamino)ethanol followed by 
substitution with sodium azide and final reaction with chloro acetylchloride yielded 151 (Scheme 29). 
Firstly, the [(NHC)2Ag] complex 143 was synthesized using Ag2O and final transmetalation with CuCl 
yielded the skeleton functionalized copper(I) complex 144 (Scheme 29). Already the hydrophobic 
[(NHC)CuCl] 144 showed high stability towards oxygen. A stock solution of 144 in CDCl3 (not degassed) 
was monitored over three days by recording several proton NMR spectra. No decomposition could be 
detected. Final click reactions in the presence of functionalized terminal alkynes 114 and 153-155 yielded 
the skeleton modified [(NHC)CuCl] compounds 145-148. Unfortunately, introduction of one ammonia 
group was not enough to increase the polarity to provide water solubility to the final complex 145. 
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Completion of the CuAAC with the PEG functionalized alkyne bearing a carboxylic acid group 154 was 
detected by UPLC-MS after 2 h. Unfortunately, the target complex 146 could not be isolated in an amount 
sufficient enough to test its catalytic activity towards oligonucleotide modification. Click reaction with a 
di-ammonium functionalized tag 153, synthesized in two steps starting from bis[2-(N,N-
dimethylamino)ethyl] ether via alkylation using chloroethanol and propargylbromide (Scheme 31), yielded 
the first water soluble skeleton modified [(NHC)CuCl] complex 147. Furthermore, it was also possible to 
post functionalize the [(NHC)CuCl] 144 complex with a short single-stranded six-mer d(TTTTTT) to 
introduce the desired water solubility. The CuAAC reaction of a commercial modified T-mer 155 with a 
hexynyl at the 5`end yielded the water soluble [(NHC)CuCl] catalyst 148.  
 
Scheme 29. Synthesis of skeleton modified NHC-Cu(I) complexes 145-148. (a) triethylorthoformate, acetic acid, 
reflux, on (31%). (b) 1042, KI, NEt3, DMF, 100°C, on. (62%). (c) triflic anhydride, 2,6-lutidine, -78°C (37%). (d) 
Ag2O, THF, 70°C, 2 h. (e) CuCl, CH2Cl2, 35°C, on, (78%). (f) 114/ 153/ 154/ 155/, CuSO4, sodium ascorbate, DMSO, 
H2O, 25-50°C. 
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Scheme 30. Synthesis of azide functionalized tag 1042. (a) HBr, 150°C (51 %), 11 h. (b) NaN3, H2O, 75°C, 15 h (60 
%). (c) chloro acetylchloride, NEt3, CH2Cl2, room temperature, 15 h (63%). 
 
Scheme 31. (A) Synthesis of ammonium functionalized alkyne 153. (B) Structure of commercial alkynes 154 and 155 
(B). (a) propargyl chloride, toluene, rt (64%). (b) chloro ethanol, MeCN, 80°C, on (48%). (c) propargylbromide, 
MeCN, 80°C, on (62%). 
Post functionalization of the [(NHC)CuCl] complex  144, via a click reaction, proofed to be the most 
efficient method to introduce the required hydrophilicity to the resulting catalyst. Additionally, skeleton 
modification showed to be an appropriate strategy to increase the stability of the final [(NHC)CuCl] 
complex. Using this approach two ammonium functionalized complexes 145 and 147 and a [(NHC)CuCl] 
catalyst covalent bound to ssDNA 148 were successfully isolated and tested towards oligonucleotide 
modification. 
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3.5 Alkylation of short single stranded oligonucleotides catalyzed by NHC-Cu(I) complexes 
Despite all of the synthetic challenges encountered, we managed to create a series of water soluble NHC-
Cu(I) complexes. Our next goal was to look at their catalytic performance in nucleic acid alkylation. 
3.5.1 Symmetrical NHCCu(I) catalyst bearing water functionalities in para position to nitrogens 
towards nucleic acid modification 
The alkylation potential of water soluble [(NHC)CuCl] complexes 103 and 105 towards oligonucleotide 
modification was investigated (Table 6). These alkylation reactions represent the first studies of 
[(NHC)CuCl] catalysts in carbene transfer reactions in the presence of ssDNA. Trinucleotides were used 
as test substrates to probe the regioselectivity of the alkylation reaction. All three short single stranded 
DNAs (d(TAT), d(TCT) and d(TGT)) were successful modified using the donor-acceptor stabilized α-
diazocarbonyl compound 16 catalyzed by 103 (Table 6, entries 1-6). The diazo species 16 was synthesized 
in three steps according to literature.139 Comparable to the reports by Dr. Tishinov using in situ reduced 
copper(I) (by mixing CuSO4 and sodium ascorbate) the nucleobases adenine, guanine and cytosine were 
targeted. In contrast to that catalytic system also thymine alkylation was detected (Figure 55-57). For 
example, d(TAT) modification resulted in six mono and one double alkylation (Table 6, Entry 1) instead 
of two mono alkylation products using in situ reduced Cu(I).140 Tandem mass analysis of these products 
point to five modification located on thymine and one on adenine (Figure 55). Assuming that the exocyclic 
amine in adenine is alkylated as reported by Dr. Tishinov, thymine modification most likely occurred at the 
carbonyl oxygens. Furthermore, d(TGT) and d(TCT) were more efficiently targeted and different amount 
of alkylated species were detected (Table 6, Entry 3 and 5; Figure 56 and Figure 57). The higher conversion 
of the oligonucleotides d(TGT) and d(TCT) can`t be directly correlated with higher catalytic efficiency of 
103 because a 20 mol% catalyst loading was used instead of 10 mol%. Nevertheless, the conversion of 
d(TAT) stayed similar in the presence of higher Cu(I) concentration (Table 6, Entry 1). Modification of 
d(TGT) showed only one main signal for the mono alkylation product and MS/MS analysis revealed the 
ion for guanine modification (Figure 56A). At this stage no further experiments were done to identify the 
exact location of guanine alkylation. It was assumed that the alkylation took place at the exocyclic amine 
as reported for adenine but there is also the possibility of O6 or N-1 modification (Figure 56B). The addition 
of a reducing agent (sodium ascorbate) to the [(NHC)CuCl] catalytic system resulted in oxidative damage 
of the ssDNAs about 25-27 % (Table 6, entry 2, 4 and 6). Without reductant in the reaction mixture more 
alkylation product was formed.  
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Table 6. Scope of short nucleic acid alkylation catalyzed by [(NHC)CuCl] 
 
Entry catalyst Asc 
[mM] 
ssDNA Diazo 
 
Time 
[h] 
Conversion 
ssDNA 
[%] 
Number 
of products  
156 
Oxidative 
damage 
[%] 
1 103 - d(TAT) 16 22 40/ 37[a] 7/ 2[b] - 
2 103 20 d(TAT) 16 23.5 50 7 25 
3 103 - d(TGT) 16 22.5 60/ 46[a] 3/ 4[b] - 
4 103 20 d(TGT) 16 24 72 3 28 
5 103 - d(TCT) 16 23 62/ 27[a] 6/ 4[b] - 
6 103 20 d(TCT) 16 24.5 82 6 27 
7 105 - d(TCT) 16 16 27 6 - 
8 103 - d(TGT) EDA 2 74 1 - 
9 CuSO4 20 d(TGT) EDA 2 84 1 - 
10 Rh2OAc4 - d(TGT) EDA 2 0 0 - 
11 no - d(TGT) EDA 2 0 0 - 
12 103 - d(TCT) EDA 1 
3.5 
52 
58 
8 - 
13 105 - d(TCT) EDA 1 
16 
8 
44 
8 - 
(a) 1 mM [(NHC)CuCl] catalyst 103 and 105, 5 mM ssDNA, 50 mM diazo, 100 mM MES buffer pH 6, H2O, room 
temperature. [a] Conversion of ssDNA after 24h, reaction condition: 0.5 mM CuSO4, 2.5 mM THPTA, 5mM ssDNA, 
50 mM diazo, 10 mM sodium ascorbate, 100 mM MES pH 6, 24 h, room temperature. [b] Reported number of 
alkylated species using in situ formed Cu(I) catalytic system. 
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Figure 55. HPLC-MS/MS analysis of d(TAT) alkylation reaction with 16 catalyzed by 103 following the general 
procedure (Table 6, Entry 1). 
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Figure 56. (A) HPLC-MS/MS analysis of d(TGT) alkylation reaction with 16 catalyzed by 103 following the general 
procedure (Table 6, Entry 3). (B) Possible alkylation sites of guanine. 
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Figure 57. HPLC-MS/MS analysis of d(TCT) alkylation reaction with 16 catalyzed by 103 following the general 
procedure (Table 6, Entry 5). 
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In the next step, the effect of the diazo substrate structure on the alkylation process was investigated. For 
the first time commercial α-ethyl diazoacetate (EDA) was investigated as carbene source for 
oligonucleotide modification (Table 6, Entry 8-13). The alkylation proceeds much faster using diazoacetate 
EDA and d(TGT) modification yielded one single peak with high efficiency (Table 6, Entry 8; Figure 59A). 
ESI-MS analysis of the corresponding isolated peak showed surprisingly the mass for the double alkylation 
product but unfortunately tandem MS analysis was unsuccessful to reveal the alkylation site. Diazo 
compounds, especially the unstabilized diazoacetates, can dimerize (Figure 58A). d(TGT) was therefore 
treated with diethyl fumurate (dimerization product of EDA) in the presence of 103 to exclude diethyl 
fumurate as the reactive species responsible for double alkylation in d(TGT) (Figure 58B). Under these 
conditions no conversion of the short ssDNA was detected in presence or absence of 103. The same 
alkylation profile for d(TGT) modification with EDA was observed using in situ reduced Cu(I), only the 
conversion of the nucleic acid was higher (Table 6, Entry 9). Surprisingly, testing d(TGT) alkylation in the 
presence of Rh2OAc4 only yielded decomposition of EDA and no alkylation product was formed (Table 6, 
Entry 10). The carbene transfer reaction was also more efficient towards d(TCT) modification using 
unstabilized EDA (Table 6, Entry 12). About six mono alkylation products could be isolated and tandem 
mass fragmentation pointed to about four different thymine and two different cytidine modifications (Figure 
59B). The number of alkylation products per nucleobase can`t be exactly determined due to co-elution of 
the alkylation products.  
 
Figure 58. (A) Possible carbene dimerization of EDA. (B) Test reaction of d(TGT) in the presence of diethylfumurate 
and catalyst 103. (a) 20 mol % 103, MES buffer pH 6, 20 v/V % tBuOH, rt, 4h. 
104 
 
Figure 59. HPLC analysis of d(TGT) (A) and d(TCT) (B) alkylation reaction with 1033 catalyzed by 103 following 
the general procedure (Table 6, Entry 8 and 12). 
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The different catalytic activity of the [(NHC)CuCl] complexes 103 and 105 is presented in Table 1 by 
comparing d(TCT) alkylation with EDA (Table 6: Entry 12 and 13). The modification of d(TCT) was much 
more efficient catalyzed by 103. Already after one hour 52% of the ssDNA was converted compared to 8 
% conversion using the ammonium functionalized catalyst 105. The main electronic differences between 
these two catalysts is the saturation in the NHC skeleton (Figure 60, highlighted with a blue box). The water 
solubilizing groups (highlighted in green) should not have a big influence on the electron density around 
the copper center. From a synthetic point of view catalyst 103 is more stable towards oxygen then 105 but 
more investigations are needed to study their different reactivity towards ssDNA alkylation. In detail, 
synthesizing their corresponding saturated 156 and unsaturated 157 partners (Figure 60) and testing them 
towards oligonucleotide modification would reveal whether the NHC skeleton is responsible for the 
different reactivity of these catalysts 103 and 105.  
 
Figure 60. Differences in electronic properties of the [(NHC)CuCl] complexes 103 and 105. Structures of 
corresponding complexes 156 and 157. 
The [(NHC)CuCl] catalysts 103 was successful implemented in nucleic acid alkylation and a diazo structure 
dependent regioselectivity was observed. The accurate alkylation site of guanine in short oligonucleotides, 
monophosphates and triphosphates with EDA was determined with in situ formed Cu(I) (see chapter 2.5.2) 
and revealed to be the O6 position. All reactions shown in Table 6 catalyzed by 103 were carried out with 
a stock solution of the Cu(I) source in water. This stock solution was stored at -20°C but still oxidation to 
Cu(II) occurred after several days. To investigate the catalyst stability, more water soluble [(NHC)CuCl] 
complexes were synthesized (see section 3.4). Finally, a backbone modification was the key in finding a 
storable water soluble [(NHC)CuCl] complex with activity in nucleic acid alkylation.  
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Table 7. Different catalytic reactivity of [(NHC)CuCl] as catalyst in GMP and dGMP alkylation 
 
 
Entry catalyst MP/ 
ssDNA/ssRNA 
Diazo 
 
Co-solvent 
[%v/v] 
Time 
[h] 
Conversion 
MP/ oligo [%] 
1 103 GMP EDA[a] DMSO, 20 1/ 1.5 80/ 84 
2 103[b]  d(ATGC) 23[a] DMSO, 20 3 32 
3 106  d(ATGC) 23 [a] DMSO, 20 1.5 71 
4 106 d(ATGC) 23 [c] Dioxane, 20 1.5 - 
5 106 d(ATGC) 25 [a] DMSO, 20 3 53 
6 106 11-mer 25 [a] DMSO, 20 3 33 
7 145[d] GMP 23[a] DMSO, 20 1.5 94 
8 145 [e] GMP 23 [e] DME, 40 0.5 95 
9 147 dGMP EDA[a] DMSO, 20 1.5/ 3.5 40/ 76 
10 147 dGMP 23 [a] DMSO, 20 0.5 94 
11 148 dGMP 23 [a] DMSO, 20 0.5 85 
12 147 13-mer 23 [a] DMSO, 20 2.5 19 
13 147 UUUUGUUUU DZ3[a] DMSO, 20 6.5 - 
(a) 1 mM [(NHC)CuCl] catalyst, 5 mM ssDNA/MP, 50 mM diazo, 100 mM MES buffer pH 6, H2O, room temperature. 
[a] Stock solution in DMSO. [b] 10 mol% catalyst loading. [c] Stock solution in dioxane. [d] Stock suspension in H2O. 
[e] Stock solution in DME = dimethoxyethane. 11-mer = d(TTTTGTTTTCC), 13-mer = d(TATTATGTTTTAA). 
The alkylation potential of the successful synthesized [(NHC)CuCl] complexes 103, 106, 145, 147 and 148 
is summarized in Table 7. Three diazo substrates EDA and the DAA 23 and 25 were used in this context as 
the carbene source. The effect of the diazo compound structure in carbene insertions was already discussed 
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in chapter 2, reminding that compound 23 typically gave the most efficient reactions. Here, we present the 
different catalytic activity of the [(NHC)CuCl] complexes 103, 106, 145, 147 and 148 towards nucleic acid 
alkylation, with complex 106 displaying the highest activity. Already after 1.5 hours d(ATGC) was 
efficiently alkylated (Table 7, Entry 3). This conversion number was the highest observed so far for 
d(ATGC) alkylation with 23. Unfortunately, the stability of compound 106 towards oxidation was low. 
Comparable to catalyst 103, the catalyst stock solutions of 106 became inactive in a short time. 
As already mentioned backbone modification of the NHC ligands enhanced the final Cu(I) complex 
stability. This skeleton functionalization yielded catalysts 144, 147 and 148, which could be reused as a 
stock solution for nucleic acid alkylation reactions. The introduction of one ammonium functionality in the 
skeleton was insufficient to give good water solubility. Nevertheless, compound 145 showed high catalytic 
activity towards GMP alkylation in a heterogenous system (Table 7, Entry 7) or homogenous reaction 
mixture using dimethyxyethane (DME) as co-solvent (Table 7, Entry 8). Finally, the click reaction of a di-
ammonium tag gave the required water solubility to the [(NHC)CuCl] complex. Guanine alkylation 
catalyzed by 147 was slower (Table 7, Entry 9) compared to a non skeleton functionalized catalyst 103. An 
additional two hours reaction time was necessary to reach a similar conversion number of the 
monophosphate. However, catalyst 147 could be stored as a stock solution in water and re-used for 
oligonucleotide alkylation. The potential of further tailoring of the [(NHC)CuCl] complexes is 
demonstrated by successful dGMP alkylation catalyzed by the T-mer modified Cu(I) species 148 (Table 7, 
Entry 11). Tandem mass fragmentation of all monoalkylation products isolated after carbene transfer 
reaction catalyzed by 103, 106, 145, 147 and 148 showed the expected ions for guanine modification (two 
representative examples: Figure 62 and Figure 63). Further investigation toward ribonucleic acid alkylation 
in a reductant free Cu(I) catalytic system was done. The test substrate UUUUGUUUU was treated with 
DAA 23 in the presence of 147 (Table 7, Entry 13). HPLC analysis of the reaction mixture showed a small 
new signal after 6.5 hours (Figure 61B, highlighted with a box) but the expected mass for the ssRNA 
alkylation product could not be detected. While monoribonucleotide react efficiently (GMP), the short 
ssRNA did not prove to be a viable substrate for carbene insertion. Unfortunately, the purity of the 
commercial RNA is low (Figure 61B). These impurities could have an influence on the system and diminish 
the catalytic activity as we have seen previously with the coordinating ligand THPTA (Chapter 2.5.3).  
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Figure 61. HPLC analysis of UUUUGUUUU alkylation reaction with 23 catalyzed by 147 following the general 
procedure (Table 7, Entry 13). (A) HPLC analysis of the reaction mixture after 0.5 h (blue), 2 h (red) and 6.5 h (black). 
(B) HPLC analysis of the reaction mixture after 6.5 (black) and 24 h (green).  
 
Figure 62. HPLC-MS analysis as representative examples of guanine modification. GMP alkylation with EDA 
catalyzed by 103 (Table 7, Entry 1). 
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Figure 63. HPLC-MS analysis as representative examples of guanine modification: d(ATGC) alkylation with 25 
catalyzed by 106 (Table 2, Entry 5).  
The limitation of this methodology is presented by the carbene insertion reaction of medium sized 
oligonucleotides. Already nucleic acids with 11 to 13 bases showed lower conversion of the ssDNA (Table 
2, Entry 6 and 12). For example modification of the 11-mer with the alkyne functionalized diazo 25 yielded 
33 % conversion to the mono alkylation product after three hours. Modification of the ssDNA with higher 
adenine content gave 19 % conversion after 2.5h, resulting in two mono alkylation products (Figure 64). 
The drop in conversion is likely related to sequestering of copper in the oligonucleotides.  
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Figure 64. (A) HPLC analysis of d(TTTTGTTTTCC) alkylation reaction with 25 catalyzed by 106 following the 
general procedure (Table 7, Entry 6). (B) HPLC analysis of d(TATTATGTTTTAA) alkylation reaction with 23 
catalyzed by 147 following the general procedure (Table 2, Entry 12). 
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3.6 Confirmation of O6-G modification in larger oligonucleotides 
3.6.1 Principle of templated nucleic acid modification catalyzed by covalent bound NHC-Cu(I) system 
Our method for O6-G modification in ssDNA catalyzed by in situ formed Cu(I) or stabilized as NHC 
complex becomes more inefficient the longer the oligonucleotide is. Therefore, selective modification of 
longer ssDNAs still remains a challenge. A template directed strategy could overcome this barrier. The idea 
was to synthesize a [(NHC)CuX] complex, functionalized with an aldehyde or azide group, to form a 
covalent bond to a guiding sequence via oxime or triazole, respectively (Figure 65). Linkers with different 
length can be installed between the catalyst and the guiding sequence to ensure flexibility of the system. 
The guiding sequence is designed to be complementary to the target sequence (10 base pairs). Hybridization 
of the sequences would then bring copper(I) close to a specific guanine. Final addition of the carbene 
transfer reagent, the diazo substrate, would result in selective guanine alkylation.  
 
Figure 65. Principle of templated directed oligonucleotide modification 
 
The synthesis of an aldehyde functionalized NHC was reported by Gao and coworkers in 2013.222 
According to the literature direct aryl quaternization of the aldehyde substituted imidazole 158 with the 
dibenzyl iodonium salt yielded the aldehyde modified NHC ligand 159 (Scheme 32). Complexation with 
112 
Cu(I) was successful but the dimeric [(NHC)2Cu] catalyst 160 was formed. A test reaction with phenyl 
hydroxylamine showed that the complex stability was too low to form the corresponding hemiaminal 161. 
Instead only oxime formation to the free ligand 162 was detected.  
 
Scheme 32. Synthesis of aldehyde conjugated NHC-Cu(I) complex 24. (a) CuI, Cs2CO3, DMF, 120°C, 40 h (54 %). 
(b) BF3. OEt2, CH2Cl2, reflux 1 h (66 %). (c) Cu(OAc)2.H2O, DMF, 100°C, 4 h (55 %). (d) aq. NH3, CuCl, H2O, rt - 
60°C, on. (e) benzylhydroxylamine, H2O, MeCN, rt, 24 h. 
As reported in section 3.5 a skeleton modification of the NHC ligand introduced more stability to the NHC 
Cu(I) bond. Therefore, the skeleton modified [(NHC)CuCl] complex 144 was clicked by Dr. Dnyanesh 
Rasale to a commercial ssDNA 10-mer bearing an alkyne functionality at the 3`end (Scheme £mA). Then 
he tested the resulting guiding catalyst 163 towards template directed oligonucleotide modification using 
two different 48 nucleotides (nt) ssDNA templates and two different diazo substrates, EDA and the alkyne 
functionalized diazoacetamide 25 (Scheme 33B). Ethanol precipitation of the ssDNAs from the alkylation 
reaction mixture and reinjection to HPLC showed a small shift of the compounds (Figure 66A and B). 
MALDI analysis of the reaction mixtures showed a higher mass than the starting templates 1 and 2. 
Unfortunately, the precision of the MALDI is not high enough to validate whether mono or double 
alkylation occurred. In the next step a 68 nt template was modified guided by catalyst 163 and the carbene 
source 25 (Scheme 34). After 6 hours the DNAs were precipitated with ethanol and further functionalized 
via click reaction with Sulfo-Cyn5-azide. Afterwards a better separation of the signals was possible in the 
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HPLC (Figure 66C). Additionally, final analysis by gel electrophoresis confirmed the modification of the 
68 nt template. Further investigations are ongoing by Dr. Dnyanesh Rasale to show whether this alkylation 
occurred template directed.  
 
Scheme 33. Templated directed oligonucleotide modification. (A) Synthesis of guiding sequence 163 (B) Alkylation 
reaction of 48 nt sequence 1 or 2 with EDA or 25, repectively, catalyzed by the guiding sequence 163. (a) CuSO4, 
sodium ascorbate, DMSO, H2O, room temperature, 2h. (b) EDA or 25, MES buffer pH 6, 31°C, 6h. 
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Figure 66. HPLC analysis of the templated directed oligonucleotide alkylation reactions. (A) HPLC analysis of 
reaction mixture after EtOH precipitation: template 1 with 25 catalyzed by 163 (red); HPLC analysis of template 1 
(black). (B) HPLC analysis of reaction mixture after EtOH precipitation: template 2 with EDA cataylzed by 163 (red); 
HPLC analysis of template 2 (black). (C) HPLC analysis of alkylation reaction mixture after Sulfo-Cy5-azide 
treatment (red); HPLC analysis of 68 nt template (black). 
 
Scheme 34. Templated directed oligonucleotide alkylation using a 68 nt template and diazo acetamide 25 guided by 
the catalyst 163 and subsequent functionalization of the alkylation product via click reaction with Sulfo-Cy5-azide. 
(a) MES buffer pH 6, 31°C, 6 h, precipitation of the DNA with EtOH then Sulfo-Cy5-azide, CuSO4, ascorbate, DMSO, 
H2O, room temperature, 4 h. 
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3.7 Conclusion and future direction 
A reducing agent free approach for copper(I) catalyzed carbene insertion reactions targeting nucleic acids 
has been developed. The method allows an efficient alkylation of short ssDNAs with α-diazo carbonyl 
compounds maintaining the selectivity for the O6 position in guanine. The catalyst copper(I) is stabilized 
as a NHC complex and utilized in an aqueous medium at ambient temperatures.  
Several water soluble [(NHC)CuCl] complexes were synthesized and showed to be active for DNA 
alkylation. The structural design of the NHC ligand highly influences the resulting reactivity and stability 
of the copper(I) catalyst. A skeleton functionalization of the NHC heterocycle with σ- donors such as 
tertiary amines, introduces higher stability to the NHC-Cu bond. Most importantly, this skeleton alteration 
provides access to further functionalization. A broad substrate scope is post-synthetic attachable to the 
NHC-Cu catalyst to fine-tune its polarity.  
Preliminary experiments for a template directed alkylation method for longer oligonucleotide modification 
were also described. To execute our approach a post-synthetic functionalization of an [(NHC)CuCl] catalyst 
was essential. Bio-conjugation of a short ssDNA via click reaction to the [(NHC)CuCl] skeleton provides 
an efficient  and easy synthesis of the guiding catalyst. 
Future work on NHC-Cu(I) system should address several questions: 
(a) Template directed alkylation of longer oligonucleotide maintaining the selectivity for O6-G 
adducts. This requires a detectable difference between the alkylation products and the unmodified 
oligonucleotide and could be realized by:  
- Labelling with specific tags (e.g. biotin and Sulfo-Cy5 dye) 
- digestion to shorter oligonucleotides or nucleotides using enzymes without affecting the 
modification site  
- Primer extension experiments with enzymes which do not tolerate the modification. This would 
lead to an extension stop at the modification sites and give the corresponding truncated 
fragments. Separation of these fragments by length with electrophoresis would give hints about 
the modification sites.  
(b) Diazo-substrate variation to investigate whether the alkylation selectivity could be changed 
- diazo substrates with alkyl groups in the α-position 
- electron withdrawing groups in the α-position 
- or silyl functionalization in the α-position 
(c) An in-depth study on the electronic properties of the [(NHC)CuCl] complexes to improve 
modification rate. 
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3.8 Experimental  
3.8.1 General Experimental Information   
All reagents and solvents used were of analytical grade. Buffers were prepared with ultrapure water. All 
chemicals were purchased from Sigma-Aldrich, Alfa Aesar or Acros and used as received. Solid-phase 
oligonucleotide synthesis was carried out on an Expedite 8909 nucleic acid synthesis system 
(PerCeptiveBiosystems) on 1µmol CPG columns using standard phosphoramidite chemistry with 0.3 M 5-
benzylthio-1-H-tetrazole as activator. Purification was carried out on a preparative Shimadzu UFLC system 
with a Gemini-NX 5 µm C18 21.2 x 250 mm (Phenomenex) column using 100 mM triethylammonium 
acetate (TEAA pH 7.25)/acetonitrile (MeCN) gradients as mobile phase. Elution was carried out at a flow 
rate of 20 mL/min monitored at 254 nm using Method A: 0-15 % MeCN in 30 min, 15-95 % MeCN in 10 
min, 95 % MeCN for 5 min for short ssDNA and Method B: 0-12% MeCN in 25 min, 12-16 % MeCN in 
10 min, 16-95 % MeCN in 5 min, 95 % MeCN for 5 min for longer ssDNA. Alkylation reactions were 
analyzed on an analytical Shimadzu UFLC system or Agilent 1100 LC system with an Eclipse XDB-C8 
4.6 x 150 mm (Agilent) column using 100 mM TEAA/MeCN gradient. Elution was carried out at a flow 
rate of 1 mL/min using Method C: 0-16 % MeCN in 18 min, 16-80 % MeCN in 5 min, 80 % MeCN for 3 
min with peak detection at 254 nm. Purification was carried out on the preperative Shimadzu UFLC system 
as described above using Method D: 0-16 % MeCN in 20 min, 16-20 % MeCN in 5 min, 20-95 % in 1 min, 
95 % MeCN for 5 min. Aqueous product fractions were freeze dried on a Christ Alpha 2-4 LDplus flask 
lyophilizer at 0.1 mbar. 1H, 13C and 31P-NMR, HMQC and HMBC spectra were acquired on a 
BrukerAvance (400, 500 or 600 MHz proton frequency) spectrometer at 298.15 K. Chemical shifts relative 
to TMS were referenced to the solvent’s residual peak and are reported in ppm. ESI MS spectra were 
measured on a Bruker Esquire3000plus mass spectrometer by direct injection in positive polarity of the ion 
trap detector.  
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3.8.2 Chemical synthesis  
Sulfonate functionalized NHC ligand (101). Compound 101 was synthesized according to a published 
procedure.205 White solid (330 mg, 95 %). The analytical data were in 
agreement with the literature. 
 
Sulfonate functionalized [(NHC)CuCl] complex (103). A suspension of immidazolium salt 101 (100 mg, 
159 µM) and sodium terpentoxide (191 µL 2.5 M in THF) were stirred 
for 60 min at room temperature. Then fresh CuCl (15.7 mg, 159 µM) 
was added and the mixture was stirred over nigth at room temperature. 
The solvent was evaporated under reduced pressure and the residue was purified by prep RP-HPLC using 
method A. The corresponding fractions were lyophilized to yield 103 as a white solid. 1H-NMR (400 MHz, 
D2O) δ 7.58 (s, 4H), 7.33 (s, 2H), 2.30 (dt, J = 13.5, 6.6 Hz, 2H), 0.95 (d, J = 6.7 Hz, 12H), 0.77 (d, J = 6.8 
Hz, 3H). 13C-NMR (101 MHz, D2O) δ/ppm: 146.72, 144.81, 136.83, 125.53, 121.90, 28.83, 23.57, 22.74. 
HRMS (ESI): C54H68CuN4Na5O12S42+ calcd.: 635.1245,  found.: 635.1255.  
 
Ammonium functionalized [(NHC)CuCl] complex (105). Compound 105 was synthesized according to 
a published procedure.212 White solid (30 mg, 69 %). The analytical data 
were in agreement with the literature. 
 
 
Azide functionalized NHC ligand (111). Compound 111 was synthesized according to a published 
procedure.217 White solid (327 mg, 74 %). The analytical data were in 
agreement with the literature. 
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General procedure for copper complexation via transmetalation reaction 
The NHC ligand, Ag2O and LiCl in THF (degased) were stirred at 70°C for 2 h, filtered over Hyflo and 
washed with DCM (degased). The solvent was evaporated under reduced pressure and the mixture re-
dissolved in DCM and degassed for 10 min by bubbling nitrogen through. Fresh CuCl was added and the 
reaction mixture stirred over night at 37°C.  After filtration over Hyflo washed with DCM (degased) and 
evaporated under reduced pressure.  
Azide functionalized [NHC)CuCl] complex (112). According to the general procedure compound 111 
(68.6 mg, 135 µM), Ag2O (68.6 mg, 135 µM), (68.6 mg, 135 µM), THF (3.5 
mL), CuCl (68.6 mg, 135 µM) and CH2Cl2 (3.5 mL) were reacted and purified 
to yield 112 as a brown solid (52.9 mg, 69 %). 1H-NMR (400 MHz, MeOD) δ 
7.61 (s, 2H), 7.02 (s, 4H), 2.58 (dt, J = 13.6, 6.8 Hz, 4H), 1.27 (d, J = 6.9 Hz, 12H), 1.24 (d, J = 6.9 Hz, 
6H). HRMS (ESI): C54H68CuN4Na5O12S42+ calcd.: 635.1245,  found.: 635.1255.  
 
Azide functionalized [(NHC)CuCl] in the skeleton (144). According to the general procedure compound 
142 (105 mg, 168 µM), Ag2O (23.43 mg, 102 µM), LiCl (35.7 mg, 842 µM), THF (3.5 
mL), CuCl (25.0 mg, 253 µM) and CH2Cl2 (3.5 mL) were reacted and purified to yield 
144 as a brown solid (77 mg, 78 %). 1H-NMR (400 MHz, CDCl3) δ/ppm: 7.48 (dt, J = 
19.7, 7.8 Hz, 2H), 7.34 – 7.26 (m, 4H), 6.59 – 6.55 (s, 1H), 2.97 – 2.89 (m, 2H), 2.89 
– 2.82 (m, 2H), 2.71 (s, 3H), 2.53 (dt, J = 13.7, 6.9 Hz, 2H), 2.64 (dt, J = 13.6, 6.8 Hz, 
2H), 1.37 – 1.21 (m, 24H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 146.04, 145.61, 144.84, 134.97, 132.26, 
130.70, 130.37, 124.59, 124.14, 108.61, 53.64, 49.07, 40.83, 29.00, 28.69, 26.04, 25.01, 24.00, 22.76. 
HRMS (ESI): C32H45 CuN7+ calcd.: 590.3027,  found.: 590.3035.  
 
Ammonium functionalized terminal alkyne (114). A solution of N,N-dimethylaminoethanol (1.00 g, 11 
mM) in toluene (1.5mL) was added dropwise to a solution of propargyl chloride (70% 
w/w in toluene, 1.25 mL, 11 mmol) in toluene (1.5mL). The reaction was stirred for one 
day at room temperature. The obtained precipitate was filtered and washed with pentane to yield 1043 as 
white solid (1.17 g, 64%). 1H-NMR (400 MHz, Methanol-d4) δ/ppm: 4.43 (d, J = 2.5 Hz, 2H), 4.05 – 3.99 
(m, 2H), 3.62 – 3.57 (m, 2H), 3.55 (t, J = 2.5 Hz, 1H), 3.27 (s, 6H). 13C-NMR (101 MHz, CDCl3) δ/ppm: 
x. HRMS (ESI): C7H14NO+ calcd.: 128.1070,  found.: 635.1255.  
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General procedure for alkylation of imidazole. To a solution of of bromoalkyl species in DMF, the 
imidazole compound was added and the reaction mixture was heated up to reflux for 3h. The imidazolium 
salt was triturated with EtOAc. The mixture was filtered and washed with EtOAc, dried and purified by 
flash RP-column chromatography using method x. The corresponding fractions were lyophilized to yield 
the target imidazolium salt. 
 
Sodium 2,2'-(1H-imidazole-3-ium-1,3-diyl)bis(ethane-1-sulfonate) (115). According to the general 
procedure 1H-imidazole (200 mg, 2.94 mM), sodium(bromoethyl)sulfonate 
(1.24 g, 5.88 mM) in DMF (7 mL) were reacted and purified to yield 115 as 
white solid (431 mg, 40%). 1H-NMR (400 MHz, D2O) δ/ppm: 8.97 (t, J = 1.7 Hz, 1H), 7.60 (d, J = 1.7 Hz, 
2H), 4.64 (t, J = 6.5 Hz, 4H), 3.46 (t, J = 6.5 Hz, 4H). 13C-NMR (101 MHz, D2O) δ/ppm: 136.79, 122.64, 
49.83, 45.22. HR-MS (ESI): C7H11N2Na2O6S2+ calcd.: 328.9848, found: 328.9848. 
 
2-(1-methyl-1H-imidazol-3-ium-3-yl)ethane-1-sulfonate (116). According to the general procedure 1-
methyl-imidazole (400 mg, 4.82 mM), sodium(bromoethyl)sulfonate (1.02 g, 4.82 mM) 
in DMF (8 mL) were reacted and purified to yield 116 as white solid (579 mg, 44%). 
1H-NMR (400 MHz, D2O) δ/ppm: 8.81 (d, J = 0.8 Hz, 1H), 7.57 (t, J = 1.9 Hz, 1H), 7.46 (t, J = 1.8 Hz, 
1H), 4.67 – 4.59 (m, 2H), 3.92 (d, J = 0.6 Hz, 3H), 3.49 – 3.41 (m, 2H). 13C-NMR (101 MHz, D2O) δ/ppm: 
136.69, 123.60, 122.37, 49.84, 45.05, 35.72. (ESI): C6H10N2NaO3S+ calcd.: 213.0304,  found: 213.0308. 
 
3-(2-hydroxyethyl)-1-methyl-1H-imidazol-3-ium bromide (117). According to the general procedure 1-
methyl-imidazole (500 mg, 6.03 mM), bromo ethanol (753 mg, 6.03 mM) in DMF (12 
mL) were reacted and purified to yield £18 as white solid (909 mg, 73%). 1H-NMR (400 
MHz, D2O) δ/ppm: 8.68 (s, 1H), 7.44 (t, J = 1.9 Hz, 1H), 7.38 (t, J = 1.8 Hz, 1H), 4.25 (t, J = 5.0 Hz, 2H), 
3.88 – 3.84 (m, 2H), 3.83 (s, 3H). 13C-NMR (101 MHz, D2O) δ/ppm: 136.64, 123.90, 122.83, 60.16, 51.98, 
36.53. (ESI): C6H11N2O+ calcd.: 127.0866, found: 127.0867. 
 
“Der Mensch erfand die Atombombe, doch keine Maus der Welt würde eine Mausefalle konstruieren.“ 
Albert Einstein (1879 - 1955) 
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Cesium (2,2-dimethoxyethyl)amino)-2,6-diisopropylbenzenesulfonate (121).  To a solution of 
compound 120 (3.30 g, 12.8 mmol) in DMF (30 mL), 2-bromo-1,1-
dimethoxyethane (2.15 mL, 17.7 mmol) and Cs2CO3 (8.36 g, 25.7 mmol) 
was  added and the reaction mixture was stirred for 16.5 h at 160°C. After that the 
solvent was evaporated under reduced pressure and the residue was purified by flash RP-column 
chromatography (H2O/ MeCN) and to obtain 121 as a yellowish solid (2.39 g, 39%). 1H-NMR (400 MHz, 
D2O) δ/ppm: 7.59 (s, 2H), 4.60 (t, J = 5.4 Hz, 1H), 3.44 (s, 6H), 3.24 (dt, J = 14.1, 7.0 Hz, 2H), 3.15 (d, J 
= 5.3 Hz, 2H), 1.6 (d, J = 6.8 Hz, 12H). 13C-NMR (101 MHz, D2O) δ/ppm: 144.30, 142.30, 137.77, 121.20, 
103.72, 54.67, 51.79, 27.61, 23.17. HRMS (ESI): C16H27CsNO5S+ calcd.: 478.0659, found: 478.0659. 
  
Cesium 2,6-diisopropyl-N-(2-oxoethyl)formamido)benzenesulfonate (122). Acetic anhydride (925 µL, 
9.71 mM) and formic acid (899 µL, 22.6 mM) were stirred at room temperature for 
2 h. Compound 121 (1.55g, 3.25 mM) was placed in a pressure tube, CH2Cl2 (20 
mL) and the previous prepared mixture from acetic anhydride and acetic acid was 
added. The reaction was stirred at 45°C for 6 h and the solvent was evaporated under reduced pressure. To 
the residue formic acid (8 mL) was added and the reaction was stirred for 24 h. The formic acid was 
evaporated via azeotropic coevaporation with toluene (3x 10 mL). The residue was purified by RP-column 
chromatography using (H2O/ MeCN) to obtain 122 as white solid (756 mg, 51 %). 1H-NMR (400 MHz, 
DMSO) δ/ppm: 9.61 (s, 1H), 8.16 (s, 1H), 7.48 (s, 2H), 4.27 (d, J = 1.0 Hz, 2H), 3.09 (dt, J = 13.5, 6.8 Hz, 
2H), 1.15 (dd, J = 7.9, 6.7 Hz, 6H). 13C-NMR (101 MHz, DMSO) δ/ppm: 196.9, 163.73, 146.63, 135.50, 
121.37, 57.40, 27.68, 24.30, 23.68. HR-MS (ESI): C15H20NO5S- calcd.: 326.1068, found: 326.1066. 
 
General procedure for cyclization of chelating ligands. To a solution of 122 in acetic anhydride and 
HBF4*OEt2 was added and after 15 minutes a white precipitate was observed. 
Et2O was added and the mixture was centrifuged at 4400 g for 5 min. The 
supernatant was carefully discarded and the pellet was re-suspended in DMF. The 
aniline species was added and the reaction mixture was stirred over night at room 
temperature. The desired product was triturated with Et2O and purified by flash RP-column 
chromatography (H2O/ MeCN). 
 
121 
4-(5-hydroxy-1-(2-sulfophenyl)-4,5-dihydro-1H-imidazol-3-ium-3-yl)-3,5-
diisopropylbenzenesulfonate (124). According to the general procedure 
compound 122 (527 mg, 1.15 mM), acetic anhydride (2 mL), HBF4*OEt2 (375 
µL, 1.38 mM) and 2-aminobenzenesulfonic acid (228 mg, 1.32 mM) in DMF (2 mL) 
were reacted and purified (two columns were necessary) to yield 124 as white 
solid (529 mg, 19 %.). 1H-NMR (400 MHz, D2O) δ/ppm: 8.84 (d, J = 1.2 Hz, 1H), 7.96 – 7.86 (m, 1H), 
7.65 (s, 2H), 7.62 – 7.58 (m, 2H), 7.53 – 7.48 (m, 1H), 6.21 (dd, J = 8.1, 3.1 Hz, 1H), 4.53 (ddd, J = 13.9, 
8.0, 1.4 Hz, 1H), 4.08 (dd, J = 14.0, 3.1 Hz, 1H), 3.09 – 3.02 (m, 1H), 2.99 (dt, J = 13.6, 6.8 Hz, 1H), 1.22 
(dd, J = 22.1, 6.8 Hz, 6H), 1.12 (dd, J = 25.2, 6.8 Hz, 6H). 13C-NMR (101 MHz, D2O) δ/ppm: 158.46, 
148.58, 147.88, 145.07, 140.52, 132.49, 131.60, 131.22, 130.73, 129.30, 128.24, 122.06, 121.83, 86.84, 
60.25, 28.51, 28.17, 23.75, 23.28, 22.65. HR-MS (ESI): C21H25N2O7S2- calcd.: 481.1109, found: 481.1111. 
 
4-(5-hydroxy-1-(2-(pyridin-2-yl)phenyl)-4,5-dihydro-1H-imidazol-3-ium-3-yl)-3,5-
diisopropylbenzenesulfonate (125). 
According to the general procedure compound 122 
(250 mg, 544 µM), acetic anhydride (2 mL), 
HBF4*OEt2 (178 µL, 653 µM) and 2-(pyridin-2-
µM) in DMF (2 mL) were reacted and purified to yl)aniline (139 mg, 816 
yield 125 and the side product 125b. Separation of the two compounds 
by flash RP-column was unsuccessful. The mixture was used for the next step without further purification. 
 
3-(2,6-diisopropyl-4-sulfophenyl)-5-hydroxy-1-(2-hydroxyphenyl)-4,5-dihydro-1H-imidazol-3-ium 
(126). According to the general procedure compound 122 (235 mg, 512 mM), 
acetic anhydride (2 mL), HBF4*OEt2 (167 µL, 614 µM) and 2-aminophenol (118 
mg, 1.08 mM) in DMF (2 mL) were reacted and purified to yield 126 as white solid 
(215 mg, 33 %.). 1H-NMR (400 MHz, D2O) δ/ppm: 10.71 (s, 1H), 9.42 (s, 1H), 
8.08 (d, J = 6.7 Hz, 1H), 7.56 (dd, J = 6.8, 1.8 Hz, 2H), 7.47 (dd, J = 8.0, 1.6 Hz, 1H), 7.29 (td, J = 7.9, 7.5, 
1.6 Hz, 1H), 7.07 (dd, J = 8.4, 1.3 Hz, 1H), 6.98 (td, J = 7.7, 1.3 Hz, 1H), 6.34 (ddd, J = 8.1, 6.6, 3.4 Hz, 
1H), 4.61 – 4.48 (m, 1H), 3.94 (dd, J = 13.5, 3.4 Hz, 1H), 3.06 (dt, J = 13.5, 6.7 Hz, 1H), 2.95 (p, J = 6.7 
Hz, 1H), 1.38 – 1.12 (m, 12H). 13C-NMR (101 MHz, DMSO) δ/ppm: 158.46, 151.56, 150.61, 145.98, 
145.81, 130.06, 129.72, 125.59, 121.64, 121.58, 119.49, 116.52, 85.88, 60.19, 27.86, 27.77, 24.79, 24.40, 
23.85, 23.28. HR-MS (ESI): C21H27N2O5S+ calcd.: 419.1635,  found: 419.1632. 
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General procedure for water elimination. To a solution of the corresponding hemiaminal in DMF, 
HBF4*OEt2 was added and the reaction mixture was stirred at 120°C for 4 d. The 
solvent was evaporated under reduced pressure and the residue was purified 
twice by flash RP-column chromatography (H2O/ MeCN). 
 
3,5-diisopropyl-4-(1-(2-sulfophenyl)-1H-imidazol-3-ium-3-yl)benzenesulfonate (127). According to 
the general procedure compound 125 (92.2 mg, 191 µM) and HBF4*OEt2 (236 
µL, 956 µM) in DMF (2 mL) were reacted and purified to yield 127 as white solid 
(43 mg, 71 %). 1H NMR (400 MHz, D2O) δ/ppm: 9.44 (d, J = 1.4 Hz, 1H), 8.16 
– 8.07 (m, 1H), 7.97 (t, J = 1.7 Hz, 1H), 7.90 (t, J = 2.0 Hz, 1H), 7.82 (s, 2H), 
7.82 – 7.77 (m, 2H), 7.74 – 7.69 (m, 1H), 2.63 (dt, J = 13.5, 6.8 Hz, 2H), 1.21 (t, J = 7.2 Hz, 12H). 13C-
NMR (101 MHz, D2O) δ/ppm: 147.17, 145.56, 138.99, 138.66, 132.72, 132.19, 131.93, 130.58, 128.64, 
128.47, 125.89, 124.23, 121.66, 28.40, 23.09, 23.06. HRMS (ESI): C21H23N2O6S2- calcd.: 463.1003, found: 
463.1004. 
 
3,5-diisopropyl-4-(1-(2-(pyridin-2-yl)phenyl)-1H-imidazol-3-ium-3-yl)benzenesulfonate (128). 
 According to the general procedure the mixture of 125 and 125b (175 mg, 365 
µM) and HBF4*OEt2 (236 µL, 956 µM) in DMF (2 mL) were reacted and purified 
to yield 128 as white solid (51 mg, 31 %). 1H NMR (400 MHz, D2O) δ/ppm: δ 
9.88  (t, J = 1.6 Hz, 1H), 8.45 (ddd, J = 4.8, 1.9, 1.0 Hz, 1H), 8.21 (dt, J = 13.4, 
1.8 Hz, 2H), 8.03 – 7.94 (m, 2H), 7.91 – 7.83 (m, 2H), 7.82 – 7.77 (m, 1H), 7.74 (dt, J = 7.8, 1.0 Hz, 1H), 
7.60 (s, 2H), 7.48 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 2.28 (dt, J = 13.5, 6.7 Hz, 2H), 1.17 (d, J = 6.8 Hz, 6H), 
1.09 (d, J = 6.7 Hz, 6H) . HRMS (ESI): C26H28N3O3S- calcd.: 462.1846,  found: 462.1851.  
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 3-(2,6-diisopropyl-4-sulfophenyl)-1-(2-hydroxyphenyl)-1H-imidazol-3-ium (129). According to the 
general procedure compound 126 (63.2 mg, 151 µM) and HBF4*OEt2 (337 µL, 
1.36 mM) in DMF (2 mL) were reacted and purified to yield 129 as white solid 
(43 mg, 71 %). 1H NMR (400 MHz, DMSO) δ/ppm: 11.03 (s, 1H), 9.98 (d, J = 
1.5 Hz, 1H), 8.38 (d, J = 1.8 Hz, 1H), 8.32 (t, J = 1.6 Hz, 1H), 7.771 (dd, J = 8.1, 
1.6 Hz, 1H), 7.64 (s, 2H), 7.50 – 7.41 (m, 1H), 7.16 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 2.42 (p, J 
= 6.7 Hz, 2H), 1.18 (t, J = 6.8 Hz, 12H). 13C-NMR (101 MHz, D2O) δ/ppm: 151.27, 150.74, 144.70, 139.01, 
131.61, 130.29, 126.18, 124.81, 124.32, 122.14, 121.29, 119.66, 116.88, 28.14, 23.77, 23.62. HRMS (ESI): 
C21H23N2O4S- calcd.: 399.1384,  found: 399.1387. 
 
Ammonium functionalized amine (152). To a solution of 2-(Dimethylamino)ethyl ether (200 µL, 1.05 
mmol) in acetonitrile (1.5 mL) chloro ethanol (70.3 µL, 1.05 mmol) was added 
and the mixture was stirred at 85°C over night. The mixture was filtered and the 
solvent evaporated to yield 152 as white solid (120 mg, 48%). 1H-NMR (250 MHz, MeOD) δ/ppm: 4.01 
(ddd, J = 6.5, 5.2, 2.7 Hz, 2H), 3.92 (dq, J = 7.3, 2.7 Hz, 2H), 3.74 – 3.67 (m, 2H), 3.64 (t, J = 5.5 Hz, 2H), 
3.61 – 3.52 (m, 2H), 3.24 (s, 3H), 2.60 (t, J = 5.5 Hz, 2H), 2.32 (s, 3H). 13C-NMR (151 MHz, D2O) δ/ppm: 
178.04, 148.66, 137.64, 136.13, 135.29, 127.50, 124.41, 117.04, 65.15, 59.11, 55.42, 50.92, 28.85, 23.75, 
22.59. HRMS (ESI): C41H62Cl3CuN10O22+ calcd.: 412.2015, found.: 412.2021. 
 
Ammonium functionalized amine (153). To a suspension of compound 152 (120 mg, 498 µmol) in 
acetonitrile (1.5 mL) propargylbromide (56.7 µL, 748 µmol) was added and 
the mixture was stirred at 85°C over night. The mixture was filtered and 
washed with Et2O, dried to yield 1045 as white solid (111 mg, 62%). 1H-NMR (400 MHz, MeOD) δ/ppm: 
4.48 (d, J = 2.3 Hz, 2H), 4.08 – 3.98 (m, 6H), 3.84 – 3.75 (m, 4H), 3.64 – 3.60 (m, 2H), 3.59 (t, J = 2.6 Hz, 
1H), 3.29 (s, 6H), 3.27 (s, 6H). 13C-NMR (101 MHz, MeOD) δ/ppm: 83.21, 72.60, 67.74, 65.95, 65.71, 
64.65, 56.90, 56.31, 53.15, 52.12. HRMS (ESI): C13H28N2O22+ calcd.: 244.2140, found.: 412.2021. 
 
1-(4-formylphenyl)-3-phenyl-1H-imidazol-3-ium (159). The NHC 159 was synthesized according to a 
published procedure.222 White solid (212 mg, 55 %). The analytical data were in 
agreement with the literature. 
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General procedure for bio-conjugation of the skeleton modified [(NHC)CuCl] complex via click 
reaction. The azide functionalized [(NHC)CuCl] complex, terminal alkyne, CuSO4 and sodium ascorbate 
were stirred for 2 h at 55°C in a DMSO/water mixture (1:1, degassed before by bubbling nitrogen through 
the solution). The mixture was purified by prep RP-HPLC using method A. The corresponding fraction 
were lyophilized (three times, the fraction were degassed before freezing) to yield the functionalized 
[(NHC)CuCl] complex. 
 
Ammonium functionalized [(NHC)CuCl] complex (106). According to the general procedure compound 
111 (29.8 mg, 52 µM), alkyne 114 (16.7 mg, 102 
µM), CuSO4 (19.59 mg, 78 µM) and sodium 
ascorbate (15.6 mg, 78 µM) were reacted and 
purified to yield the target complex 106 as white solid. (27 mg, 58 %). 1H-NMR (600 MHz, D2O) δ/ppm: 
8.96 (s, 2H), 7.79 (s, 4H), 7.66 (s, 2H), 4.95 – 4.85 (s, 2H), 4.25 – 4.10 (m, 2H), 3.68 – 3.51 (m, 2H), 3.26 
– 3.22 (s, 7H), 3.21 – 3.14 (q, J = 7.3 Hz, 1H), 1.25 – 1.20 (d, J = 7.1 Hz, 12H). 13C-NMR (151 MHz, D2O) 
δ/ppm: 178.04, 148.66, 137.64, 136.13, 135.29, 127.50, 124.41, 117.04, 65.15, 59.11, 55.42, 50.92, 28.85, 
23.75, 22.59. HRMS (ESI): C41H62Cl3CuN10O22+ calcd.: 412.2015, found.: 412.2021. 
 
Ammonium functionalized [(NHC)CuCl] complex (145). According to the general procedure compound 
144 (53.8 mg, 99.0 µM), alkyne 114 (15.4 mg, 94.1 µM), CuSO4 (24.7 mg, 99.0 
µM), sodium ascorbate (19.6 mg, 99.0 µM) were reacted and purified to yield 
145 as white solid (36.7 mg, 49 %). 1H-NMR (400 MHz, MeOD) δ/ppm: 8.02 
(s, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 7.7 Hz, 
2H), 7.36 (d, J = 7.8 Hz, 2H), 7.21 (s, 1H), 4.71 (s, 2H), 4.26 (t, J = 6.7 Hz, 2H), 
4.19 – 4.02 (m, 2H), 3.45 (m, 2H), 3.14 (s, 6H), 2.73 (s, 3H), 2.72 – 2.64 (m, 
2H), 2.56 (p, J = 6.7 Hz, 2H), 1.34 – 1.21 (m, 24H). 13C-NMR (101 MHz, 
MeOD) δ/ppm 147.54, 147.09, 146.59, 136.56, 131.90, 131.49, 125.82, 125.23, 112.30, 66.39, 60.54, 
57.02, 55.96, 51.82, 41.14, 30.20, 29.91, 26.64, 25.30, 24.36, 23.09. HRMS (ESI): C37H56ClCuN7O+ calcd.: 
712.3525, found: 712.354. 
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Ammonium functionalized [(NHC)CuCl] complex (147). According to the general procedure compound 
144 (30.1 mg, 51.0 µM), alkyne 153 (17.6 mg, 49.1 µM), CuSO4 
(19.25 mg, 77.0 µM), sodium ascorbate (15.3 mg, 77.0 µM) were 
reacted and purified to yield 147 as white solid (36.7 mg, 49 %). 1H-
NMR (500 MHz, D2O) δ/ppm: 7.84 (s, 1H), 7.56 (dt, J = 13.1, 7.8 
Hz, 2H), 7.42 (d, J = 7.7 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.28 (s, 
1H), 4.60 (s, 2H), 4.46 (t, J = 5.9 Hz, 2H), 4.13 – 3.98 (m, 7H), 3.75 
(t, J = 4.5 Hz, 2H), 3.61-3.60 (m, 4H), 3.23 (s, 6H), 3.20 (d, J = 6.3 
Hz, 2H), 3.10 (s, 6H), 2.79 (s, 3H), 2.79 (p, J = 6.8 Hz, 2H), 2.59 (p, J = 6.8 Hz, 2H), 1.29 – 1.08 (m, 24H). 
13C-NMR (151 MHz, D2O) δ/ppm: 174.37, 146.38, 146.20, 145.57, 134.97, 134.36, 131.90, 130.46, 130.37, 
128.57, 124.29, 124.09, 112.28, 66.18, 64.42, 64.35, 64.25, 63.41, 59.40, 55.29, 55.18, 52.10, 50.59, 47.38, 
39.52, 28.44, 28.30, 25.39, 24.02, 23.00, 21.73. HR-MS (ESI): C43H70ClCuN8O22+ calcd.: 414.2298; found: 
414.2299. 
 
d(TTTTTT) functionalized [(NHC)CuCl] complex (148). 5`hexynyl modified d(TTTTTT) (10  µL, 19.7 
mmol stock solution in H2O) was placed in a 1.5 mL eppendorf tube (1.5 
mL), DMSO (85 µL, degased), H2O (50 µL, degased), compound 144 (15 
µL, 15 mM in degased DMSO) and sodium ascorbate (20 µL, 50 mM stock 
solution in H2O) were added and the mixture was degased for 30 seconds. 
The CuSO4 stock solution (20 µL, 50 mM stock solution in H2O) was added 
and the mixture was stirred at rt for 4h. Then NaOAC (20 µL, 3 M stock 
solution in H2O) and EtOH (550 µL HPLC grade, degased) were added and 
the mixture was placed for 30 min at -20°C. After centrifuging at 4°C for 15 min the supernatent was 
removed and the obtained pellet washed with EtOH  (550 µL HPLC grade, degased) centrifuged again at 
4°C for 15 min, the supernatent was removed, H2O (degased) was added and the solution was lyophilized 
to yield the target complex 148 as white solid (50 µL a 797 µM, 27 %). HPLC and MALDI-TOf analysis 
of complex 148 are presented in Figure 67.  
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Figure 67. HPLC and MALDI-Tof analysis of NHC-Cu complex 148. 
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